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ABSTRACT
Parkinson disease (PD) is an incurable movement disorder clinically characterized by resting 
tremor, bradykinesia and other cardinal features. A Japanese kindred with autosomal 
dominant PD showed linkage to a novel locus on chromosome 12pl 1.2-q 13.1, subsequently 
given the designation PARK8. A British family showed linkage to the same region on 
chromosome 12, encompassing PARK8, with a maximal LOD score o f 3.55. Genes within a 
1-LOD support interval were subsequently prioritized for sequencing. A tyrosine to cysteine 
substitution at amino acid 1699 (Y1699C) that segregated with disease in the British family 
was discovered in the gene LRRK2. Subsequent studies demonstrated that mutations within 
LRRK2 are the most common genetic cause of PD, accounting for approximately 2-3% of 
apparently sporadic PD, 7-8% o f familial PD and as much as 40% of PD in North African 
Arabic populations.
LRRK2 is large protein consisting o f multiple protein interaction motifs as well as GTPase 
and kinase domains. Analysis o f LRRK2 suggests it is largely cytoplasmic and mutations 
within LRRK2 increase aggregation formation, kinase activity and neuronal toxicity. Further 
investigation indicates LRRK2 is able to self interact, forming at least a dimer and may 
represent a potential mechanism for the aggregation o f LRRK2.
LRRK2 also interacts with fasciculation and elongation factor zeta 2 (FEZ2), a mammalian 
orthologue of the Caenorhabditis elegans UNC-76 protein, which is involved in the axonal 
outgrowth and synaptic organisation. Although the function o f LRRK2 is unknown, 
therapies directed towards LRRK2 are likely to have a great clinical impact and may bring us 
closer to understanding the pathogenic processes underlying PD.
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CHAPTER1; INTRODUCTION
Parkinson Disease (PD) was first described in 1817 by James Parkinson in his ‘An Essay on 
the Shaking Palsy’1. In this paper, Parkinson described the clinical presentation o f several 
individuals whose symptoms included shaking, slowness o f movement and muscle stiffness 
l. In 1895, Brissaud reported lesions within the substantia nigra (S N )2’3 and, together with 
Meynert’s previous observation 3’ 4 that the basal ganglia is involved in abnormal 
movements, concluded that injury o f this region was responsible for the motor symptoms of 
PD 3’5. This central observation was further emphasized by studies conducted by Tretiakoff,
who discovered cellular damage in the SN o f patients with post encephalitic parkinsonism 5’
6
Nearly half a century later, in a co-operative effort between Carlsson, Ehringer and 
Homykiewicz 71 *, dopamine was not only found to be a neurotransmitter within the brain, 
but deficient in the SN o f PD patients. This led to the development o f levodopa (L-dopa, 
metabolic precursor of dopamine) as a treatment for PD and this remains the most commonly 
used symptomatic treatment for PD.
PD affects approximately 5 million people globally 12' 14, with a prevalence o f 2% in persons 
older than 65 years o f age. The primary risk factor for PD is aging, with incidence rising to 
approximately 4-5% by the age o f 85 15, 16. I7. However, the contribution o f other risk 
factors, such as environmental insults or genetic susceptibilities is less clear. For many 
years, it was believed that PD was primarily the result o f environmental insult as several 
studies had recognized that individuals exposed to certain chemicals such as l-methyl-4- 
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) could develop a disease with parkinsonian 
features 18. Further studies showed that a PD phenotype could arise from multiple different
18
etiologies including vascular insults, infections (Post-encephalitic parkinsonism caused by 
the influenza virus) and frontal lobe tumors 19,2°.
Research into PD was revolutionized when a genetic basis for PD was established with the 
identification o f monogenic forms. Although genetic studies have highlighted biological 
pathways involved in PD, they have neither advanced our understanding o f why the SN 
specifically degenerates, nor have they led to an effective treatment to halt the underlying 
progressive neurodegeneration.
CLINICAL CHARACTERISTICS OF PARKINSON’S DISEASE
PD belongs to a heterogeneous family o f diseases referred to as parkinsonian syndromes 3’21. 
Within this group there are many diseases; progressive supranuclear palsy (PSP) 22,23, diffuse 
Lewy body disease (DLB) 24, 25 and environmentally induced parkinsonism (exposure to 
MPTP and other pesticides) 18,26. A clinical diagnosis of PD requires the presence o f tremor, 
rigidity and akinesia 27'29. In addition, there are other criteria which must be fulfilled: i) No 
detectable cause (exposure to environmental toxins or infection) ii) No cerebella deficits iii) 
limited pyramidal signs iv) no lower motor dysfunction v) limited gaze palsy vi) minor 
autonomic deficits 28,29. The exclusion criteria limit the clinical diagnosis o f PD and are 
meant to distinguish from other parkinsonian syndromes.
PD is a late onset disease, primarily occurring in the fifth or sixth decades *’ 3’ 27, although 
some forms, particularly the recessive genetic diseases, can begin in childhood. Disease in 
individuals where a specific etiology is not known and where there is no clear family history 
o f PD are classified as sporadic PD. The early symptoms o f PD may be nonspecific, 
including mild depression and mood changes and subtle autonomic dysfunction.
19
Subsequently, an intermittent tremor can develop with asymmetrical rigidity, moving to the 
other side o f the body within 3-5 years. Within five years, bradykinesia and postural
• •  •  30  • •instability ensue . Many individuals also experience non-motor symptoms such as fatigue, 
depression, anxiety, sleep disturbances, constipation, bladder and other minor autonomic 
disturbances . With prolonged disease duration there is a greater risk o f dementia perhaps 
reflective o f the track and progression o f neuronal loss in PD 32,33. At present, approximately 
40% of patients experience cognitive impairment although the prevalence o f  dementia maybe 
underestimated 31,34.
The average mortality rate in PD is approximately 1.5 times above the general population 35, 
. On average, disease duration is 13 years, and the mean age at death is 73 years. The most 
common causes o f death in PD patients are pneumonia through lack o f activity, 
cardiovascular disease or severe injury through falling 30,37.
PATHOLOGY OF PARKINSON’S DISEASE
The proximal cause for the movement disorder, and a pathological hallmark o f PD, is the loss 
o f neuromelanin-containing neurons in the substantia nigra pars compacta (SNpc) 32, 33 
(Figure 1A). It is increasingly recognized that the pathology is not confined to the SNpc as 
non-dopaminergic systems, such as caudal brainstem nuclei (e.g., dorsal motor nucleus o f the 
gloss-pharyngeal and vagal nerves) and anterior olfactory nucleus are also affected, perhaps 
significantly preceding dysfunction within the dopaminergic system ’ ’ .
20
Substantia nigraCut section  
of the midbrain 
where a portion 
of the substantia 
nigra is visible
Diminished substantia 
nigra as seen in 
Parkinson s disease
Figure 1: The pathological hallmarks of Parkinson disease: A) Loss of neurons in the substantia nigra 
underlies the clinical aspects of PD B) Typical Lewy body in PD: Hematoxylin and Eosin stain. C) Lewy 
body stained with anti-a-synuclein, the core component of Lewy bodies. (Pictures from (A) 
http://www.nlm.nih.gov/medlineplus and (B) www.saigata-nh.go.jp/.../neuropat/index.htm).
Release of dopamine from the nigral projections to the striatum 38 40 modulates activity by 
two pathways: the direct pathway mediated by the dopamine D1 receptor and the indirect 
pathway via the dopamine D2 receptor. The overall effect of striatal dopamine release is a 
reduction in basal ganglia output, leading to increased activity of thalamocortical projection 
neurons 40. Voluntary movements are initiated at the cortical level o f the motor circuit with 
outputs to brain stem, spinal cord, and multiple subcortical targets, including the putamen. 
Intermittent activation of the direct pathway by cortical inputs results in reduction of 
inhibitory basal ganglia output, disinhibition of thalamocortical neurons and facilitation of 
movement. By contrast, activation of the indirect pathway leads to increased basal ganglia 
output and to suppression of movement. In PD, loss o f dopamine leads to increased activity 
o f the subthalmic nucleus, with increased excitation of GPi/SNr neurons and greater 
inhibition of thalamocortical cells. This eventually leads to the decreases activation of the
21
cortex, including the premotor and prefrontal cortex and subsequent development o f akinesia 
or bradykinesia (Figure 2 ) 41,42.
Glutamate
Cortex Striatum
D1
R E C E P T O R
D 2
R E C E PT O R
Glutamate GABA AND 
ENKEPHALIN
DOPAM INEGABA AND 
SU B ST A N C E  Pi
Globus Pallidus 
externaThalam us Substantia Nigra 
Pars Com pacta
Brainstem GABA
G lobus Pallidus 
interna
GABA
Subthalmic
Nucleus
Glutamate
Substantia Nigra 
Pars reticulata
Figure 2: Neuronal pathways in the basal ganglia: The overall effect o f striatal dopamine release is to 
decrease basal ganglia output, leading to increased activity o f thalamocortical projection neurons. Lack 
of dopamine results in increased activity o f globus pallidus interna and substantia nigra pars reticulate. 
This ultimately leads to disruption and inhibition o f brainstem motor areas and thalamocortical motor 
system.
The dysregulation o f the basal ganglia results in symptoms after 60-80% of the SN neurons 
are lost as remaining neurons are able to compensate by the sensitization o f dopamine 
receptors and up regulation o f various dopamine synthesizing enzymes, such tyrosine 
hydroxylase (TH) 43'45. This implies that there is a substantial preclinical period in PD, 
perhaps of five to ten years, which is supported by functional imaging studies45'49.
The second major pathological hallmark o f PD are Lewy neurites (LN) or Lewy bodies (LB), 
discovered by Frederic Lewy in 1912 (FigureIB and 1C) 50. These are insoluble inclusion 
bodies, which develop as spindle- or thread-like LNs in cellular processes, and in the form o f
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globular LBs in neuronal perikarya51. LBs are found in the surviving dopaminergic neurons 
o f the SN, but can also be seen in noradrenergic neurons o f the locus coeruleus, cholinergic 
neurons of the nucleus basalis o f Meynert, dorsal motor nucleus o f the vagus, spinal cord, 
and in the peripheral nervous system 33,52. LBs consist o f a central dense core surrounded by 
a halo of 7-10-nm wide radiating fibrils, composed primarily o f  a-synuclein with various 
other proteins (e.g. ubiquitin, neurofilaments and heat shock proteins)51.
Both of these key pathological hallmarks are important for the identification o f PD and in the 
distinguishing o f PD from other parkinsonian disorders. A pathological diagnosis o f PD 
requires both loss o f dopaminergic cells in the SN and the presence o f LBs in surviving 
neurons in the presence o f an intact striatum 30, 53, 54. A term often used for a clinical 
syndrome that overlaps with PD but where there is no evidence o f LBs, is parkinsonism.
ROLE OF ENVIRONMENT AND MITOCHONDRIA IN PD
There are different theories for the etiology o f PD, which involves considering both 
environmental and genetic factors. Strong support for an environmental hypothesis o f PD 
emerged in the 1980s, when drug addicts inadvertently self administrated MPTP 55. This 
consequently led to a disease that was, apart from the age o f onset, clinically 
indistinguishable from typical PD 55'58. Pathological analysis revealed that these individuals 
developed pure nigral degeneration (preferential cell loss in the SNpc but relatively little loss 
o f neurons in the locus coeruleus) without the formation o f LBs 55,59,6°.
As MPTP can induce clinical symptoms indistinguishable from PD, identifying its molecular 
target may provide an understanding o f the molecular pathogenesis o f the sporadic disease. 
MPTP is readily transported across the blood-brain barrier where it is converted to MPP+ by
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glial monoamine oxidase B (MAOB). MPP+ is subsequently and specifically, taken up by 
the dopamine transporter (DAT) resulting in specific accumulation in DAT-positive SN 
neurons 26,61,62. The mechanisms o f MPP+ toxicity primarily involves inhibition o f the 
mitochondrial multi-enzyme complex 1 59’63, although adverse interactions between cytosolic 
enzymes and MPTP 61,64 may also contribute.
Mitochondria are primarily responsible for the synthesis o f adenosine triphosphate (ATP) via 
the electron transport system located in the inner membrane 65. The electron transport system 
(ETS) is comprised o f five complexes (Complex I-V) that transfer electrons between them to 
eventually reducing oxygen to form water. The reduction o f oxygen also results in the 
production of excess protons in the cytosol, creating an electrochemical and pH gradient. 
Protons move from the cytosol into the mitochondria as result o f  the gradients, inducing the 
phosphorylation o f adenosine diphosphate (ADP) to ATP via complex V of the ETS.
Complex I of the mitochondria is responsible for the transfer o f electrons to ubiquinone and 
oxidation of NADH 65. Inhibition o f the process results in increased production of reactive 
oxygen species (R O S)66 and decreased ATP production, which has several consequences for 
the cell:
1) ROS can lead to increased oxidative damage o f both nuclear and mitochondrial DNA 
(mtDNA), as well as modification of multiple different proteins (e.g. DJ-1) , lipids 
and other biomolecules.
2) Lack o f ATP may result in insufficient energy for essential cellular processes such as 
transcription, translation and protein turnover.
If the toxic insult continues, the cell is unable to repair itself and apoptosis can be induced by 
the formation of the mitochondrial permeability transition pores 65. This leads to the loss of
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mitochondrial membrane potential and release o f factors such as Cytochrome C 65,67 into the 
cytosol that can trigger caspase activation and apoptosis.
Many lines of evidence support a role o f mitochondrial damage in the pathogenesis o f PD. 
Complex I activity is systematically decreased in human PD brains 68,69 and administration 
o f MPTP to rats, mice and monkeys recapitulates many aspects o f PD 61,70. Perhaps the most 
persuasive evidence comes from rats treated with rotenone, another complex I inhibitor 71. 
These rats developed symptoms similar to PD and were responsive to L-dopa. Furthermore, 
they demonstrated selective neurodegeneration o f the SN and formation o f LB type
71 AO /"q "7 7  "77
pathology . However, as complex I is reduced in several areas o f the PD brain 5>0 > 
and inhibition o f complex I by rotenone is not specific to dopamine neurons, it is not clear if 
mitochondrial dysfunction alone is sufficient to cause nigral cell loss or P D 74'76. 
Mitochondrial genome encodes for only 13 genes, with the remainder o f mitochondrial 
components coming from nuclear encoded genes. Therefore, deficits in complex I and the 
selective vulnerability o f SN neurons to mitochondrial toxins could potentially be explained 
by genetic mutations in nuclear and/or mitochondrial genes encoding mitochondrial 
components. A contribution o f mtDNA mutations to the pathogenesis o f PD has been
77 77  78suggested for several years ’ ’ . Cells devoid o f mitochondria (by exposure o f host
mitochondria to ethidium bromide) can be repopulated with mitochondria from PD patients
• 77 78to form cybnds (cytoplasmic hybrid) ’ on a uniform nuclear background. This technique 
has demonstrated that the reduced complex I activity seen in PD can be transmitted stably 
into cybrid cell lines, which suggests that it may result from mutations in mtDNA 78. Only 
recently have two studies implicated specific mutation of SN mitochondria as causes for 
impairment of cellular respiration, specific neuronal vulnerability and age dependent risk
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associated with PD 79, 80. Amplification of mitochondrial DNA revealed more somatic 
deletions within SN mitochondria than mitochondria from other brain regions 79’80 and that 
deletions in SN mitochondria were higher in PD cases than controls 79. By the age 70, 
nearly all the SN neurons had elevated levels of mtDNA deletions 79,80, implying that these 
types of deletions might contribute to the age-dependent pathogenic processes seen in PD. 
However, why SN neurons have higher levels of mtDNA damage compared to other regions 
of the brain is unresolved. One hypothesis is the activities of TH, MAO and auto-oxidation
O 1
of dopamine (formation o f dopamine quinines) cause the formation o f H2O2 ’ (Figure 3). 
As a consequence, dopaminergic neurons have a higher basal oxidative burden than other 
neurons. This would cause higher levels of oxidative damage to biomolecules including
09 01 09
mtDNA, thus increasing cellular susceptibility to toxic insults ’ (Figure 3).
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Figure 3 Mechanisms of neurotoxicity caused by dopamine synthesis and metabolism: Formation of 
dopamine quinones and breakdown of dopamine can lead to increased production of reactive oxygen 
species. Both free radicals and dopamine adducts can damage DNA, covalently modify proteins and
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impair mitochondrial function leading to reduced ATP production and increased free radical formation. 
(ROS-reactive oxygen species, 3-M T-3-methoxytyramine, DOPAC-3, 4-dihydroxyphenyIacetic acid, 
DAT-dopamine transporter)
There are several caveats to this hypothesis. Only one study 79 has shown an increase in SN 
mitochondrial deletions in cases compared to controls, thus larger studies are required are 
needed to determine if the difference is statistically significant.. From recent work, neuronal
T9 “X 3loss is not restricted to the SN ’ . Therefore one needs to determine if  mitochondria in 
other regions (e.g. caudal brainstem and anterior olfactory nucleus) suffer from significant 
levels of mitochondrial deletions. It is hypothesized that the environment created by 
dopamine synthesis and metabolism contribute to neuronal vulnerability. However, not all 
neurons o f the dopaminergic system are affected in PD, with little or no neuronal loss
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observed in the ventral tegmental area (VTA) or retro-rubral field ’ ’ . Therefore,
dopamine per se is not a sufficient explanation for selective vulnerability and other factors
o4  ozr
must play a role in the determination o f the differences between SN and VTA ' .
It is feasible that mutation and damage o f mitochondria contribute to the preferential 
vulnerability o f SN neurons and disease progression, but it remains unclear if  accumulation 
of mitochondrial mutations is the fundamental pathogenic event in the majority o f PD 87 65,67, 
88. Based on current data, exposure to toxins like MPTP are unlikely to account for the 
majority o f PD, as not all sufferers o f PD are exposed to these chemicals. Furthermore, 
environmental factors that could account for a greater fraction o f PD have not been found 61 
20,89. It is probable that genetic variability at different loci contributes and predisposes some 
individuals to accumulating higher levels o f mitochondrial mutations and damage, thus
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leading to sufficient neuronal loss and clinical manifestation o f disease. As a consequence, 
various strategies have been employed to identify the genetic causes o f P D 90.
GENETICS OF PARKINSON’S DISEASE
Many diseases have a genetic component, whether it is due to inherited mutations or as a 
result o f genetic variation controlling the response to environmental stresses such as viruses 
or toxins. The identification o f the genetic causes o f a disease allows one to isolate the 
primary pathogenic mechanism and/or contributors to a disease. The ultimate goal is to use 
this information to identify and develop new ways to treat, cure or even prevent the disease. 
Twin studies are a common method used to determine the relative contribution o f genetics to 
disease in a population. This is performed by comparing concordance o f disease in 
monozygotic (MZ) twins (who share all autosomal genes) and dizygotic (DZ) twins (who 
share, on average, 50% of autosomal genes). The theory o f this technique is that if genetic 
factors are the primary cause of disease then concordance in MZ pairs will be higher, and on 
average double, when compared to DZ twins. Several PD twin studies have shown similar 
rates o f concordance in MZ and DZ twin pairs, suggesting genetic predisposition plays a 
relatively minor role in d isease9196 . However, there were many aspects o f these studies that 
were criticized 47, 97" .  Most o f these studies were cross-sectional and did not follow 
individuals over time to exclude the possibility that disease may develop at a later date in 
individuals who were scored initially as unaffected. Recent evidence, based on positron 
emission tomography (PET) studies measuring [18F]-6 fluorodopa (18F-dopa) uptake, indicate 
that there may be decreased dopaminergic function even in the absence o f signs and 
symptoms of parkinsonism in the asymptomatic twin o f a PD patient 43'45,48, l0°. Indeed
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concordance rates have been reported to be three times higher in monozygotic compared to 
dizygotic twins using this outcome measure (58% vs. 18% respectively) 46. These data 
indicate that the initial twin concordance studies may have underestimated the role o f 
genetics in PD, but also suggest genetics is not the sole determinant o f disease. These data 
are consistent with the more prevalent hypothesis, that the majority o f typical PD cases are a 
result o f a complex interplay between genetic variability, environmental exposures and 
stochastic factors 101. However, it should be noted that there is a lack o f definitive evidence 
for this model of disease risk as no environmental or genetic factors have been unequivocally 
established as underlying the majority o f typical PD.
In contrast to twin studies, the analysis o f multiple nuclear families or isolated populations 
has led to the identification o f  multiple genes and loci that cause Mendelian PD (autosomal 
recessive or dominant) or increase risk for PD (Table 1).
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Locus Protein Name Inheritancepattern Phenotype
PARKl
PARK4
a-SYNUCLEIN AD
AOO ~ 40-50 years 
Features of dementia with 
Lewy bodies
PARK2 PARKIN AR
AOO -3 5  years 
Slow disease progression. 
L-dopa responsive 
No Lewy bodies
PARK 3 UNKNOWN AD WITH REDUCED PENETRANCE
AOO—50 years 
Typical PD 
L-dopa responsive 
No pathology available
PARK5 UCHLrl AD
AOO -5 0  years 
Typical PD 
L-dopa responsive 
No pathology available
PARK6 P1NKI AR
A O O -35-45 years 
Slow disease progression 
L-dopa responsive 
No pathology available
PARK7 DJ-l AR
AOO -  30-40 years 
Slow disease progression 
L-dopa responsive 
No pathology available
PAKK8 LRRK2 AD
AOO -5 0  years 
Typical PD 
L-dopa responsive 
Variable pathology
PARK 9 ATP13A2 AR
AOO —16 years 
Levodopa-responsive 
parkinsonism with 
pyramidal degeneration, 
supranuclear gaze palsy, and 
dementia
PARK10 UNKNOWN RISK FACTOR
AOO-50-60 years 
Typical PD 
No pathology available
PARKl 1 UNKNOWN RISK FACTOR
AOO-50-60 years 
Typical PD 
No pathology available
PARK12 UNKNOWN RISK FACTOR
AOO-50-60 years 
Typical PD 
No pathology available
Chromosome 5 (5q23) UNKNOWN RISK FACTOR
AOO-50-60 years 
Typical PD 
No pathology available
Table I Genetic Loci implicated in Parkinson’s disease. Abbreviations: AOO; Average age of Onset, AR; 
autosomal recessive, AD; autosomal dominant
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I. SNCA (PARKl: PARK4: g-svnuclein)
The role o f SNCA in PD became evident in 1997 when a mutation (A53T) within a Greek 
kindred was shown to cause autosomal dominant PD 102. Subsequently, two additional 
missense mutations (A30P and E64K) 103,104 have been identified as rare causes of disease, 
as have multiplications o f the genomic segment containing the gene encoding a-synuclein
105-107
Soon after the discovery o f mutations in SNCA as the first genetic cause o f PD, this protein
1 ORwas found to be the major component o f LBs, the pathological hallmark o f PD . The study 
o f this rare familial form o f PD has relevance to idiopathic PD because the major deposited 
protein species in typical PD is encoded by a gene that when mutated results in PD. 
However, the pathology in individuals with SNCA mutations is not typical o f idiopathic PD 
and is usually more widespread with LBs not only in the SN but throughout the cortex 109 no. 
Several patients have been described whose presentation is similar to diffuse Lewy body 
disease (DLB). The parkinsonian associated with SNCA mutations presents at a relatively 
early age (30s to 50s) and is rapidly progressive. In many cases, the disease in patients with 
SNCA mutations, progresses to include prominent dementia and hallucinations111, likely a 
reflection of the extensive cortical pathology noted in these patients 111,112.
Aggregates o f a-synuclein define a series o f disorders collectively referred to as 
synucleinopathies (e.g. DLB, multiple system atrophy (MSA) and Hallervorden-Spatz 
disease) 1,3115 . Clinically these diseases can be distinguished from PD although they can 
present with parkinsonian features, such as rigidity 113. Pathologically, the location and 
distribution o f a-synuclein aggregates differs in each o f these diseases 113. For example, the 
primary aggregates in MSA are glial cytoplasmic inclusions 116. The clinical and
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pathological (a-synuclein positive aggregates and dysregulation o f the basal ganglia- 
thalamocortical circuitry) overlap between these diseases may represent a spectrum o f the 
same underlying patho-physiological mechanism. As a consequence, understanding how a- 
synuclein causes neuronal degeneration may aid our understanding o f all these different 
diseases.
Much speculation remains about the physiological function o f a-synuclein with many 
hypotheses regarding its role in the pathogenesis o f PD. a-synuclein is part o f a gene family 
including p and y synuclein 117 118120, characterized by an imperfect 11-amino acid repeat of 
the consensus sequence KTKGEV at the N-terminus o f the protein. Following this repetitive 
region, there are more variable regions in a-synuclein, such as a central hydrophobic core 
region and a negatively charged acidic carboxyl terminal 121. a  and P-synuclein are 
expressed at high levels in the brain 122 123 while y-synuclein is more abundant in the 
peripheral nervous system 120.
a-synuclein was initially cloned as a protein that was located at the presynaptic nerve 
terminals and therefore a role in maintaining or contributing to synaptic function was 
hypothesized 119, 122, l24. This hypothesis was strengthened by the observation that a- 
synuclein can bind to acidic phospholipids 119,125 at the synaptic junction, but its function at 
the synapse is not fully understood 126' 128 129. In a-synuclein knockout mice there is a 
decrease in the numbers o f undocked synaptic vesicles 127' 129? suggesting a role in vesicle 
maintenance, a-synuclein may also be required for pre-synaptic activity dependent negative 
regulation o f dopamine neurotransmission 127. a-synuclein knockout mice show impairment 
of synaptic response to a prolonged train o f repetitive stimulation capable o f depleting 
docked and reserve pool vesicles 128. However these deficits are generally small and in other
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respects knockout mice develop normally, indicating a-synuclein is not critical for synaptic 
formation or function. However, since there is significant homology between the synuclein 
family members, functional compensation by p and y synuclein may occur and knockout o f 
all three might be required to define the endogenous functions o f this protein family.
Because SNCA was the first gene implicated in PD and because its protein product is the 
major deposited species in the hallmark lesion o f the sporadic disease, considerable efforts 
have been made to understand the pathophysiological process that results from mutation o f 
a-synuclein. Initially, this work focused on the consequences o f qualitative changes in a -  
synuclein (i.e. missense mutations A53T and A30P); however, with the discovery that 
overexpression o f the wild-type a-synuclein, in the form of genomic multiplication, can 
result in PD 13°, this has grown to include analysis o f how quantitative changes in this protein 
can lead to disease. There are several lines o f thought on the pathogenicity o f a-synuclein 
mutations. Firstly, a-synuclein can aggregate under a number o f different conditions m ; a- 
synuclein can aggregate into oligomers that can then further develop into fibrils 131? 132. The 
end product o f a-synuclein aggregation is the formation o f insoluble polymeric fibrils, which 
are thought to be the species that are deposited as LBs. This process is promoted by both the 
A53T mutation and overexpression o f a-synuclein (Figure 4) 133,134. Fibrillar-aggregates of 
a-synuclein may themselves be directly toxic to cells, either inhibiting normal cellular 
processes such as protein trafficking and/or protein degradation by the proteasome and 
lysosome 112, l35. Conversely, A30P slows the rate o f fibril accumulation but increases the 
rate o f a-synuclein oligomer (protofibril) formation 121,136’137. Because o f this and other data 
137-Mo, 133 jt  j § ^ a s  k e e n  SUggested that an oligomeric species, which are themselves relatively 
soluble, are the toxic species 121,137,140,141.
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The role o f protein deposition into inclusion bodies in disease processes is unclear but may in 
fact represent a protective mechanism. Evidence for this hypothesis is emerging from recent 
work involving the Huntington (HTT) protein and P301L MAPT transgenic mice. As with 
a-synuclein, mutant forms o f HTT aggregate but surviving neurons contain inclusion bodies, 
suggesting the formation o f these structures aids in cell survival 142. In P301L MAPT 
transgenic mice, induction o f mutant TAU expression causes neuronal loss and behavioral 
impairment. When mutant TAU expression is turned off, cognitive abilities improve and no 
further neuronal loss is observed. However TAU continues to accumulate suggesting that 
soluble TAU aggregates do not result in neuronal cell death 143. Animal models o f a- 
synuclein support the hypothesis that fibrillisation of a-synuclein may actually protect 
against PD 133,144. In transgenic mouse models over-expressing or mutant (A30P or A53T) 
human a-synuclein, do not contain fibrillar a-synuclein inclusions 145,146 and exhibit neuronal 
loss, while fibrillar inclusion formation can occur in transgenic Drosophila, without neuronal 
cell loss 144’147,48.
a-synuclein inclusion formation is associated with phosphorylation at Ser-129 and it is this 
species that is primarily deposited in LBs 149. Altering this residue to either prevent or mimic 
phosphorylation, suppresses or enhances a-synuclein toxicity respectively in Drosophila 
transgenic models ,5°. The phosphorylation status o f a-synuclein is not only correlated with 
its toxicity, but appears to prevent its aggregation. As increased toxicity appears to be 
associated with reduced numbers o f inclusion bodies, this observation also suggests that 
inclusion formation may be protective 150,151.
As the formation o f a-synuclein fibrillar-aggregates may be protective, other mechanisms of 
cell death mediated by mutation and over-expression of a-synuclein intermediates 152 153 154
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have been suggested, a-synuclein protofibrils have the ability to form pores-like structures 
133 which can cause leakage o f vesicles 141 . Furthermore, PD associated mutations are able 
to increase the permeabilizing activity o f a-synuclein by increasing protofibril formation. 
The subsequent binding and formation o f pores in the mitochondrial or vesicular membranes 
155 or at the cell surface, could lead to disruption of numerous cellular activities and cell 
d ea th 135’155' 157’ .
Mutation or overexpression o f a-synuclein may also impair the 26S proteasome 158 160 161>162. 
The 26S proteasome is part o f the ubiquitin-proteasome system 163 160, responsible for the 
intracellular degradation o f ubiquinated proteins. The proteasome itself is a barrel shaped 
multi-protein complex, composed o f a 20S core protease unit and two 19S regulatory units. 
Ubiquinated proteins dock on the 19S cap and unraveled in an ATP-dependent process. 
Once unraveled, proteins are degraded into 3-25 amino acid peptides which are subsequently 
released. Mutant forms o f a-synuclein are more resistant to degradation by the 26S 
proteasome ,64’165 and thus impairment o f the proteasome by too much or mutant a-synuclein 
166 could result in the accumulation o f potentially cytotoxic abnormal proteins 162,165. The 
accumulation of these proteins could subsequently lead to mitochondrial damage, up- 
regulation of pro-apoptotic factors 167 and impairment o f other crucial cellular processes 155,
156, 158, 166
The potential mechanisms of a-synuclein toxicity described above may not be mutually 
exclusive. Damage to cellular membranes, such as the mitochondrial membrane may result 
in the increased production o f ROS and decrease in ATP production. As a consequence, a- 
synuclein may be modified, which promote its aggregation 66,150,153’ 168170? and impairment
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of the proteasome through lack o f ATP ’ ’ . Conversely, a-synuclein may impair the
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proteasome, leading to the accumulation o f cytotoxic proteins, mitochondrial damage and 
general perturbation o f cellular processes. Further work is needed to discern how a- 
synuclein causes toxicity.
II. PRKN (PARK2: PARKIN)
The gene (PRKN) encoding PARKIN was the first to be identified with mutations that 
underlie autosomal recessive juvenile parkinsonism (ARJP) and represents the most common 
known cause o f early onset parkinsonism 173. PRKN mutations account for approximately 
50% familial cases where the age o f onset is below 40 years 174,175 but are less common in 
patients with older ages o f onset.
The clinical picture o f PRKN linked disease is distinct from typical PD, as patients 
commonly present with young age o f onset (<40 years), dystonia, hyper-reflexia, slow 
progression, more symmetrical onset and early complications from L-dopa treatm ent21, 176 
177. The symptoms associated with PRKN linked disease may represent a separate clinical
  1 *7Q 1 *7Q
entity from typical PD ’ . However, an accurate diagnosis o f PRKN linked disease
cannot be based only clinical manifestation o f the disease 18°, as affected individuals can 
present with symptoms clinically indistinguishable from idiopathic PD in cases with a later 
age of onset m . Patients survive an average o f 10 to 20 years 182,183.
Despite the relative abundance o f PRKN linked cases, there is a paucity o f neuropathological 
data from patients with disease unequivocally caused by PRKN mutation. A key question is 
the role o f LB pathology in PRKN linked disease. While the majority o f  reports indicate a 
lack of LB pathology, more recent studies have suggested a-synuclein positive LBs may be a 
feature of this disease 184, 185 181. Despite the questions remaining about LB pathology in
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PRKN linked disease, there is certainly degeneration and dysfunction o f the dopaminergic 
neurons and as such, establishing the mechanism o f the preferential vulnerability o f this 
neuronal system in PRKN linked disease is likely to be directly relevant to typical PD 184,185. 
PARKIN contains an N-terminal ubiquitin-like homology (UBL) motif and two RING finger 
motifs separated by an in-between RING (IBR) finger domain at the C terminus 178,186. The 
presence of these motifs, suggested PARKIN was a component of the ubiquitin proteasome 
system. Further work confirmed and identified PARKIN specifically as an E3 ubiquitin 
ligase 187, which is responsible for the addition o f ubiquitin molecules to specific target 
proteins, that are subsequently recognized by the proteasome and degraded 188,189.
The ubiquitin-proteasome (UPS) mediated degradation pathway is involved in a variety of 
important intracellular processes such as cell cycle progression, removal of 
damaged/misfolded proteins and signaling cascades 160. Ubiquitylation and the subsequent 
degradation of proteins, require the actions o f three enzymes. Ubiquitin is initially activated 
in an ATP-requiring step by an activating enzyme, E l. Once activated, ubiquitin binds to El 
and transferred to the next enzyme, E2. These two proteins are essential in transfer o f active 
ubiquitin to the final enzyme class E3, which is responsible for catalyzing (directly or 
indirectly) the transfer o f ubiquitin to Lys residues on the target protein and is thus critical for 
substrate specificity. Polyubiquitin chains are formed by repeated cycles o f ubiquitin 
addition and are usually degraded by the 26S proteasome complex (Figure 4 ) 160,163.
As a consequence o f the large deletions and multiple mutations throughout the gene, 
decreased PARKIN activity 121 ’ 178,186,190 may lead to the accumulation o f one or more o f its 
substrates and subsequently to nigral cell death via impairment o f the mitochondria l72, 191 
and/or proteasome 152,171. Support for this hypothesis has come from transgenic flies over-
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expressing PAEL-R and rats over-expressing CDCrel-1 192, 193 , both PARKIN substrates, 
where specific degeneration o f dopamine neurons was noted 193,194. The phenotype could be 
rescued by over-expression o f wild type but not mutant PARKIN 193,194. However, there is 
no accumulation o f PAEL-R or other PARKIN substrates 195,196 in PARKIN knockout mice. 
This is perhaps due to the redundancy in the ubiquitin proteasome system or may be because 
the substrates identified are not in vivo substrates 197. In fact, PARKIN null mice show very 
mild impairments in behavior and dopaminergic transmission and metabolism 195,196. Further 
work is required to confirm PARKIN substrates in vivo and if they contribute to 
neurodegeneration in PD.
Although PARKIN null mice do not show accumulation o f any o f the identified substrates, 
they do show reduced levels o f proteins involved in mitochondrial oxidative phosphorylation 
and protection from oxidative stresses 198,199. Knockout o f PARKIN homologues from both 
mice and Drosophila cause decreases in mitochondrial respiratory capacity 198, 200 
demonstrated by reduced lifespan, locomoter defects due to apoptotic cell death 191,201 and 
male sterility due to spermatid individualization defects. It is unknown if PARKIN prevents 
apoptosis by inhibiting the release o f cytochrome C 65,191 apoptosis or indirectly, as PARKIN 
may ubiquinate and degrade components of the pro-apoptotic signaling cascade 202 (e.g. 
BAG5) and/or intracellular apoptotic stimuli (e.g. PAEL-R). How PARKIN maintains 
mitochondrial function and protects neurons is a critical question that remains unresolved. 
However, this is especially interesting as other genes mutated in PD (PINK1 and DJ-1) 
directly link mitochondria to neuronal loss.
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III. DJ1 (PARK7J
DJ-1 mutations are found in young-onset autosomal recessive parkinsonism 203 but are the 
rarest known genetic cause o f parkinsonism (<1-2% of familial PD) 204,205. Given the rarity 
o f DJ-1 mutations there is limited clinical data and no pathological data available in DJ-1 
linked patients 206 but DJ-1 does appear to localize to small percentage o f LBs 207,208. The 
two families originally shown to have disease caused by DJ-1 mutation were from an isolated 
population in the Netherlands and a small family from Italy with consanguineous parents. 
The patients in these families presented with PD at a very early age and followed a relatively 
benign course 203. Consistent with loss o f function, DJ-1 is recessively inherited and one of 
the original families possessed a large deletion encompassing the start codon o f DJ-1. 
Subsequently, multiple point and splice mutations have been described within DJ-1206.
101 ODQ Oil
Although the current function o f DJ-1 is unclear ’ ' , some mutations (e.g. L166P)
destabilize DJ-1 212-214 thus leading to increased degradation by the proteasome 212 213’215-217# 
As a consequence there is insufficient DJ-1 which is hypothesized to increase neuronal
o i c  oifi oon
vulnerability to toxic insult and apoptosis ’ ‘ .
Several hypothesizes exist as to how DJ-1 protects cells from toxic insult 87,221. DJ-1 is a
ono ooo189 amino acid member o f the ThiJ/PfpI/DJ 1 super family, ubiquitously expressed ’ and 
localizes to both the cytosol and mitochondria 215,223 as well as the nucleus in dividing cells. 
Under oxidative stress conditions, such as exposure to paraquat or MPTP, DJ-1 undergoes an 
acidic shift in pi by modifying the side chain o f cysteine 106 to form a sulfinic acid 215’224. 
This is correlated with the protein relocating from the cytosol to the outer mitochondria 
membrane 215, 219. In support o f this hypothesis overexpression o f DJ-1 in culture can 
decrease sensitivity to specific stressors, such as paraquat and MPTP ’ ’ . Conversely,
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loss o f DJ-1 in mice, cell culture and Drosophila models leads to increased sensitivity to
^  i  q  'j'jc 'yon
oxidative stresses ’ ' . Mutation (Cl 06A) o f the cysteine residue primarily modified in
the presence o f oxidative stresses 215 leads to the loss o f protection conferred by DJ-1. Thus, 
oxidation o f DJ-1 is an essential part o f its protective function. In addition, increased 
oxidation o f Cl 06 has been confirmed in animal models exposed to oxidative stresses219 and 
in sporadic PD patients suggesting modification o f this residue may also be related to 
disease pathogenesis.
DJ-1 only has a weak ability to scavenge free radicals and thus, DJ-1 is unlikely to primarily 
function as an anti-oxidant protein. Consequently, a role for DJ-1 as an oxidative stress 
sensor has been suggested 220,224,226. DJ-1 may have an analogous role to the DNA damage 
sensing enzymes (e.g. ATM, ATR and RAD proteins) where specific enzymes recognize 
different types o f DNA damage and are able to mediate the appropriate response (e.g. 
apoptosis, cell cycle arrest, transcription) 82. As DJ-1 was cloned as part o f a RNA protein
Oil 01T OOQbinding complex ’ ’ , it is postulated that DJ-1 may control transcription and/or
translation of particular RNA species in response to oxidative stress 23°.
Alternatively DJ-1 has been shown to bind to numerous proteins 209-211*222 such as D AX X 231, 
preventing it from activating the apoptotic pathway and decreasing cell sensitivity to 
oxidative stresses. However, many o f these DJ-1 interactors still require validation in vivo, 
both to confirm the interaction and to establish that they play specific roles in DJ-1 mediated 
cell survival.
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IV. PINK1IPARK6: PTEN induced kinase II
Mutations in the gene PINK1, encoding PTEN induced kinase 1, were identified in four 
Italian families with recessive early onset PD 232. Initial screens for PINK1 mutations in 
early-onset familial cases revealed that PINK 1 mutations are a more common cause of young 
onset PD than DJ-1 mutations, but not as prevalent as PRKN mutations. PINK1 mutations 
are estimated to cause 4%  o f familial recessive PD ' .
The clinical course o f individuals with PINK1 mutations resembles that o f typical PD, except 
the age o f onset is earlier (approx 35 - 45 years o f age) and disease progression is slower. 
Similar to PRKN linked disease, dystonia at onset appears to be more frequent in individuals 
with PINK1 mutations 237,240'242. No pathology data is available from any PINK1 mutated 
cases 206 but PINK1 can localize with a small proportion (5-10%) o f LBs in sporadic cases
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PINK1 is predicted to be a serine-threonine kinase that is targeted to the mitochondria 232. 
Once PINK1 enters the mitochondria, the N-terminal mitochondrial targeting motif is 
cleaved. There is some evidence that the mature kinase can be redirected to the cytosol, 
although this data is largely derived from overexpression studies in cell culture and it is not 
clear if this is true in more physiologically relevant systems 244.
Although no substrates o f PINK1 have been identified, the recessive nature o f the disease 
and the presence o f truncating mutations in PINK 1-linked cases 232, suggest loss o f kinase 
activity may result in cell loss 244,245. As PINK1 is a mitochondrial kinase and can protect 
cells against oxidative stresses such as paraquat and MPTP 232,244 (Figure 4), PINK1 may 
phosphorylate multiple proteins to maintain mitochondrial function and inhibit apoptosis. In 
support of this observation, knockout o f Drosophila PINK1 results in male sterility, apoptotic
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muscle degeneration, defects in mitochondrial morphology and increased sensitivity to 
oxidative stress 246,247.
As the phenotype associated with PINK1 knockout Drosophila is very similar to PARKIN 
knockout Drosophila 148 2015 Drosophila over expressing PARKIN were crossed with PINK1 
knockout Drosophila 246, 247. Surprisingly, PARKIN transgenic flies are able to rescue 
PINK1 null flies but the reverse is not true. Moreover, removing both PINK1 and PARKIN, 
results in identical phenotypes as PINK1 null flies, suggesting that PARKIN is downstream 
of PINK1. How PINK1 and PARKIN co-operate in the same pathway is unknown. 
Potentially, PINK1 may phosphorylate activators o f PARKIN or may co-operate with 
PARKIN in clearance o f particular substrates218’246'248. Precedence for this idea is shown by 
the observations that phosphorylation o f the amino terminus o f p53 reduces its affinity for 
MDM2, an E3 ligase, thus decreasing the degradation o f p53.
As mutations within PINK1 were only recently identified in PD, more work is needed to 
determine what the endogenous function of PINK 1 is and how mutations within PINK1 can 
cause selective degeneration o f the SN.
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Figure 4: A proposed model for mechanisms of cellular toxicity in PD. PRKN mutations and oxidative 
stress can inhibit PARKIN mediated ubiquitination of specific substrates leading to their accumulation. 
These substrates may inhibit both the proteasome and mitochondria. The formation o f a-synuclein 
protofibrils and aggregates can be toxic to both the mitochondria and proteasome. PINK1 and DJ-1 
promote cell survival, either directly or indirectly by protecting mitochondria from oxidative stress.
V. NR4A2, SYNPHILIN-1, GLUCOCEREBROSIDASE (GBAL UBIQUITIN C- 
TERMINAL HYDROLASE L I OJCHL1). QMI/HTRA2 AND PARK9: TH EIR  
POTENTIAL RO LE IN PD
SNCA, PRKN, PINK1 and DJ-1 were identified through linkage analysis and subsequent 
sequencing of candidate genes within the linked region. Although questions remain about
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the pathogenicity o f specific reported mutations, these genes are considered to be 
unequivocally linked to PD.
However, multiple genes have been implicated in PD by sequencing candidate genes without 
prior knowledge o f linkage to a genomic region. This approach has undoubted proven 
successful in the past 249,250 but is liable to a greater false positive rate, particularly in the 
implication o f rare non-pathogenic polymorphisms that coincidentally segregate with disease 
in small families.
Homozygous mutations in the glucocerebrosidase gene (GBA) cause Gaucher’s disease, a 
glycolipid storage disorder characterized by cellular accumulation o f glucocerebrosides 251. 
Gaucher disease type-1 (non-neuronopathic) can present with parkinsonism as an element of 
its clinical presentation and inclusions o f a-synuclein have been noted in Gaucher patients 
252-254 j n  a d d i t i o n ,  reduced GBA activity and/or accumulation o f GBA, may lead to aberrant 
protein degradation by the lysosomal pathway, specifically a-synuclein 255, as it too can be 
degraded by the lysosome.
Thus GBA was screened for six common gene mutations in 99 Ashkenazi Jewish patients 
with PD and 1543 controls. 31% of the PD group carried mutations (almost all were 
heterozygous) compared to 6% of controls 256'259. The authors concluded that heterozygous 
mutations in this gene predisposed individuals of Ashkenazi Jewish population to PD. This 
finding has not been consistently replicated in the general population therefore the relevance 
to PD is questionable 260, 261. GBA mutations within the Ashkenazi Jewish population 
probably arose as a founder event and as this population was relatively isolated and 
homogeneous, these variants have been enriched leading to their increased prevalence. Thus, 
it is possible that GBA is a risk factor for PD in the general population but at a much lower
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frequency compared to Ashkenazi Jews. Larger case control studies would therefore be 
required to detect a significant genetic affect262.
Mutations in UCHL-1, PARK5, were initially described in single affected German sib pair 
with a family history compatible with autosomal dominant PD, although the transmitting 
father was asymptomatic, suggesting incomplete penetrance o f the mutation 263. The clinical 
features were typical o f idiopathic PD, however, the age o f symptom onset (49 and 51 years) 
was marginally younger 263. UCHL-1 has a plausible biological role in PD as it is a neuron 
specific protein that may have dual functions as an ubiquitin hydrolase and an ubiquitin 
protein ligase 264‘266, potentially placing UCLH-1 in the same pathway as PARKIN 264. 
Despite extensive screening, no further mutations in UCLH-1 have been described 264,267-271. 
Several groups have also analyzed a S18Y polymorphism within UCHL-1 as a risk factor for 
sporadic PD. Initially, this polymorphism appeared to be protective against PD as it was 
over-represented in controls compared to PD cases 272. In support o f this finding, S18Y 
appeared to enhance the hydrolase activity o f UCHL-1 increasing the availability of ubiquitin 
for proteolytic degradation o f substrates 273 and preventing the accumulation o f potentially 
toxic proteins. However genetic studies o f the S18Y polymorphism in PD patients have been 
inconsistent 90, 264. Some of the studies that suggested a positive effect o f the S18Y 
polymorphism did not correct for population allelic frequency differences and deviations 
from Hardy Weinberg equilibrium 272,274'279. in addition the increased hydrolase activity 
associated with the S18Y polymorphism could not be replicated 280. Therefore, the role o f 
UCHL-1 in either sporadic or familial PD remains ambiguous.
Recently, a heterozygous mutation within OMI/HTRA2 (G399S) has been described in four 
individuals with PD and a polymorphism (A141S) has been associated with increased risk for
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PD 28'. 0M I/HTRA2 is a serine protease which can induce apoptosis by binding to inhibitor
0C7__________
of apoptosis (IAP) proteins ’ . OMI/HTRA2-knockout mice display parkinsonian
phenotypes, including rigidity and tremor 284. Striatal neurons are most susceptible but 
neurodegeneration progresses to the brain stem and spinal cord, including motor neurons 284. 
OMI/HTRA2 does map to a locus implicated in PD (PARK3, Table 1) but no mutations were 
found in the original PARK3-linked families 285 and another mouse model harboring a point 
mutation (S276C), perhaps a better model o f the heterozygous mutations observed in PD 
patients, has a more severe phenotype with weight gain, followed by ataxia, repetitive 
movements and akinesis . Further work is needed to determine if mutations within 
OMI/HTRA2 are a cause and/or a risk factor for PD.
Heterozygous mutations have been described in both NURR1 286 and SNCAIP1287. NURR1 
is a transcription factor required for the differentiation o f the midbrain neurons 288 and 
SYNPHILIN-1 may interact with both a-synuclein and PARKIN 289,290. Although both 
proteins may be involved in SN function or interact with other proteins implicated in PD, 
there have been no additional mutations discovered, leaving their pathogenicity uncertain.
For all five genes (UCHL-1, NURR1, SNCAIP1, OMI/HTRA2 and GBA) there has been no 
replication o f the original study in independent populations and thus evidence for association 
is limited to the original families or populations. These genes may be involved in the SN 
function and/or regulation, but it is unclear if any o f the genes have a genetic involvement in 
PD.
Kufor-Rakeb syndrome was originally described in an Arabic family 291 inheriting an
• • 292 •autosomal recessive disease and subsequently given the designation, PARK9 . This 
syndrome has many o f the features associated with parkinsonian disorders, including
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bradykinesia and response to L-dopa. However, the disease also has several other features 
such as spasticity, vertical gaze deficits and an early dementia that is distinct from the 
dementia seen in late PD patients. Therefore it has been suggested that Kufor-Rakeb 
syndrome is a disease where parkinsonism is part o f the clinical spectrum 293 and that is not 
true PD.
The gene underlying PARK9 was recently cloned as the lysosomal ATPase, ATP13A2 294 
and together with the clinical overlap with Niemann-Pick disease Type C, suggest Kufor- 
Rakeb syndrome may be a lysosomal storage disorder 293. As Kufor-Rakeb disease can 
present with parkinsonian features, it is unclear if it should be regarded as part o f PD. It is 
not until pathological data is available that can one classify this disease, thus its relevance to 
the molecular pathways involved in PD are uncertain.
VI. RISK FACTOR LOCI
Immense progress has been made in the last eight years to understand and identify the 
genetic factors contributing to PD. Nevertheless, they account for <2% o f total PD and 
therefore the etiology o f the majority o f PD remains elusive. To discover additional loci that 
either cause or contribute risk for disease, numerous population based approaches have been 
used.
Affected Sib pair analysis 295,296 has implicated the presence o f several loci contributing to 
genetic risk for PD. This method looks for genomic regions which are shared between 
affected siblings at an increased rate relative to the background sharing o f alleles between 
siblings. The linkage peaks o f two loci (on chromosome 2p 13 -  PARK3 and chromosome 
5q23) have overlapped in at least three independent sib pair studies and merit further study
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297-303 p a r k ]  ] a n ( j ] 2  300,304 a jSQ i d e n t i f i e d  usjng this methodology, but linkage 
of these regions with increased risk for PD have yet to be replicated in independent PD 
populations 301>305’306
An alternative approach to the affected sib-pair design is to use small genetically isolated 
populations. The principle is that individuals who have PD and are distantly related will 
share smaller chromosomal regions compared to individuals without disease and are closely 
related. This has been used very effectively by the biopharmaceutical company deCODE, 
who traced the genealogy o f over 100,000 individuals from Iceland and identified a 
susceptibility locus for late onset PD on chromosome lp32 (PARK 10) 307. This locus has 
been subsequently replicated in a different population 306, 308 suggesting that this 
susceptibility factor is not unique to PD patients o f Icelandic origin, but the identity o f the 
underlying gene change has not been resolved, leaving the locus uncertain 306,309,31°.
VII. PARK8
In 2002, autosomal dominant PD within a large Japanese kindred from Sagamihara was
->11
linked to the pericentromeric region o f chromosome 12 . This region was given the
designation PARK8. Further linkage o f autosomal dominant PD in two families to PARK8 
confirmed the locus and suggested that the gene could be a common cause o f PD 312'314. The 
aims of the studies reported in this thesis were to identify the gene responsible for PARK8 
and, once identified, begin biological characterization o f the protein product to understand its 
pathological role in PD.
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CHAPTER 2: IDENTIFICATION OF GENE UNDERLYING
PARK8-LINKED PD 
INTRODUCTION
The PARK8 locus was originally described in a large multi-generational pedigree from Japan 
with autosomal dominant parkinsonism 311’315. Affected members from this family presented 
with a clinically typical L-dopa responsive PD, with an age at onset o f approximately 50 
years 315. Neuropathologically, individuals exhibited pure nigral degeneration in the absence 
of LBs. Genome-wide linkage analysis in this family, provided evidence for a novel locus on 
chromosome 12 segregating with disease, with a maximal parametric two point LOD (log o f 
odds ratio) score o f 4.32 at marker D12S435 ( 12pl 1.2). Haplotype reconstruction and 
analysis limited the disease interval to a 13.6cM interval, between markers D12S1631 and 
D12S339. Several unaffected individuals shared the disease-carrying haplotype which 
suggested the possibility o f incomplete penetrance of the mutation. A subsequent report 
identified two additional families with autosomal dominant PD 3I6,317 with a maximal LOD 
score o f 3.33 on chromosome 12 (D12S1701). Clinical features in this family included 
bradykinesia, rigidity, resting tremor and good response to L-dopa but pathological analysis 
yielded variable findings, with some individuals showing TAU pathology 317.
As disease within multiple independent families had shown significant linkage to a region 
encompassing the PARK8 locus, there was sufficient evidence to reliably link this area to 
PD. Therefore, I undertook genetic analysis o f a family from Lincolnshire 313 with autosomal 
dominant PD to identify the gene underlying PARK8-linked PD
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MATERIALS AND METHODS
Family information: Lincolnshire Kindred
All subjects gave informed consent. The study was approved by the Ethics Committees o f the 
National Hospital for Neurology and Neurosurgery (NHNN). A pathological diagnosis of 
PD was made using the UK PD society brain bank criteria 318. A clinical diagnosis o f PD 
required two o f the three cardinal signs; tremor, rigidity and bradykinesia; responsiveness to 
L-dopa; unilateral/asymmetric symptoms at onset and no atypical features. One affected 
member was scanned using 18Fdopa and PET.
Linkage analysis o f chromosomal 12 markers:
Linkage o f this family to other regions o f the genome implicated in PD (Table 1) had been 
excluded 319. Whole genome linkage analysis had previously been completed 313 and 
suggested segregation o f disease with a region on chromosome 12 with a maximal LOD 
score o f 3.55 at marker D12S364. Additional markers (Table 2) were run in the region to 
confirm and refine the genomic disease interval.
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Marker Name cM position Forward Primer Reverse Primer Fraqment length
D12S98 27.51 5' FAM - TATAGTGACTGGCTGCCCAA CAAAGCCT GACGTAGAAGCA 217
D12S1580 30.91 5' FAM - GCATGTGGATGGATGGATTT GACTCTCAACCCACTGCTGG 345
D12S1630 35.25 5' FAM - GATGTGTTTAGATGCTTGGAAGG GCTCATCAGTGAGTTGACCTGT 270
D12S1654 39.55 5' FAM - TCAAATGGCTGTGCTCTCAA GATCTGTGGAGTTATTTGGGAGAG 253
D12S1606 42.85 5' FAM - ATGGACTTAAGAGTGCATTGACTAC TTGTGTCAGGGTCACTGATTT 184
D12S1640 49.54 5' FAM - GAAAGAGGACATCTTAAGGGAGG TTTGCAATGTTCATTCCTGG 170
D12S1681 53.43 5' FAM - CTGGTCCATTCCCAACTGAG AACCCTTGGTGTCCCTTACC 271
D12S85 60.49 5' FAM - TTTCTGGCACCTCTCACTCC GCACTCTACATGTGCAAAGTCAA 158
D12S1590 63.23 5* FAM - CACCATGCTCAGCCTCTATTT GCTGCAGTGAGCCATGAT 206
D12S347 65.16 5’ FAM - TATTGACTGCCACTGCTGCT GCTCCATCCATTACTTAATGACTCT 379
D12S1724 69.88 5’ FAM • CGCACCCAGCCAACTATTA CCGTGCTGGTTCTATCTGTG 276
D12S1644 72.76 5' FAM - CTGTCCAGCGAGTTCAAGG AGGGACCTGGGTAGAAGGAG 201
Table 2 Additional linkage markers run on chromosome 12 to confirm and delineate chromosomal region 
linked to disease
PCR mix for amplification o f linkage markers:
Component Amount per reaction
1 Ox buffer 2.5pl
dNTPs (25mM each dNTP) 0.4pl (Final concentration o f each dNTP -  200pM)
MgCl2 (25mM) 1.5pl(lm M )
Forward Primer (1 OpM) 1 pi
Reverse Primer (1 OpM) 1 pi
Taq (Applied Biosystems) 0.15pl
DNA (50ng/pl) lpl
ddH20  17.45pl
PCR cycling conditions for amplification o f linkage markers: 
1 cycle: 95°C -  2 min
35 cycles: 95°C -  30secs
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60°C -  30secs 
72°C -  30secs 
1 cycle 4°C - HOLD
Products were diluted 1:100 with ddH20 and 1 jul o f diluted PCR products were combined 
with 12pl o f formamide and 0.3pl o f 400HD ROX size standard (Applied Biosystems). 
Samples were heated at 95°C for 5 minutes and run on ABI PRISM 3100 Genetic Analyzer. 
All runs included CEPH1331-1 DNA to correct for inconsistencies between runs.
After electrophoresis, results were analyzed using GeneScan v3.6 and Genotyper v3.7 
software (Applied Biosystems). Following data analysis, all genotypes and pedigree data 
was exported and managed in Cyrillic v2.1 software.
Statistical Analysis o f chromosomal 12 markers:
Parametric 2-point LOD score calculations were performed using the MLINK program of 
the LINKAGE package 320‘324. The disease allele frequency was set to 0.001 and the model 
used for the disease assumed an autosomal dominant trait. Penetrance was set at 70% as the 
largest family with PARK8-linked disease 311 demonstrated a penetrance o f approximately 
70%.
Multipoint linkage analysis was performed using SIMWALK2 with the above parameters. 
SIMWALK2 was also used to reconstruct haplotypes with the minimum number of 
recombinations and verify marker inheritance patterns to identify marker typing 
incompatibilities.
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Allelic frequencies for each marker were obtained from public databases 
(http://www.gdb.org; http://www.cephb.fr/). Genetic distances were obtained from the 
Marshfield sex averaged linkage map (http://research.marshfieldclinic.org/genetics).
Candidate gene sequencing:
Genes within a 1-LOD support interval o f the maximal two point LOD score (D12S1640 to 
D12S85) (Table 3) were considered as candidate genes. Variants that were identified within 
coding regions and splice sites o f each gene were compared with those listed on the NCBI 
SNP database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp). 
Variants that were not listed on the NCBI SNP database were genotyped in the family to 
confirm segregation with the disease haplotype.
Genomic primer design for all genes was performed using Exon-primer 
(http://ihg.gsf.de/ihg/ExonPrimer.html). Each exon and at least lOObp o f flanking intronic 
sequences was amplified. PCR amplification for all the sequenced genes except for LRRK2 
was performed using a standard reaction mixture (pg 54-55) although conditions for 
individual exons varied with respect to annealing temperature, primer and MgCE 
concentration.
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Chr 
position  
(bp) start
Chr 
position  
(bp) stop
G ene Name
Chr 
position  
(bp) start
Chr 
position  
(bp) stop
G ene Name
Chr 
position  
(bp) start
Chr 
position  
(bp) stop
G ene Name
30753754 30798715 C1QDC1 33486879 33499660 LOC390301 41139341 41269745 PRICKLE1
30810101 30844209 LOC400019 34070139 34072501 ALG10 41316885 41317210 LOC390308
30861088 30906379 LOC390299 34081640 34100942 LOC144631 41734153 41734454 MRPS36P5
30996973 31032485 LOC390300 34208975 34211156 LOC260338 42007112 42010592 LOC400025
31118077 31148992 DDX11 36758977 36768884 LOC401715 42034279 42231991 ADAMTS20
31155860 31163465 DKFZp434C0631 36881636 36883817 LOC 121014 42249839 42271090 LOC400026
31296164 31297990 LOC387850 36886300 36904590 LOC390305 42340088 42341171 LOC401717
31324785 31370340 C12orf14 36996645 37004051 LOC144245 42408758 42438817 DKFZP434G1415
31368517 31370146 FU13224 37332269 37585687 CPNE8 42439047 42468166 IRAK4
31428985 31635219 MGC24039 37674838 37751521 LOC 121216 42473793 42486445 PTK9
31521677 31522058 MRPL30P2 37973297 38123185 KIF21A 42516229 43069808 DKFZp434K2435
31641308 31641610 LOC341356 38146513 38164195 LOC390306 42687843 42690385 ZNF75B
31658655 31660757 LOC387851 38232814 38300237 ABCD2 43188332 43556405 NELL2
31703388 31713168 MGC50559 38306287 38588369 FU40126 43742668 43745461 FKSG42
31715343 31773697 LOC196394 38438831 38785928 SLC2A13 43853114 43896056 LOC51054
31798920 31799484 LOC144383 38905080 39049354 DKFZp434H2111 43896170 44112401 DKFZp313M0720
31835854 31836367 LOC400022 39073517 39224969 LOC441636 44405781 44407955 LOC400027
32029259 32037306 FU10652 39222629 39250821 MUC19 44409887 44586590 ARID2
32151452 32422078 BICD1 39588426 39750361 CNTN1 44601462 44610015 SFRS2IP
32546361 32684940 FGD4 40117841 40254659 PDZRN4 44867833 44948824 SLC38A1
32723491 32788621 DNM1L 40761917 40826522 LOC283464 45038238 45052814 SLC38A2
32788348 32800080 CGI-04 40840421 40918264 YAF2 45063727 45332625 LOC387853
32835055 32940957 PKP2 40966980 40968629 LOC400024 45444811 45506006 SLC38A4
32941351 33031271 LOC283343 40992156 41006174 MADP-1 45584459 45637559 LOC390310
33419615 33484021 SYT10 41006214 41128690 PPHLN1 45755756 45759915 AMIG02
Table 3: List o f candidate genes within a 1-LOD support interval o f the maximal multi-point LOD score 
(between markers D12S1640 and D12S85). Abbreviations: Chr-Chromosomal
PCR mix for candidate gene amplification:
Component Amount per reaction
1 Ox buffer 2.5pl
dNTPs (25mM each dNTP) 0.4pl (Final concentration o f each dNTP -  200pM)
MgCl2 (25mM) 1.5pl(lm M )
Forward Primer (1 OpM) 1 pi
Reverse Primer (1 OpM) 1 pi
Taq (Applied Biosystems) 0.15pl
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DNA (50ng/pl) 
ddH20
1 (j,l
17.45pl (total volume 25pl)
PCR cycling conditions for candidate gene amplification:
1 cycle: 95°C -  2 min
35 cycles: 95°C -  30secs
60°C -  30secs 
72°C -  30secs 
1 cycle 4°C - HOLD
General PCR product purification protocol:
1. Add ddH20  to PCR mixture with lOOpl total volume.
2. Place in MultiScreen P C R ^  Filter Plate (Millipore)
3. Vacuum for lOmin at 20 inches Hg
4. Add 20ul o f water and place on plate shaker for approximately 1 Omin.
5. Remove resuspended purified products and place in PCR plate for sequencing reaction.
DNA Sequencing Reaction Mix Protocol:
1. 50ng o f DNA (generally, 2.5pl o f purified PCR product)
2. 1 pi of 3.2 pmol primer
3. 0.5pl Big Dye (Applied Biosytsems)
4. 2pl 5x Sequencing Buffer
5. Enough ddH20  to make total volume lOpl/well
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Sequencing cycling reactions:
1 cycle: 96°C -2 m in
25 cycles: 96 °C -  lOseconds
50 °C -  5secs 
60 °C -  4min 
1 cycle: 4°C -H O L D
Purification o f Sequencing PCR products:
1. Resuspend sequencing products to 20ul with ultrapure water
2. Place in MultiScreen P C R ^  Filter Plate (Millipore)
3. Vacuum for 5min at 25 inches Hg
4. Remove from vacuum and add a further 20ul o f ultrapure water
5. Re-vacuum for 5min at 25 inches Hg
6. Add a further 20ul o f water and place on plate shaker for approximately lOmin.
7. Remove resuspended and purified products and place in plate.
Purified sequencing products were run on an ABB 100 Genetic Analyzer and analyzed with 
Sequencher software (Genecodes, VA).
LRRK2 exon amplification reaction:
In the case o f LRRK2, the PCR amplification was performed using Abgene l . lx  Thermo- 
Start PCR Master Mix. Thermo-Start DNA Polymerase is a chemically modified Taq 
Polymerase, which requires activation for fifteen minutes 95°C incubation. The 
amplification mixture contains:
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Component Amount per reaction
Thermo-Start PCR Master Mix 1.1 x 13jnl
Primers F/R (1 OpM) 1 pi
DNA (50ng/pl) lpl
PCR cycling conditions are the same as those described above (PCR cycling conditions for 
candidate amplification, pg 55) except for a 15 minute incubation at 95°C.
Assay o f control subjects for LRRK2 mutation within Lincolnshire kindred 
The variant (Y1699C) identified in the British family was screened in the CEPH Human 
Genome Diversity Panel Cell Line (http://www.cephb.fr/HGDP-CEPH-Panel/), which is 
made up of 1051 samples from different populations, many o f which are European 326. A 
further 650 control subjects from North America were screened for the mutation.
Assay o f LRRK2 in PD cases with familial history o f PD:
All 51 exons of LRRK2 were sequenced in a total o f 117 pathological cases with one or more 
affected first-degree relatives. A pathological diagnosis o f PD was made using the UK Brain 
Bank criteria 318. One proband was also included with prominent postural tremor with a 
family history of parkinsonism (Figure 11; 11.2, Family 4). An autosomal dominant mode of 
inheritance (one or more affected first-degree relatives across two generations) was present in 
60 patients. The remaining 57 subjects were sibling-pairs.
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RESULTS
Clinical and pathological description o f Lincolnshire kindred:
The mean age o f onset o f PD was 57 years o f age (range 40-75) with affected individuals 
initially presenting with unilateral leg tremor. All reported hemi-parkinsonism symptoms 
typical o f progressive parkinsonism. Cognition was not significantly abnormal despite 
lengthy disease duration in some subjects. All affected individuals demonstrated a good and 
sustained response to L-dopa with minimal development o f L-dopa induced dyskinesia. 
Behavioral alterations, such as anxiety, depression and paranoia were observed in total o f 
seven patients313
PET imaging showed a pattern o f nigrostriatal dysfunction (presynaptic reduction of 
putamenal 18F-dopa uptake with relative sparing of the caudate) similar to idiopathic PD 327. 
Pathological examination o f  an individual after 20 years o f disease duration revealed no 
evidence of brain atrophy. There was severe pallor o f the SN and the locus coerulus was 
indiscernible. Histological examination showed severe loss o f pigmented neurons in the 
dorsal and ventral tiers o f SN with marked gliosis. LBs and LNs were present in the locus 
coerulus and olfactory bulb. Cortical LBs were observed with a frequency corresponding to 
brainstem predominant Lewy body disease. Neurofibrillary tangles (NFTs) were also present 
in the hippocampus, subiculum, entorhinal and transentorhinal cortices corresponding to 
Braak and Braak stage I I 313.
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Linkage analysis of chromosome 12 markers in Lincolnshire kindred 
As mentioned above, ail known PD genetic loci had been excluded from this family 319. In 
addition, whole genome linkage analysis provided significant evidence (LOD score o f 3.55 
0= 0.00 at marker D12S364) to chromosome 12 313. Thus, I focused on decreasing the 
disease linked interval by typing an additional 12 markers around D12S364 (Table 2, Figure 
5).
I l a d . i o l
Figure 5: Example of a dinucleotide marker DI2S1606. Allele size scored using the program Genotyper.
All data was corrected to CEPH control and exported to Excel (Microsoft) where the data 
was formatted for the linkage programs MLINK and SIMWALKv2. Multipoint linkage 
analysis using SIM WALK 2 gave a maximal LOD score of 2.2 between markers D12S85 
and D12S1590 (Figure 6). Two point LOD scores were calculated using MLINK which gave 
a maximal LOD score o f 2.04 at marker D12S1681 (Table 4)
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Figure 6: Multipoint linkage analysis results. Maximal LOD score o f 2.2 was observed between markers 
D12S85 and D12S1590.
j LOD Scores at recombination fraction 0
: Markers deCODE position (cM) 0.01 0.05 0.1 0.2 0.3 0.5 Max Lod score
ID12S98 27.51 -1.4 -1.14 -1 -0.7 -0.37 0 0
D12S1580 30.91 1.56 1.44 1.28 0.92 0.54 0 1.59
D12S1630 35.25 0.53 0.46 0.39 0.27 0.16 0 0.55
D12S1654 39.55 -0.28 -0.32 -0.33 -0.23 -0.1 0 0
D12S1606 42.85 -0.63 -0.19 -0.04 0.03 0.02 0 0.03
D12S1640 49.54 -0.31 0.26 0.43 0.45 0.32 0 0.47
D12S85 60.49 -0.86 -0.35 -0.17 -0.07 -0.04 0 0
ID12S1590 63.23 0.29 0.15 -0.02 -0.22 -0.19 0 0.32
ID12S347 65.16 0.11 0.02 -0.08 -0.18 -0.16 0 0.13
D12S1724 69.88 1.78 1.65 1.46 1.06 0.63 0 1.81
ID12S1644 72.76 -1.32 -1.05 -0.72 -0.33 -0.13 0 0
Table 4: MLINK two point LOD score results. Maximal two point LOD score was observed at marker 
D12S1681.
Haplotypes were reconstructed using SIMWALK2, in order to refine the disease interval 
(Figure 7). No recombination events were observed in affected individuals. Individuals who 
carried portions o f the disease haplotype (e.g. Figure 7, individuals IV: 3 and IV: 11), did not 
present with any symptoms but were still below the average age o f onset. Thus genes within 
a 1-LOD support interval o f the maximal two point LOD score were prioritized for 
sequencing.
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Figure 6: Multipoint linkage analysis results. Maximal LOD score of 2.2 was observed between markers 
D12S85 and D12S1590.
LOD Scores at recombination fraction 8
Markers deCODE position (cM) 0.01 0.05 0.1 0.2 0.3 0.5 Max Lod score
D12S98 27.51 -1.4 -1.14 -1 -0.7 -0.37 0 0
D12S1580 30.91 1.56 1.44 1.28 0.92 0.54 0 1.59
D12S1630 35.25 0.53 0.46 0.39 0.27 0.16 0 0.55
D12S1654 39.55 -0.28 -0.32 -0.33 -0.23 -0.1 0 0
D12S1606 42.85 -0.63 -0.19 -0.04 0.03 0.02 0 0.03
D12S1640 49.54 -0.31 0.26 0.43 0.45 0.32 0 0.47
h h h i 53.43 ’ 1.86 1,66 1.24 0.76 0 2 04
D12S85 60.49 -0.86 -0.35 -0.17 -0.07 -0.04 0 0
D12S1590 63.23 0.29 0.15 -0.02 -0 22 -0.19 0 0.32
D12S347 65.16 0.11 0.02 -0.08 -0.18 -0.16 0 0.13
D12S1724 69.88 1.78 1.65 1.46 1.06 0.63 0 1.81
D12S1644 72.76 -1.32 -1.05 -0.72 -0.33 -0.13 0 0
Table 4: MLINK two point LOD score results. Maximal two point LOD score was observed at marker 
D12S1681.
Haplotypes were reconstructed using SIMWALK2, in order to refine the disease interval 
(Figure 7). No recombination events were observed in affected individuals. Individuals who 
carried portions o f the disease haplotype (e.g. Figure 7, individuals IV: 3 and IV: 11), did not 
present with any symptoms but were still below the average age o f onset. Thus genes within 
a 1-LOD support interval of the maximal two point LOD score were prioritized for 
sequencing.
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Figure 7: Pedigree of Lincolnshire Kindred. Affected individuals are denoted by fdled symbols. Haplotypes highlighted in black represent the 
predicted disease haplotype. Marker order is as chromosomal order (Table 3 and 17) but markers D12S1654 and D12S1644 have been omitted from 
the pedigree as neither was informative.
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Sequencing o f candidate genes:
A total o f 12 genes were sequenced; CPN8, A M IG02, PTK9, ADAMTS20, CNTN1, 
MGC24039, SLC38A1, SLC38A2, SLC38A4, SLC38A12, DDX11, FGD4 and KIF21A. 
The majority o f variants identified did not segregate with disease or were not listed on the 
NCBI SNP database.
In collaboration with Dr. Perez-Tur and Dr. Singleton, a K543R variant within KIF21A 
was identified and segregated with disease in three out o f four Basque families (UGM03, 
UGM05 and UGM06) 328. These families had previously been linked to the PARK8 
region with a maximal LOD score o f 3.21 for marker D12S345 (family UGM05) 328. 
This variant was assayed in 1039 samples o f the CEPH Human Genome Diversity Panel 
Cell Line and in 58 Basque control subjects. The variant was identified in two o f the 58 
Basque samples but absent from the diversity series. With an allele frequency o f 0.01 in 
the Basque population (two o f 116 chromosomes carried K543R) and the added 
observation that no mutations within this gene could be found in the British family, the 
data argued that K543R was a rare variant and not the mutation responsible for PARK8- 
linked PD. However, the rarity o f this allele, coupled with the evidence that these 
families were linked to the PARK8 locus, suggested that the UGM03, UGM05 and 
UGM06 families were ancestrally related. In the absence o f a common inter-kindred
'I'JQ #
haplotype, as defined by the previous microsatellite markers used for linkage (Figure 
8), these data suggested that the causal gene defect was close to KIF21A. A further 23 
SNPs were genotyped between markers D12S331 and D12S1668 in all members o f the 
four Basque families (Figure 8). The results o f this SNP genotyping limited the disease 
haplotype to an area o f 3.2 Mb by finding that the three families who contained the
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KIF21A variant did not share the same genotype for rs 10876410 (Figure 8). Secondly, 
the data verified that all four Basque families shared a smaller inter-kindred disease 
haplotype, which was flanked by rs4548690 and D12S1653 marker, further reducing the 
linkage area further to a region o f 2.6 Mb (Figure 8 and 9).
BASQUE FAMILY ID
IDENTIFIER t>P CONSENSUS UGM3 I UGM4 | UGM5 I UGMO
D12S1098 30855980 - 122 120 118 124
D12S1021 31754700 . 191 191 191 191
rs l523118 37515900 - T T C/T* T
D12S331 37547321 . 177 177 177 177
rs l1169992 37003474 - C C C
rs1O87041O 37708557 T a n* T A
rs10876040 37887093 T T T T
r»10747730 37912177 - T C T T
rsl0747730 37912177 _ T T T
rs10870870*’ 38011203 _ A _ A A
rs l1171789* 38024258 T c T T
K543R* . G A G G
rs10876880*’ 38035530 _ C A/C* C C
rs l1172282 38101804 . G C/G* G G
rs11172541 38229025 - A . A A
rs10877201 382985-04 - C T/C* C C
rs4548090 38475137 - T C T T
rs7284010 38494030 T T T T T
rs4423249 38554997 T T T T T
rs5!5205 38089229 A A A/G* A A
rs937110 38815159 C C C/G* C
SNP1 38815103 T T T T T
rs4708224 38947070 T T T T T
IVS13-54* 38943803 C C/G* C C C
IVS13+08* 38944038 G G/A* G G G
R1390G4 38890503 C C C C C
M10O1T* 39011294 G G G G G
rs12423507 39003583 G G . . G
rsl 2423507 39003583 G G G G G
r»10784010 39117987 C C C C C
r s l1012870 39250712 T T - T T/C*
rsl 0784800 39380304 C C C C C
rs10879192 39471471 C c C/T* C C
D12S1008 39489795 235 235 235 235 235
D12S1053 4l693501 ........*............I | 2 1 5 2 1 5 j 1 1 I 215
Figure 8: Markers used to fme-map the candidate interval and determine Basque interfamily shared 
haplotype and the boundaries o f this haplotype. The K543R variant that did not segregate with 
disease in all three families is highlighted in yellow box. The black outline indicates the extent of the 
haplotype common between the Basque families. a Phase not determined; b Within KIF21 A ; c Within 
DKFZp434Hl 11
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Figure 9: Ideogram of chromosome 12 showing the linked areas defined by Funayama et al. in 2002, 
the refined area, and the region shared by all four Basque families.
(B) Schematic representation of the known genes and predicted transcripts in the area shared by the 
Basque families. Highlighted gene (red) represents the putative transcript where mutations in 
PARK8-linked families were identified.
Identification of a mutation within LRRK2 in the Lincolnshire kindred:
All genes and predicted open reading frames (Figure 9b) were sequenced in two affected 
and unaffected members from UGM03 and UGM05 families. Only one of them, 
LOC441636, was not analyzed as it was similar to submaxilary apomucin, MUC19 and 
unlikely to play a role in neurodegeneration. Mutations in one predicted transcript, 
DKFZP43H2111, were identified (Figure 10) in both the Basque (R1441G) and 
Lincolnshire kindred (Y1699C). Both mutations segregated with disease and neither 
variant were present in Basque (80 control patients), 650 North American controls or 
1039 controls from the diversity series. Thus it was highly likely we had identified the 
gene responsible for PARK8-linked PD.
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Figure 10: Chromatogram of Y1699C mutation identified within Ex35 of DKFZp434H2111 (LRRK2) 
in the Lincolnshire kindred. Upper chromatogram is sequencing of affected individual IV: 9 while 
lower chromatogram is sequencing of an unaffected individual.
Identification of additional LRRK2 mutations
Out o f a series o f 117 patients with a family history of PD, 5 (4 autosomal dominant, 1 
sib pair) LRRK2 substitutions were identified. A G2019S mutation was identified in 
three patients (Family 1, 2 and 5; Figure 11), R1941H in one subject (Family 3; Fig. 11) 
and T2356I mutation in another (Family 4; Fig. 11). Overall, mutations were found in 
5.1% of the 118 families screened. In addition, healthy subjects with LRRK2 mutations 
were also identified: III.3, aged 55 years (Family 4; Fig. 11) and II.5, age unknown 
(Family 5; Fig. 11). These mutations were not found in a total o f 1438 control 
chromosomes.
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Figure 11 Families in which LRRK2 mutations were identified; Family 1 2 and 5 had the G2019S 
mutation. Family 3 had a R1941H mutation and Family 4 had a T2356I mutation. LRRK2 
mutations were also identified in asymptomatic individuals; Family 4-III.3 and Family § -  11.5
DISCUSSION
As the family showed significant linkage (LOD score 3.55; 0=0.00) to chromosome 12 
313, further markers were genotyped to both confirm disease haplotype segregation and to 
refine the disease interval. No affected individuals possessed a recombination which 
reduced the disease interval, so based on both multi-point and two points LOD scores 
(2.2 and 2 respectively), genes between markers D12S1640 and D12S85 were prioritized
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for sequencing. As discussed in the results, the critical disease interval was refined to a 
2.6Mb region. A mutation (Y1699C) in the British family was identified in exon 35 of 
the DKFZp434H2111 gene (LRRK2), which segregated with disease and was not present 
in controls. In addition to the discovery o f mutations in both the Basque (R1441G) and 
British families, mutations were also described in the original PARK8 family 329 and in 
the two families described by Wszolek et al ’ . Thus, the genetic lesion
underlying PARK8-linked PD is in the LRRK2 gene.
After the identification o f the gene, multiple sequencing projects were undertaken to 
assess the genetic contribution o f LRRK2 to PD. Sequencing o f a pathologically 
confirmed cohort o f PD cases with a family history identified three different mutations 
(R1941H, G2019S and T2356I), which accounted for approximately 5% PD cases. A 
single mutation, G2019S accounted for 2.5% of the PD cases.
In terms o f genetic testing, LRRK2 is the most important gene linked to PD discovered to 
date, as sequencing has yielded multiple mutations 33,'333? with one single mutation 
(G2019S) accounting for 1-2% o f sporadic PD and 5-6% o f familial European PD 334 337. 
In addition, the G2019S mutation is present at much higher rates in other populations 
(11% Portuguese cohort; 23% Ashkenazi Jewish population; 40% North African Arab 
population) 335’ 338 339.
The clinical presentation associated with the G2019S LRRK2 mutation is similar to 
idiopathic PD; with asymmetric presentation o f bradykinesia, rigidity, tremor, L-dopa 
responsive and the absence o f major cognitive abnormalities 3I3,340,341. However, the age 
of onset associated with the G2019S is extremely variable, ranging from 28-88 although 
collectively, the mean age o f onset is approximately 56 years o f age 334,337,338,342'344. The
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penetrance associated with LRRK2 mutations is also extremely variable, as current 
estimates for the G2019S mutation are close to 30% 339,345,346 while other mutations such 
as, Y1699C, appear to be 100% penetrant 3I3,33°. The penetrance associated with the 
G2019S mutation is highly age dependent, increasing from 21% at the age o f 50 years to 
81 % at the age o f 70 years 343.
Not only is there variability in the clinical presentation but also in the pathology 
associated with LRRK2 mutations. The pathology in the British family is similar to 
idiopathic PD 313 as both LB and cell loss in the SN were present. However, in the 
original description o f the Japanese kindred, nigral degeneration without LBs was 
reported 347. Two other LRRK2 kindreds also have diverse pathologies. Histopathology 
from patients in Family D (R1699C mutation) 3,7’330? js more consistent with diffuse LB, 
nigral degeneration and PSP-like pathology. A second family, Family A, has clinical and 
pathological features consistent with a motor neuron disease where anterior horn cell 
degeneration and gliosis were observed 313 3I7,33°. Interestingly, this family shares the 
same Y1699C LRRK2 mutation as the Lincolnshire kindred whose phenotype, pathology 
and functional imaging is strikingly similar to idiopathic Parkinson’s disease 317,33°. The 
heterogeneous pathology, which includes LBs, TAU and amyloid, raises the possibility 
that LRRK2 may interact directly or indirectly with other pathways that lead to 
neurodegeneration or the pathology observed may simply be co-incidental. It should be 
noted that limited sequencing o f  LRRK2 in other neurodegenerative diseases has not 
identified any mutations 344. More extensive sequencing o f LRRK2 is needed to 
determine if mutation o f LRRK2 is involved in other neurodegenerative diseases.
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The variability in the disease occurrence, presentation, progression and endpoint suggests 
that there are other genetic, environmental or stochastic events that modulate the disease 
process caused by LRRK2 mutation. Unlike mutations in other genes that cause PD, the 
frequency with which mutations in LRRK2 occur, affords us the opportunity to 
investigate these specific modulators o f disease, and one would hope these will also be 
relevant to idiopathic PD 348.
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CHAPTER 3: ASSEMENT OF COMMON VARIATION
WITHIN LRRK2 AND THEIR CONTRIBUTION TO 
SPORADIC PD IN EUROPEAN POPULATIONS
INTRODUCTION
It has been suggested that PD is a complex disease and is the result o f intricate 
interactions between the environment, genes and stochastic factors l2. Much o f the 
research aimed at identifying genes associated with typical PD has focused on the role of 
common variation in modulating lifetime risk for disease. This often involves a 
candidate gene association analysis, where a gene is typically chosen based on its 
function, expression or genomic position, common variants are assayed within the gene 
and the frequency o f these variants are compared between cases and controls 2%’349. The 
ease and low cost o f this approach has resulted in hundreds o f candidate gene association 
studies being published in PD, many o f which have not been consistently replicated 350,
351
There are many possible reasons for the poor reproducibility o f association studies in PD, 
and in other disorders. Firstly, PD is almost certainly a heterogeneous group o f disorders 
that may have the same, different or overlapping susceptibility factors 177,352. This is 
analogous to the heterogeneity observed in Mendelian PD where a phenotype associated 
with a particular genetic mutation may not be distinguishable from the phenotype of other 
genetic forms 89. A second problem is inadequate study design, which can involve
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several factors. Many studies involve small sample sizes (greater false negative/positive 
rate) 349, poor selection o f control populations (increased false positive rate), failure to 
correct for population stratification 350 and multiple testing (increased false positive rate) 
353 354 and failure to utilize linkage disequilibrium patterns (LD) to track and distinguish 
the true causative mutation (failure to replicate association in other populations) 355 356.
An ideal case control study needs statistical power and hence a large sample size. Cases 
and controls should be matched for age and ethnicity to avoid population stratification 
bias, whereby subgroups have allele frequency differences. For example if one 
population subgroup has a higher disease prevalence, then alleles more frequent in that 
population will tend to be associated with disease, even if  they do not influence it. Study 
design such as the use o f unlinked genetic markers (genomic control) or a longitudinal 
analysis o f healthy individuals may help resolve this, although these strategies are 
technically difficult.
For all statistical approaches that use multiple tests, the appropriate p value correction 
(e.g. Bonferroni correction), should be applied to protect against a false positive result. A 
caveat is that if the correction is too conservative it is possible to miss a true positive. 
This is particular pertinent in the current climate o f genome wide searches, where 
thousands o f comparisons are often made. Replication o f a positive association is 
essential and will dissect a true positive 349,357, l06.
Two well characterized genes in terms o f genetic association with typical PD are those 
encoding SNCA and MAPT. When the a-synuclein triplication was discovered 106 a 
logical question that arose was whether smaller increases in a-synuclein could increase 
the risk for sporadic disease. Many studies have attempted to address this question but,
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as with most studies looking at risk factors in complex diseases, they have been largely 
inconclusive. Even though a polymorphic multi-allelic repeat in the promoter o f a- 
synuclein (R epl) can negatively regulate a-synuclein expression, genetic analysis o f  this 
marker has produced mixed results as to whether variation at this locus affects risk for 
sporadic PD 358'363. Examination o f common variability in other genes involved in 
monogenic forms o f PD has failed to reveal a consistent association with sporadic PD 90, 
although a recent meta analysis has suggested that individuals with a 263bp Repl allele 
are approximately 1.5 times at greater risk o f developing PD 363.
Perhaps the most robust genetic association with increased risk for PD comes from 
analysis o f the microtubule associated protein, TAU. Mutations in the MAPT gene cause 
Frontotemporal Dementia and Parkinsonism linked to chromosome 17 (FTDP-17) 364. 
The TAU protein forms NFTs in many diseases, collectively referred to as tauopathoies 
such as Alzheimer’s Disease (AD), progressive supranuclear palsy (PSP) and 
corticobasal degeneration (CBD) 365. Consequently, MAPT was considered as a 
candidate gene for these diseases 366 and a specific haplotype (referred to as the HI 
haplotype) has been consistently associated with increased risk for PSP and CBD 367‘369. 
As PSP and CBD can often present with parkinsonian features 3?0, and PD can present 
with TAU pathology 317,330,371, a role for MAPT in PD has been evaluated. Thus far, 
numerous studies demonstrate that individuals that are homozygous for the HI haplotype 
are approximately 1.5 times at greater risk o f developing PD l77.
Although MAPT and SNCA have been extensively investigated, the role o f common 
genetic variability in these genes in risk for PD is still debatable 90. The advent o f the 
HapMap project (www.hapmap.org) and the availability o f technology for genome wide
72
association studies promise a more complete genetic analysis o f PD. These data should 
reveal common genetic variability underlying disease and, in the absence o f association, 
give a reasonable indication o f a lack o f a single common genetic variant underlying 
disease 372. This latter point leads to another reason why there has been a general failure 
to identify common genetic risk variants for disease; namely that perhaps there are no 
common variants that individually confer a detectible risk. There is preliminary evidence 
for the lack o f a single strong genetic risk factor in PD from the first whole genome 
association study carried out in this disease 306. By its very nature, high-density genome- 
wide SNP association results in many false positives. Where the genetic variability 
underlying disease is only o f minor to moderate effect, the level o f "noise" and true 
signals will be about equivalent, and the former will outweigh the latter 354. This was the 
case in this study and while the absence o f a single overwhelming positive in the initial 
experiments may at first be disappointing, this misses the advantage o f this relatively 
unbiased type o f experiment. With some caveats, these data tell us not only what might 
be there, but also what is not there. It suggests that in PD there is not a single common 
variant o f large effect, such as the effect o f ApoE alleles in AD. This is invaluable data 
when we come to consider and design experiments
Even though common variation (allele frequency >5%) has not been found to increase 
risk for PD, recently, heterozygous mutations within PINK1 and PRKN have been 
suggested to act as risk factors for disease development l82,238, 240,241 ’ 373, as unaffected 
carriers can present with a sub-clinical phenotype. There is also significant over­
representation o f heterozygote mutation carriers in PD cohorts compared to controls 240, 
3 7 4 . 3 7 5  p g j  imaging o f heterozygous PINK1 and PRKN patients suggests a degree o f
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dopaminergic dysfunction as they showed a significant decrease in l8F-dopa uptake 373
“i n f .  1 7 c
It remains unclear if and how heterozygous mutations within PRKN or 
PINK 1 cause a disease with a later age o f onset 379 380 180,381 when the Mendelian forms o f 
these two genes cause a recessive disorder with early onset.
The studies discussed above suggest that common variants in genes associated with 
Mendelian forms o f PD might contribute to the risk o f sporadic disease but that the 
effects may be small. To assess if common variation within LRRK2 could contribute to 
risk o f PD, a rigorous case-control association study was performed that included 
multiple populations to address the issue o f independent replication.
MATERIALS AND METHODS
Clinical description o f Finnish and Greek cohorts:
A case-control study was performed in order to evaluate association with risk for PD and 
common variants within the LRRK2 locus. Two different European cohorts, from 
Finland and Greece were used for this study.
The Finnish cohort consists o f 283 subjects, 147 patients (87 men, 60 women) with 
sporadic PD and 136 controls (50 men, 86 women). The mean age at examination o f the 
patients was 67.2 years (range 38-88) and mean age o f controls was 65.8 years (range 
37-87). The PD diagnoses were verified with a clinical follow-up for at least 4 years or,
p i
alternatively, clinical follow-up for at least 2 years plus I-P-CIT-SPECT findings 
supporting idiopathic PD. Patients with dementia or patients who reported first-degree
74
relatives with parkinsonism were excluded. Controls were neurologically normal 
subjects living in the same geographical area.
The Greek cohort consists o f 217 PD patients and 221 healthy controls age, gender and 
ethnicity-matched. The mean age o f examination was 69.8 ± 8.7 years (range 44-95); 
while their mean age at onset o f disease was 68.3 ± 12.8 years (range 32-93). The 
diagnosis o f PD was based on established criteria 28. Controls were neurologically 
normal subjects living in the same geographical area. Experienced neurologists 
performed all clinical assessments. Informed consent was obtained from all subjects.
Identification o f tagging SNPs for LRRK2:
Linkage disequilibrium (LD) is the non-random association between two or more alleles 
such that certain combinations o f alleles (haplotypes) are more likely to occur together 
than other combination o f alleles. The strength o f LD between SNPs is eroded over time 
due to genetic recombination. This process leads to discrete blocks o f sequences, within 
which SNPs are in strong LD with each other and are flanked by recombination hotspots. 
SNPs between LD blocks are generally not in LD. LD can be measured by two different
-y loi
methods D’ and Rz When D’ is equal to 0, then the two markers are completely 
independent; when D’ is equal to 1.0, then one maker is able to completely predict the
'y
genotype o f the other. R is a stricter measure o f LD and can only equal 1 when marker 
loci have an identical allele frequency and every occurrence o f an allele at each marker 
perfectly predicts the other marker. When SNPs are in LD with each other and form 
haplotypes, there is redundant information contained within the haplotype. One can 
predict the state o f one marker knowing information about another. Thus, one can infer
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within a region o f reasonable LD (D’ and R2>0.5), a large proportion o f the variation by 
typing a small number o f key ‘tagging’ SNPs (tSNPs). tSNPs can only effectively and 
reliable infer genetic variation where the minor allele frequency (MAF) o f  the SNP is 
greater than 5% 384.
tSNPs were selected from 215 SNPs across the LRRK2 locus, identified from the 
HapMap Project (www.hapmap.org). SNPs with a minor allele frequency <0.05 were 
excluded from the analysis. A total o f 31 tSNPs were identified using TagIT v2.03 384, 
which selects tSNPs using a criteria based on the R2 measure o f association and allows 
analysis o f trio and population data 384. First, the LRRK2 haplotype structure was 
characterized, and the tSNPs that represented the most common haplotypes, were 
identified. A further five potentially functional SNPs, o f which four are non-synonymous 
changes (rs7308720, rs 10878307, rs71339914, rs 11564148) and one in the predicted 
promoter region (rs2201144) o f LRRK2, were genotyped. The tSNPs and the five 
potentially functional SNPs were structured in three different LD blocks, containing 17, 7 
and 7 tSNPs respectively. Finally all tSNPs, spanning 0.13 Mb were typed in idiopathic 
PD patients and control subjects in order to screen for association with risk for PD. 
Genotyping for all the samples was performed using Assays-by-design Service-SNP 
Genotyping (Applied Biosystems). All genotype data obtained from the Finnish and 
Greek cohorts were stored and analyzed using the GERON genotyping database 
(http://neurogenetics.nia.nih.gov/index.html).
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Genotyping o f tSNPs:
SNP genotyping was performed using Assays-by-Design Service-SNP Genotyping 
(Applied Biosystems). PCR amplification was performed in 5ul reaction, which contains 
the following PCR reagents:
Component Amount per reaction
TaqMan mix 2.5pl (TaqMan, Universal PCR Master Mix, Applied Biosystems)
ddH20  0.875pl
Probe (20pM) 0.125pl
DNA (lOng/pl) 1.5pl
Thermo cycling parameters were:
1 cycle: 50°C 2min
40 cycles: 95°C, lOmin
95°C, 15secs 
60°C, lmin 
1 cycle: 4°C, HOLD
In allelic discrimination assays, the PCR included a specific, fluorescent, dye-labeled 
probe for each allele at the 5’ end. During the PCR amplification, each probe anneals 
specifically to the complementary sequence and the fluorescence generated, indicating 
which alleles are present in the sample. Fluorescence is detected using the ABI Prism 
7900HT sequence detection system and analyzed with SDS software (Applied 
Biosystems).
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Statistical analysis o f tSNPs and risk for PD
In order to compare allelic and genotypic distribution between case and control 
populations the Pearson chi-square (^2) test using GERON genotyping 
(http://neurogenetics.nia.nih.gov) was performed. P-values were corrected for multiple 
testing using the Bonferroni correction (P=0.05/n where n is the number o f tests). 
Haplotype construction and tests o f  haplotype association were performed using the 
program Genecounting in association with the module Genecounting Permute 385. 
Genecounting implements the expectation-maximization (EM) algorithm for haplotype 
analysis o f unrelated individuals. Genecounting Permute performs permutation tests for 
global association and significance o f specific haplotypes using Freeman-Tukey and
• IOC
proportion tests . One thousand replications were performed for each analysis using a 
random number seed. Haplotype associations were performed individually for each o f 
the three previously identified blocks o f LD except for block 1, which had to be split into 
2 overlapping sections, la  (rs2201144 to rs2723264) and lb  (rs2046928 to rs4272849), in 
order to reduce computation time.
RESULTS
No association between common variation in LRRK2 and risk for PD:
A total o f 36 SNPs, 31 tSNPs identified from the Caucasian HapMap data using TagIT 
v2.03 and five potentially functional SNPs (Table 5), were typed in idiopathic PD 
patients and control subjects. The selected SNPs captured and predicted 95% of the
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identified genetic variation across the gene. These variants were distributed in three 
blocks of LD (Figure 12).
SNP rs  n u m b e r Contig position Minor Allele (Frequency) Tagging/Coding
1 rs2201144 38897130 C tO.093) prom oter
2 rs l4 9 1 9 4 1 38907082 C (0 .373) tSNP
3 rs l0 8 7 8 2 4 4 38917875 A (0 .134 ) tSNP
4 rs l  087824 5 38918058 T (0 .492 ) tSNP; L153L
5 rs l0 8 7 8 2 4 7 38918367 T fO.321) tSNP
6 rs l0 8 7 8 2 5 8 38927959 G (0 .229) tSNP
7 rs l4 9 1 9 3 8 38931897 T (0 .489) tSNP
8 rs l0 7 8 4 4 5 l 38936155 A (0 .183 ) tSNP
9 rs2046928 38938661 G tO.059) tSNP
10 rs2723264 38938787 T fO.250) tSNP
11 rs4 293 189 38943492 A fO.427) tSNP
12 rs l0 7 8 4 6 6 1 3894 3804 G (0 .192) tSNP
13 rs7308720 38943967 G (0 .088) N551K
14 rs4 768224 3 8 9 4 7 6  70 A (0 .369) tSNP
15 rsl 1 56420 7 3 8 9 5 0 9 1 0 A (0 .1 0 7 ) tSNP
16 rs7308193 38951494 i tSNP
17 rs l0 8 7 8 2 9 9 38953142 ,0.::58;. tSNP
18 rs7971935 38956661 A .0 .851 , . tSNP
19 rs4 272849 38957068 C (0 .483) tSNP
20 G ( 0 . 0 6 1 ) I723V
21 rs4 3 18033 38967208 G (0 .067) tSNP
22 rs7957754 38972305 G (0 .449) tSNP
23 rs79665S0 38974962 C (0 .150) tSNP; L953L
24 rs l0 7 8 4 4 9 8 38983701 A (0 .2 8 7 ) tS NP
25 rs7133914 38989178 A (0 .092) R1398H
26 rs l  1564148 39000168 A (0 .324 ) S164 7T
39012195 G (0 .069) tSNP
28 39015274 tSNP
29 rs l4 2 7 2 7 3 39018997 tSNP
30 rsl 1564147 39025760 i', , , ; tSNP
31 rs l0878405 39028521 A (0 .324 ) tSNP: E2108E
32 rs4768235 39030353 A (0 .127) tSNP
33 rs7303525 39031042 C (0 .196) tSNP
34 rs7132187 3903107  5 A (0 .298) tSNP
35 rs7 3 0 7 3 l0 39031448 T (0 .092) tSNP
36 rs890575 39034662 G (0 .117) tSNP
Table 5: List of tSNPs and coding polymorphism genotyped in both the Finnish and Greek 
populations to assess if common variation within LRRK2 contributes risk for PD. Regions 
highlighted represent the LD block in which each SNP is located in. Five non-synonymous and 
promoter SNPs were not part of the tagging set. Minor allele frequency and chromosomal position 
are based on NCBI reference sequence build 124.
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Figure 12: SNP locations and LD structure for LRRK2 and approx 20kb upstream of LRRK2. The 
triangle plot is constructed by connecting every pair of SNPs along lines at 45 degrees to the 
horizontal track line. The colour of the diamond at the position that two SNPs intersect indicates the 
amount o f LD: more intense colours indicate higher LD. LRRK2 LD structure demonstrates 3 blocks 
of high LD separated by relatively well-defined boundaries of low LD, denoted by the three 
differentially shaded boxes above the triangle LD plot.
O f the 36 SNPs genotyped in the Greek and Finnish cohorts, three SNPs deviated from 
Hardy Weinberg equilibrium (HWE) and were subsequently excluded from the 
appropriate analysis. R sl0878247 deviated from equilibrium in both Greek case and 
control cohorts, rs7132187 deviated only in the Greek control cohort and rs4293189 was 
broke HWE in both Finnish and Greek control cohorts
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In order to compare allelic and genotypic distribution between case and control 
populations, a Pearson chi-square (x2) test was performed using GERON genotyping. A 
small significant association at SNP r s l0878258 was identified in the Greek cohort for 
both allelic (p=0.05) and genotypic (p=0.013) frequencies. A significant association 
(p=0.03) at SNP rs2723264 was also identified in genotypic frequency for the Greek 
cohort. Neither o f these two SNPs was associated with PD in the Finnish cohort, and no 
significant association was found at other SNPs in Finnish and Greek cohorts. Both 
SNP-wise genotypic and allelic P-values were calculated and none o f  the SNPs 
genotyped were significant after applying the Bonferroni correction for multiple testing 
(Figure 13).
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Figure 13: A) Genotypic and B) Allelic -log  P values for single SNP association between LRRK2 and 
PD. P-values are not adjusted for multiple testing.
There was no association in any of the three haplotype blocks extending over the LRRK2 
region, in either the Finnish or Greek populations (Table 6).
G reek F in n ish
i 2 DF P value
Standard
error DF P value
Standard
error
Block la 84.30 1013 0.685 0.014 30.96 1013 0.826 0.011
Block lb 51.90 502 0.285 0.014 38.86 502 0.240 0.013
Block 2 41 .18 1013 0.588 0.015 30.22 1013 0.370 0.015
Block 3 38.48 120 0.599 0.015 11.92 120 0.863 0.010
Table 6: Results of association analysis between LRRK2 haplotypes and PD.
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DISCUSSION
With any genetic finding arising from a rare Mendelian disorder, one hopes it will 
translate into a greater understanding o f the genetic contribution to the more common 
sporadic disease. Since mutations in LRRK2 have also been found to occur in idiopathic 
PD, we wanted to know if common variation within LRRK2 could increase risk for 
disease development. Therefore we performed a rigorous case-control association study 
using 36 SNPs (31 tSNPs, 4 coding SNP and 1 promoter SNP), which captures 95% of 
the variability within LRRK2 locus, in Finnish and Greek populations. The analyzed 
SNPs were found to be distributed in three haplotype blocks o f LD.
Even though LRRK2 point mutations have been described in apparently sporadic PD 334' 
337, our work indicates that common variation within LRRK2 does not appear to increase 
risk for PD as neither SNPs nor haplotypes, are significantly over-represented in a PD 
population 386,387. This work has been replicated in a larger (340 cases) independent 
population 388, where a total o f 121 SNPs (81 tSNPs and 40 coding SNPs) were 
genotyped, thus representing a more comprehensive analysis o f the genetic variability 
within LRRK2.
One group has reported a significant association between LRRK2 (driven by the SNP
ion
rs 10506151) and increased risk for PD in a Chinese population . This study represents 
the largest cohort analyzed to assess if common variation within LRRK2 affects risk for 
PD (446 cases and 486 controls). However, the associated SNP in this population was 
not identified as a tSNP in either o f the two European population studies, reflecting the 
genetic diversity between European and Asian populations and the need to design 
different tSNPs sets for independent ethnic populations. Furthermore, as this study was
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conducted within a Chinese population, it may represent a true genetic risk factor within 
this population and not in others, as may be the case may be for GBA 256,257,259'261’390 (pg 
43-44). Other studies have demonstrated that rare variation within LRRK2, G2385R
1 Q 1  l Q l
(MAF~3%), is significantly over-represented in the Chinese population ' . The 
G2385R variant may be a population specific variant and analogous to the G2019S 
variant, which is rare in the Chinese population 394.
The ability o f tSNPs to capture genetic information decreases dramatically as the marker 
allele frequencies decreases 262,383, thus if a variant within LRRK2 that contributes to risk 
o f PD is rare (MAF<5%), as is the case for the G2385R variant in the Chinese population 
391 393, then none o f the studies conducted to date would be able to reliably detect them. 
To detect these variants, systematic sequencing o f all exons in large PD cohorts is 
needed. In addition, neither o f the two cohorts used are sufficiently powered to detect 
risk factors with modest allelic odds ratio (2<OR<3). This statement strictly depends on 
several factors including disease and marker allele frequencies, strength o f LD and the 
allelic odds ratio o f the disease gene (for review see ).
The contribution o f common genetic variation to sporadic PD is unknown 351 but one can 
almost be certainly sure that no risk factors such as APOE exist in PD 395. As APOE e4 
homozygotes have an odds ratio o f approximately 3, one can detect its effect with as few 
as 150 cases and 150 controls 395. At best, common variation within LRRK2, only has a 
modest effect on risk for PD (1<0R<2), therefore case control series o f 500 to 1000 cases 
are needed to discern a true effect o f LRRK2 on risk for PD 262. At present there is no 
evidence for common variation within the LRRK2 locus influencing risk for PD in a 
European population but larger studies are required to confirm or refute this finding.
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CHAPTER 4: CLONING AND PRELIMINARY
BIOLOGICAL ANALYSIS OF LRRK2
INTRODUCTION
Prior to the identification o f PD-causing mutations in LRRK2, the gene had been 
annotated as part o f the kinase super family and was named for leucine-rich repeats and 
the kinase domain 396 397,398 (LRRK2). LRRK2 belongs to a newly identified family of 
proteins referred to as ROCO proteins 399, 400 that contain two conserved domains i) a 
ROC (Ras in complex proteins) domain that belongs to the Ras GTPase super family and 
ii) a COR domain (C-terminal o f  ROC). In addition, LRRK2 contains multiple protein 
interaction motifs such as HEAT/ARMADILLO (ARM) 401, WD40 402 as well as the 
leucine rich repeats (LRR) 403’404. Very little is known this family o f proteins, with only 
three members having being investigated 403; human DAPK 405, and the Dictyostelium 
GbpC 406 and Patsl 407.
Although LRRK2 belongs to this family o f proteins, its primary amino acid sequence and 
the motifs suggest that it has unique properties 400. The closest homolog o f LRRK2 is 
LRRK1, but this protein differs significantly, lacking approximately 500 amino acids 
from the N-terminus that includes the HEAT/ARM repeat motifs while the remainder o f 
the protein domain structure is similar 403. As LRRK2 is a unique protein and mutations 
have been identified in all predicted domains o f LRRK2 408, it is difficult to predict how 
mutations in LRRK2 might affect its function. Therefore, in the present study, wild type
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and mutant versions o f LRRK2 were created and expressed in mammalian cells to 
determine how mutation o f LRRK2 might alter function.
MATERIALS AND METHODS
RNA isolation for LRRK2 cDNA synthesis:
RNA was isolated from BE (3)-M17 dopaminergic neuroblastoma using Trizol reagent 
(Invitrogen) according to the manufacturer’s instructions. However, after sequencing o f 
cloned fragments, multiple mutations were present within all the different clones chosen. 
As a result, total brain RNA (Ambion) was purchased cDNA was prepared using 
Superscript III First Strand Synthesis System for RT-PCR (Invitrogen). Manufacturer’s 
protocol for Oligo dT reverse transcription were followed
Amplification o f LRRK2 cDNA:
Overlapping cDNA fragments o f LRRK2 were amplified using the primer pairs shown in 
Table 7.
Fragment (bp position) Forward Primer Reverse Primer
Amplicon 1 (1-1261) ATGGCTAGTGGCAGCTGTCA C ATT C GC A GAT GC C T GG A A A
A m plicon2 (1107-3094) C GC AT GC T GG GC A CT A A AT A C AC AT A GCT GTT GT G GA A A GC
Amplicon 3 (2385-4717) CCTGGATGTGGCCAACAATA CT GC GT G A GG A A GCT C ATTT
Amplicon 4 (3373-4717) CCCTTGAGACTGAAGGAACT CTGCGTGAGGAAGCTCATTT
Amplicon 5 (4337-6227) CT GT GATT CT C GTT G GC A C A C CC TC T ACT ATT CT A C CT CC
Amplicon 6 (5041-7584) GA GC TT C C CC ATT GT G A  GA A ATGA GA C G A AC AT CT GTT GA GT A A
Table 7: Primers used to am plify portions o f LRRK2 cDNA
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PCR mix for amplification o f LRRK2 cDNA fragments:
Component Amount per reaction
ddH20  40.6ul
lOx cloned Pfu reaction buffer 5.0ul
dNTPS (25mM each dNTP) 0.4ul (Final concentration o f each dNTP -  200pM)
cDNA template (1 Ong/ul) 1 .Oul
Forward Primer (lOpM) 1 .Oul (Final concentration o f Primer 200pM)
Reverse Primer (10pM) 1 .Oul (Final concentration o f Primer 200pM)
PfuTurbo DNA polymerase (2.5U/ul)1.0ul 
Total Reaction volume 50ul
LRRK2 cDNA PCR cycling conditions and cloning: 
1 cycle 95°C 2mins
4cycles 94°C 30secs
60°C 30secs
72°C 1 min/kb
16cycles 94°C 30secs
60°C (-0.4°C/cycle) 30secs 
72°C 1 min/kb
4cycles 94°C 30secs
50°C 30secs
72°C 1 min/kb
1 cycle 4°C HOLD
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Amplified fragment were run on 1% agarose gels and bands matching expected sizes, 
were extracted using a gel extraction kit (Qiagen) as per manufacturer’s instructions. 
Isolated fragments were A-tailed using the following procedure:
1. 7pl o f purified PCR product
2. lu l2m M dA T P
3. lul lOx PCR buffer
4. lul Taq DNA polymerase (Qiagen: lU /pl)
5. Products were incubated at 70°C for 30 minutes
A-tailed PCR products were cloned into the pGEM-T easy vector system (Promega) as 
per manufacturer’s instructions. Disruption o f the LacZ reporter gene was used to 
identify insert positive clones. Clones were subsequently grown in ampicillin -containing 
media and plasmids extracted using the plasmid extraction kit (Qiagen) as per 
manufacturer’s instructions. Plasmids were sequenced (General sequencing protocol pg 
55-56) with appropriate primers (Table 8) in addition to M13 forward and reverse 
primers.
A non-synonymous change was introduced into Amplicon 2 (1 107bp-3094bp) to remove 
an MscI site and aid in the cloning protocol. The plasmid was subsequently re-sequenced 
in its entirety to ensure no additional mutations were created. A variety o f different 
primers were designed to sequence LRRK2 cDNA (Table 8).
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Fotwaid R*y««e
cDNAl CGAAGAGGACGAGGAAACTCT TCOCGACTCTC AT AT AGGAG
cDNA2 CCTCC AAGTT ATTTC A AOOC TGGTGAACACCAAGGACTTC
cDNA3 OrrOOOTTOGTCACTTCTOT GTTAGGAGGAGATCTAAGGTC
cDNA4 GCCAOTGT AAACTTGTCAGTG TGOCTGGAAATGAOTOCATG
cDNAi TGOCATOCACTCATTTCCAG GT AAGCCT ATGGAGCA AACAGC
cDNA6 GTGGAAGTCCTCATGAGTG CTGCAATGCTGCATTCTCTG
cDNA7 CGAAGTCCATGAGTTTGTGG TTTGT A AC AGGCTTCC AGCC
cDNA8 OGCTOGAAGCCTGTT AC AAA OGCCATCTTCATCTCCAATC
cDNA9 CGCATGCTOGGC ACTAAAT A CATTCGCAGATGCCTGGAAA
cDNAlO GCTCAT AGGGAAGTOATGCT ACAGCCACTTTCAGCCACTT
cDNAll TGAAGTGGCTGAAAGTGGCT GCTGCACTGGTAATGATGTC
cDNA12 CCCTOGAT AT AATGOC AGC A CCTGTTCAAAGCTGCTAGGA
cDNA13 CC AOOGAGGAT AC AGAAT GGAT ACATCTGC AGTGTG
cDNAU T ATCCCTGGAAGGTGCT ATG C AGC AGATGTCC AGTTCCT A
cDHA15 ATAOOAACTGOACATCTGCTGG GAATOATOCACCAGCAGCTTAG
cDNA16 CTAAGCTGCTOGTGCATCATTC GAAGATCCCTCCTTTGCTTG
cDNA17 TGCTAGAGAGAOCGTGTGAT T ATTOTTGGCC ACATCC AGO
cDNA18 CCTGGATGTGGCCAACAAT A GAGC A A AC AC ACTGTCC AT AG
cDNA19 GTGCTGTOGAAGAAGGAACA GGTGAGC AACGCTGT AAT AC
cDNA20 GTATTACAGCGTTGCTCAOC CACAT AGCTGTTGTGGAAAGC
cDNA21 CCCATATGAGGCATTCAGAC AAACCACTGAGGGTCCAATG
cDNA22 ATGACATTOGACCCTCAOTG CTCTCCACTTTAOGACAAGC
cDNA23 CCCTTGAGACTGAAOGAACT GAGGCAAGA AAGGC AT AGCA
cDNA24 TGCTATGCCTTTCTTOCCTC CAAAGATTTCCAGTGTGCGG
cDNA25 CCGCACACTOGAAATCTTTG ACAGCCAATCTCAGGAGGAA
cDNA26 TCCTCCTGAGATTGGCTGT CCCACACATTT AOGACGAGA
cDNA27 GC AT AGATGTGAA AGACTGGCC TGAAGAGCCAAGGCTTCATG
CDNA28 GAGC ATTGT ACCTTGCTGTC GTGGT A ATCTCGT ATOGC AO
cDNA29 CTGTGATTCTCGTTGOCACA CTGCGTGAGGAAOCTCATTT
cDNA30 TCAGCTTGTTGTTGGACAGC TGCAGTGCTGGGTCTTGAAA
cDNA31 GGAACCC AAGTOGCTTTGT A CGCGAAAT A ATOCCCTT AGO
cDNA32 CCTAAGGGCATTATTTCOCO GTTCTCACAATGGOGAAGCT
cDNA33 GAGCTTCCCCATTGTGAGAA GACA AT AAGCTTCAGGAGACC
cDNA34 GGTCTCCTGAAGCTT ATTGTC AATCTCCAGCAACCCAGGAA
cDNA35 TTCCTGGGTTGCTGGAGATT TTCT AGGC AGGTTC AGCC AAA
cDNA36 GATCAACCAAGGCTCACCAT TTCTCCTTCATAGGCTGCTC
cDNA37 GAGCAOCCT ATGAAOGAGAA TTTOTCCTGCTGAAGCAGG
cDNA38 GATATCTTTGCTGGCAGCTG CAATGCCOT AGTCAGCA ATC
cDNA39 GATTGCTGACT ACGGC ATTG CCCTCT ACT ATTCT ACCTCC
cDNA40 CCTGAAGTTOCCAGAGGAAA TTCTCA ACCAT AGGCCATGG
cDNA41 CC ATGGCCT ATGGTTGAGAA CCCAGCCAAATGCTTGCATT
cDNA42 GGAATGCAAGCATTTGGCTG CTTCGOT ATTGATGACC AGO
cDNA43 ATTOTOTCTGGGACACAGTC CTAACTTGCCATCAGCGGTT
cONA44 GAACCOCTGATOGC AAGTT A AATCTTTGTGCCACATCCTCCC
cDNA45 GGGAGGATGTGGCACAAAGATT GTGC ACGC AGTCTATT AGTC
cDNA46 GTGGACT AAT AGACTGCGTG GCTGTGCTGTCATCATGACT
cDNA47 GCTCTTTGGATAGGAACTGG TTCCGGTTGTAGCCCAATAC
cDNA48 GT ATTGGGCT ACAACCGGA A CGAC A AGC A AT AGTCCTGTC
cDNA49 TGT AAAACGACGGCC AGT CAGGAAACAGCTATGACC
Table 8: List o f primers used to sequence LRRK2 cDNA. M 13 primers were also used to sequence 5’ 
and 3 ’ ends o f the cDNA. All non-synonymous sequence differences between cDNA cloned and 
published sequence (NM -198578) were confirmed as polymorphisms and not altered.
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1107bp 3094 bp
Digest with Mtcl
1 bp
1 bp
Digest with Sac I 
/
1261 bp
Digested fragments gel 
punfied and ligated
3373 bp 4717bp
\
Digest with Ncol Digest with SacI
4337 bp 6227 bp
3373bp
Digested fragments gel 
puhfied and ligated
6227 bp
Digest with Alel
2385bp 4717 bp —  Digest with SacI —
Digested fragments gel 
punfied and ligated
5041 bp 7584 bp
Digest with Avril
2385bp 6227bp
Digest with SacI 
; *
Digested fragments gel 
puhfied and ligated
2385bp 7584 bp
Digest with Ndel
3094 bp
Digest with SacI
1 bp 7584 bp
Figure 14: Schematic representation of cloning strategy employed to clone LRRK2 cDNA. All 
fragments were TA cloned into the pGEMT easy vector. This was done to use the unique SacI site (— 
— ) in the poly-linker o f pGEIMT easy vector.
Once the cDNA was constructed in the pGEM-T easy vector (Figure 14), the cDNA was 
re-amplified using primer cDNAl forward and cDNA49 reverse (Table 8; LRRK2 cDNA 
PCR cycling conditions and cloning, pg 87) and ligated into the pCR®8/GW/TOPO 
vector (Invitrogen). Once positive clones were identified, the insert was sequenced 
(General DNA sequencing reaction, pg 55-56) for orientation (5’-3’) and for the presence 
o f additional mutations. After the identification of a correct clone, a series of 
mutagenesis reactions were performed using XL-site directed mutagenesis kit to remove 
the stop codon and introduce various mutations (Table 9). Clones with mutations were
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amplified, sequenced in their entirety and digested with EcoRI (NEB) to ensure that no 
additional mutations were created and no spurious recombination events had occurred.
M utation Fonward R avaraa
11122V GGAAATAAAATATCAGGGGTATGCTCCCCCTTGAG CTCAAGGGGGAGCATATCCCCGATATTTTATTTCC
R1441C TTCAATATAAAG GCTTGCGCTT CTTCTTCCC GGGAAGAAGAAGCGCAAGCCTTTATATTGAA
Y1000C TATATGAAAT GCCTTO1 1' I'ICCAATGG GATT AATCCCATTGGAAAACAAGGCATTTCATATA
G2019S AAG ATTGCTGACTACG GCATTGCTCAGTACT AGTACTGAGCAATGCTGTAGTCAGCAATCTT
020190 AAG ATTGCTGACTACG ACATTGCTC AGTACT AGTACTGAGCAATGTCGTAGTCAGCAATCTT
Q020T TTGCTGACTACGOCACTOCTCAGTACTGCTG CAGCAGTACTGAGCAGTOCCGTAGTCAGCAA
T2366I CAGTGATTCCAACATCATAATAGTGGTGGTAGACACTGC GCAGTGTCTACCACCACTATTATGATGTTG GAATCACTG
OCH2829LYS CGAACATCTGTTGAGAAAAAGGGCGAATTCGAC GTCGAATTCGCCC1 1I I IC ICAACAGATOTTCQ
Table 9: Prim er sequences used to create pathogenic mutations. In addition, the stop codon, for all 
constructs, was mutated to a lysine residue to allow the addition o f a C-terminal tag.
After construct verification, inserts were transferred to a series o f different destination 
vectors, to tag them at both the N and C-termini with either GFP or V5, using the 
Gateway LR clonase reaction (Invitrogen) using the manufacturer’s protocol. Mutations 
(Table 9) were also created on a ‘kinase dead’ background in which three critical residues 
within the kinase domain had been mutated to theoretically make a non-functional kinase 
(K1906A, D 1994A and D2017A).
Mammalian cell expression o f LRRK2:
For mammalian cell transfection, prepare full length LRRK2 using the Endofree maxi kit 
(Qiagen). Modifications to manufacturer’s protocols are as follows. Treat LRRK2 
plasmids as low copy plasmids:
1) Grow plasmids in a overnight culture volume o f 300ml
2) After the protein precipitation step, spin lysates at 4500*g for 10 mins prior to 
loading onto QiaFilter cartridge.
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3) Warm DNA elution buffer to 55°C prior to DNA elution 
Measure the DNA concentration and purity. Only use plasmids with an A /A above 
1.8 for transfections.
Mammalian cell transfections
Mammalian cell transfections were carried out in COS-7, HEK and SY5Y cells. Cells 
were maintained in Opti-MEM I (Invitrogen) supplemented with 10% fetal bovine serum 
and grown with 5% CO2 . Transfections were performed using Fugene transfection 
reagent (Roche).
Plate cells at lxlO 6 cells per 10cm2 cell culture dish in serum containing media. The 
following day, replace media with serum free media and transfect as per manufacturer’s 
recommendations. The ratio o f transfection agent to DNA to use is 3:1. Add transfection 
agent/DNA mix to the cells and replace the media the following day, with serum 
containing media. Harvest cells 48hrs post transfection to run on SDS page and western 
blot.
Protein Extraction from mammalian cells:
Solutions:
Wash Buffer 
TBS (used ice cold)
• 137mM NaCl 8g/litre
• 2.7mM KC1 0.2g/litre
• 25mM Tris Base 3g/litre
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Extraction Buffer:
•  lOmM Tris.HCl pH 7.4; 2% SDS; Protease Inhibitor 
Method:
1. Wash each cell line twice with 4ml o f cold wash buffer.
2. Add 1ml wash buffer and scrape cells from flask into microfuge tube.
3. Pellet 5000g, 5min 4°C.
4. Resuspend pellet in 50pl o f extraction buffer and sonicate lOsec (1 second pulses).
5. Store at -80°C following the removal o f an aliquot for BCA protein assay (PIERCE) 
as per manufacturer’s protocol.
Western blot protocol:
Solutions for western blotting:
• Tris-Glycine SDS sample buffer Laemelli (2x). Add 5% (v/v) p-mercaptoethanol 
(Sigma) to an aliquot immediately before use.
• Tris-Glycine SDS running buffer: dilute 1:10 from stock (Biosource)
• 1 Ox transfer buffer: 100 mM CAPS, pH 11.0: 22.13 g CAPS (Sigma) in approx.
800 ml water, pH to 11.0 with 1M NaOH, make up to 1 liter and store at 4°C.
• Transfer buffer: 10 mM CAPS (SIGMA), 10% methanol.
• TBS-Tween (TBS-T) (20 mM Tris.HCl, pH 7.6, 137 mM NaCl, 0.1% Tween).
Dilute lOx TBS (Biosource) and add lmL Tween 20 (Sigma) per liter.
•  Block buffer: 5% dried skimmed milk powder in TBS-T
• ECL + reagents (Amersham)
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Method for Western blotting:
1. Mix protein extracts in a ratio o f 1:2 with 2x sample buffer (plus (3- 
mercaptoethanol) and heat 65°C, 15 mins (or 90°C, 5 mins).
2. Assemble sufficient 4-20% Tris-glycine gel(s) (Biorad Ready Gels) in lx  
Running buffer.
3. Load lOpg total protein per lane. Load stained biotinylated markers.
4. Run gel(s) at 120V constant till sufficient separation o f ladder and loading dye 
front has migrated out o f the gel.
5. Towards the end o f the gel run: pre-wet PVDF membrane (Millipore, Immobilon 
P) with methanol (~30s), then water (~2 min) then lx  Transfer buffer. Soak two 
pieces o f filter paper per gel in lx  transfer buffer. Once the gel has run, also soak 
this in lx  transfer buffer for approx 5 min.
6. Assemble the transfer stack with the membrane towards the positive electrode.
7. Transfer overnight at 30V.
8. Remove membrane from transfer tank. Rinse in TBST once.
9. Block in block buffer - lh.
10. Primary antibody: Appropriate antibody (generally 1:2000) in block buffer for 
lhr.
11. Wash TBST, 3x5 min.
12. Appropriate secondary antibody: anti-mouse Ig, HRP conjugated (Jackson labs)
1:5000 in block buffer. Also incubate markers with Streptactin (BioRad) 1:1500 
in TBST. lh at room temperature.
13. Wash TBST, 3x5 min.
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14. Mix ECL+ reagents 1+2 together according to product insert (Amersham). 
Incubate blot in this 5 min.
15. Expose blot to BIOMAX film (KODAK) for appropriate amount o f  time. 
Develop film in the automatic developer.
Preparation o f Primary Rat Cortical Neurons
Solutions for the preparation o f primary rat cortical neurons:
Papain solution
• 250pl o f 0.1 % DNAase (Worthington Biochemical Corp)
• 500pl o f EBSS (Sigma)
• Papain (Worthington -  199 units)
STOP solution
• 250pl o f 0.1 % DNAase (Worthington)
• 0.6mg o f Papain Inhibitor (Worthington)
• 5.4ml o f EBSS (Sigma)
10/10
• 10ml EBSS (Sigma)
• O.lg BSA (Sigma)
• O.lg Trypsin Inhibitor (Sigma)
Modified neurobasal Media
• Neurobasal Media (Invitrogen)
• 10ml 200mM stock Glutamine (Sigma)
• 10ml B27 (Invitrogen)
• Filter sterilize media
Method for the preparation o f primary rat cortical neurons:
Dissected rat brain from E l8 pups was kindly provided to us by Dr. Kesavapany.
1. Coat plates/coverslips (22mm) with poly-L-lysine (Sigma, 2mg/ml) either at room 
temp overnight or in 37 °C incubator for 1-2 hours.
2. Wash with distilled water and leave to dry
3. Place cortex in papain solution and triturate with 5ml pipettes 10 times. Incubate 
solution for 40 minutes at 37°C with mixing every 10 minutes
4. Triturate the sample a further 10 times with a 5ml pipette
5. Centrifuge for 5 minutes at lOOOrpm
6. Remove supernatant and discard
7. Add 3ml o f STOP solution and triturate a further 2-3 times. Incubate at room 
temp for a further 10 minutes
8. Gently pipette supernatant into 10/10 solution
9. Centrifuge at 800rpm for 10 minutes
10. Add modified neurobasal media and count cells.
11. Plate 5x105 neurons per 22mm coverslip
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Transfection o f Primary Rat cortical neurons
Allow neurons to attach to cover slips and recover for 3 days before proceeding to 
transfection. On the third day, remove neurobasal media from neurons (conditioned 
media) and store at 37 °C. Add fresh modified neurobasal media. Add DNA to 
Lipofectamine 2000 (Invitrogen) as per manufacturers’ instructions. Add 
DNA/Lipofectamine complex to neurons for 6 hours before replacing with conditioned 
media. Fix cells after 72 hours.
Immunocvtochemistrv o f mammalian cells and rat primary cortical neurons 
Solutions:
•PFA recipe: Heat 50 ml distilled water in a fume cupboard to about 50°C. Add 
4g paraformaldehyde with stirring. As it stirs in, add a few drops o f 1M NaOH 
until the solution clears. Remove from the heat and allow to cool. Add 10 ml o f 
lOx PBS. Check the pH (should be 7.2 -  7.4, adjust with HC1 if needed) and 
make up to 100 ml with water. Store at 4°C for up to a week. Before use, allow 
to come up to room temperature.
Method:
1. Fix with 4% PFA in PBS, pH 7.2 -7 .4  for 30min RT
2. Wash out excess fixative with PBS (3 times)
3. Permeabilize with 0.1% (w/v) saponin in PBS, 10 minutes
4. Quench excess fixative by incubating with 0.1M Glycine in PBS, 20 min, RT
5. Block buffer with 5% FCS, 5% Goat serum in PBS lhr
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6 . Primary antibody; Monoclonal antibody/s 1:200 (Anti-GFP or Anti-MYC -  
ROCHE) and/or Rabbit polyclonal anti-pl39 TAU - O/N 4°C.
7. Wash cells with PBS, 3x5 minutes
8. 2° antibody e.g., Goat anti-mouse IgG/AlexaFluor 568 or Goat anti-rabbit 
IgG/AlexaFluor 488, 1:200 in block buffer, Ih RT
9. Wash cells with PBS, 3x5 minutes and counterstained with lpM  T 0-PR 03 
(Molecular Probes).
10. Mount under ProLong antifade kit (Molecular probes)
11. Slides examined using a Zeiss LSM510 META confocal microscope
Confirmation o f LRRK2 self interaction:
From yeast two hybrid results, LRRK2 was also able to bind to itself. Differentially 
tagged versions o f LRRK2 were co-transfected into COS-7 cells and immunoprecipitated 
(Co-immunoprecipitation protocol, pg 149-153) to determine if LRRK2 could bind to 
itself in mammalian cells.
RESULTS
Cloning and mammalian cell expression o f  LRRK2 cDNA:
At the onset o f this study, LRRK2 was only a predicted gene with short cDNA expression 
clones as evidence. To confirm and construct the full transcript length o f LRRK2, 
several overlapping fragments were amplified from brain cDNA. Sequencing o f the 
cDNA fragments yielded a transcript with an open reading frame o f 7584bp encoding a
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2527 amino acid protein (Figure 15). One deviation in the LRRK2 amino acid sequence 
from (XP-935913) was found at position 150bp (A50H). This nonsynonomous change is 
a reported polymorphism (db SNP accession no. rs2256408) so was therefore not altered.
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Figure 15: PCR products of overlapping fragments for LRRK2. Table 7 shows primer sequences 
used for each amplicon.
The complete LRRK2 cDNA was cloned into several gateway entry vectors, various 
mutations were created (Figure 14, Table 9) and subsequently transferred into 
mammalian expression plasmids with a GFP or V5 tag either at the N or C - terminus. 
Verified constructs were transiently transfected into COS7, HEK 293 and SY5Y cells 
(Figure 16; data not shown for HEK and SY5Y cells) and analyzed by western blotting 
using antibodies directed against the appropriate tag.
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Figure 16: Expression of differentially tagged versions of LRRK2 extracted from COS7 mammalian 
cells. Panel A) N-terminal GFP, B) C-terminal GFP, C) C-terminal V5, D) N-terminal GFP and E) C- 
terminal GFP. Abbreviation: KD- kinase dead.
All forms of tagged LRRK2 (GFP or V5; Figure 16), either N or C-terminal tagged, 
produced a single band of approximately 280KDa (V5 tagged) or 300kDa (GFP-tagged).
Localization of LRRK2
To determine the cellular localization o f LRRK2, COS7 cells were transiently transfected 
with LRRK2 (mutant, wild type and the appropriate kinase dead) tagged with either GFP 
or V5 at the N or C terminus. Transfected cells were fixed, stained and imaged using 
confocal microscopy. Preliminary analysis of LRRK2 localization in COS7 cells 
suggested the protein was primarily cytoplasmic (Figure 17 and 18; Data not shown for C 
tagged GFP-LRRK2 and N tagged V5-LRRK2). There was no discernable difference in 
localization between N and C tagged forms of wild type or mutant forms o f LRRK2, and 
differentially tagged versions of LRRK2 (GFP or V5).
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I1122YLRHK2 R1441C LRRK2 Y1699C LRRK2 G2019S LRKK2
IU22V KINASE R144LC KINASE Y1SS9C KINASE G2QI9DLRRK2
DEADLBBK2 DEAD LRRK2 DEAD IRRK2 DEAD LRRK2
Figure 17: Immuno-staining o f COS7 cells transfected with N-terminal GFP tagged LRRK2. Cells 
were stained with mouse anti-GFP and secondary goat anti mouse IgG AlexaFluor 488. Cells were 
fixed and analyzed with confocal microscopy. Mutant forms of LRRK2, notably R1441C and 
Y1699C, formed perinuclear inclusion bodies indicated by white arrows. Magnification x63.
WILD IYEE LRRK2 II122YLRRK2 R1441C LHRK2 Y1699C LRRK2
H
WILD TYPE H 8 t H  I1122V KINASE B1441C KINASE Y1S99C KINASE G2019D LRRK2
DEADLRBK2 DEADLRRK2 DEADLKRK2 DEAD LRRK2
Figure 18: Immunostaining of COS7 cells transfected with C-terminal V5 tagged LRRK2. Cells were 
fixed and stained with mouse anti aGFP and goat anti mouse IgG AlexaFluor 488. Cells were 
analyzed with confocal microscopy. Mutant forms of LRRK2 formed perinuclear inclusion bodies 
indicated by white arrows. Magnification x63
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However, mutant versions o f LRRK2 formed perinuclear inclusions at a significantly 
greater rate than wild type (Figure 17 and 18, white arrows). Some mutations were more 
dramatic in their ability to form inclusion bodies. For example, R 1441C and Y1699C 
formed larger inclusion bodies whereas G2019S and G2019D formed fewer and smaller 
aggregates. To determine if  inclusion body formation required the kinase activity o f 
LRRK2, cells were transfected with the corresponding kinase dead mutant. Kinase-dead 
versions o f the protein formed significantly fewer inclusion bodies than mutant ‘kinase 
active’ forms.
Next we wished to determine if  LRRK2 mutant aggregate formation was unique to 
overexpression in COS7 cells or a general property o f the protein. The LRRK2 
constructs were transfected into HEK 293, SY5Y and primary rat neurons (Figure 19 and 
20).
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Figure 19: Primary rat E18 rat cortical neurons transfected with N-terminus Myc tagged LRRK2. Cells were stained with mouse-aGFP, rabbit- 
phospho TAU and counterstained for nuclei using DAPI. Secondary antibodies used were anti-mouse AlexaFluor 488 (green) and anti-rabbit 
AlexaFluor 568 (red). (A-D) Wild type LRRK2; (E-H) R1441C LRRK2; (I-L) Y1699C LRRK2. Upper left of each quadrant (A, E, I) shows DAPI 
staining o f nuclei. The upper right o f each quadrant shows (C, G, K) shows staining for phospho-TAU. Bottom left of each quadrant (B, F, and J) is 
the staining for LRRK2. Bottom left o f each quadrant (D, H, and L) is the merged version of the three channels. LRRK2 inclusion bodies are indicated 
by white arrows (F, J). Magnification x63.
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Figure 20: Primary E18 rat cortical neurons transfected with N-terminus Myc tagged LRRK2 kinase dead constructs. Cells were stained for with 
mouse-anti GFP, rabbit anti-phospho TAU and DAPI for DNA. Secondary antibodies used Ig anti-mouse AlexaFluor 488, anti-rabbit AlexaFluor 568. 
(A-D) Wild type kinase dead LRRK2; (E-H) R1441C kinase dead LRRK2; (I-L) Y1699C kinase dead LRRK2. Upper left o f each quadrant (A, E, I) 
shows DAPI staining o f individual nuclei. The Upper right o f each quadrant shows (C, G, K) shows staining for phospho-TAU. Bottom left of each 
quadrant (B, F, and J) is the staining for LRRK2. Bottom left of each quadrant (D, H, and L) is the merge o f all three images. Magnification x63.
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Primary rat cortical neurons were transfected and stained for MYC-LRRK2 and the 
neuronal marker protein, TAU and analyzed by confocal microscopy (Figures 19 and 20). 
Mutant forms o f the protein formed significantly greater number o f inclusion bodies 
compared to wild type LRRK2, which was distributed throughout the cytoplasm and 
along neuronal processes. Quantification and characterization o f the aggregates’ formed 
by LRRK2 were carried out by Dr. Greggio as reported elsewhere (See Manuscripts 
published during thesis; Greggio et al, 2005)409.
Self interaction o f LRRK2
A yeast two hybrid was performed to identify potential protein interactors o f LRRK2 
(Chapter 4). A region encompassing LRRK2 RAS domain, bound to three different 
regions o f LRRK.2 (18-186aa, 1123-1200aa and 2084-2217aa). To validate the self 
interaction, differentially tagged versions o f LRRK2 were transfected into mammalian 
cells and immunoprecipitated. DJ-1 was used as a non-specific control for LRRK2 self
191 910interactions, as numerous studies have been undertaken to identify DJ-1 interactors ’ ’
211,229,231 a n c j none studies have identified LRRK2 as an interactor. 
Immunoprecipitation o f V5-LRRK2 followed by GFP blotting, detected the presence o f 
GFP-LRRK2 (Figure 21; Lanes 1 and 2). The converse was also true (Figure 21; Lane 3 
and 4). V5 or GFP-LRRK2 did not precipitate in absence o f the other (lane 5-8) and 
GFP-LRRK2 did not precipitate in the presence o f DJ-1 (Figure 21; 9-12).
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Figure 21: Self interaction of LRRK2. Precipitations were performed as described on pgl51-153. 
Lysis and Wash conditions: 50mM Tris pH7.5, 5mM EDTA, 150mM NaCl, 0.25% NP-40, protease 
cocktail inhibitor (Roche) and HALT (PIERCE). Monoclonal GFP (Roche) and monoclonal V5 
(Invitrogen) were used. Precipitation of V5 or GFP tagged LRRK2 resulted in the 
immunoprecipitation of either GFP or V5 tagged LRRK2 respectively (Lane 1-4). LRRK2 did not 
precipitate when transfected in alone (Lane 5-8) or in the presence o f V5-DJ-1 (Lane 9-12) 
demonstrating there is no non-specific binding of LRRK2 to either the antibody or the protein 
agarose. Abbreviations: IN-lnput; IP-immunoprecipitation.
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DISCUSSION
Preliminary analysis o f the LRRK2 gene products, indicate it is a 2527aa protein which is 
expressed as a single band o f approximately 280KDa (V5 tagged) or 300kDa (GFP- 
tagged). Localization o f LRRK2 in mammalian cells suggests it is primarily a 
cytoplasmic protein. This is consistent with in silico analysis o f the protein sequence, 
which did not reveal any targeting signals for specific subcellular organelles 400’410. This 
finding is also consistent with other recent results 411, 412, although subcellular 
fractionation have suggested LRRK2 is associated with the cell membranes 41,’413’4,4? jn 
particular the outer mitochondrial membrane. This discovery is intriguing as other 
proteins implicated in PD (DJ-1 and PINK1) suggest a role for mitochondrial dysfunction 
in PD pathogenesis. Further studies o f LRRK2, using suitable specific antibodies that 
can detect endogenous levels, are needed before a definitive statement can be made about 
subcellular localization.
Compared to wild type LRRK2, transient transfections o f mutant versions did not change 
its localization, but did form perinuclear inclusions at a significantly higher frequency 
than wild type protein 409' 415. This finding was subsequently replicated in a number o f 
different cell types (HEK293, SY5Y and primary rat cortical neurons) suggesting it is not 
an artifact associated with over-expression in COS7 cells. As mutations within LRRK2 
have been shown to increase kinase activity 409’4,14l4’4,6> ft was hypothesized that kinase 
activity was required for the formation o f inclusion bodies. Thus ‘kinase dead’ 244 
versions o f wild type and mutant LRRK2 were created by replacing the lysine residue 
that orients the gamma-phosphate o f ATP (K1906A), the active site aspartate (D1994A) 
and the aspartate that chelates divalent metal cations (D2017A) with alanine. Compared
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to mutant versions o f LRRK2, the ‘kinase dead’ versions o f the mutants formed inclusion 
bodies at a significantly lower rate 409.
In support o f LRRK2 being able to form aggregates, the ROC domain o f LRRK2 bound 
to several regions o f LRRK2 (the N-terminus-18-186aa, the LRR dom ain-1123-1200aa 
and the WD40 domain-2084-2217aa) in a yeast two hybrid screen (Chapter 4). This 
interaction was subsequently re-created in mammalian cells and replicated by two other 
groups 414, 417. It has been suggested that homo-dimerization may be necessary for the 
function and/or activation o f LRRK2 414. Other proteins similar to LRRK2, such as 
DAP-kinase, MLK-3 or Raf-1 399’400’406’418i require homodimerization for their function 
419. It remains to be seen if  endogenous LRRK2 naturally exists as a dimer and whether 
this is relevant to the apparent tendency o f the protein to form inclusion bodies, as is the 
case for a-synuclein l33, 420,421. Numerous methods can be employed to determine if 
LRRK2 can form higher order structures 422 such as analysis on non-denaturing western 
gels 423, various techniques based on light scattering 424,425 or chromatography (e.g. gel 
filtration chromatography or fast protein liquid chromatography) 425.
As mutations within LRRK2 increase the formation o f inclusion bodies, one might expect 
individuals with LRRK2 mutations to have LBs that are immunopositive for LRRK2. 
Very recently, LRRK2-positive dystrophic neurites were seen in nigral neurons from a 
G2019S mutation case 426. In idiopathic PD cases, LRRK2 was seen in the cytoplasm o f 
the cell bodies and neuronal processes but also stained the halo o f 10-15% o f LBs 409. 
LRRK2 has subsequently been shown to be a component o f LBs with some antibodies 
427"429, although not all antibodies may specifically recognize LRRK2. There is, 
therefore, some in vivo evidence that LRRK2 can accumulate and form aggregates in
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both familial and sporadic cases o f PD. Additional studies are needed to determine if 
mutation o f LRRK2 increases its propensity to aggregate by affecting its stability and/or 
degradation.
In addition to increasing the aggregation properties o f LRRK2, mutant versions o f 
LRRK2 are significantly more toxic to cells and primary neurons than wild type LRRK2 
409, 412, 415,416  Furthermore, the toxic effects o f LRRK2 are associated with the kinase 
activity o f LRRK2. Increasing the kinase activity o f LRRK2 by introducing pathogenic 
mutations (Y1699C, G2019S) 409, 411 results in increased toxicity. The converse is also 
true; decreasing or abolishing kinase activity results in the loss o f the toxic affects o f 
mutant LRRK2 409’416, Thus mutations within LRRK2 may lead to neuronal loss via an 
increase o f kinase activity. The caveat with the studies to date is that the assays for 
kinase activity, autophosphorylation o f LRRK2 in vitro, may not reflect a physiological 
activity and are therefore a limited measure o f activity 409, 4 1 412, 414. A more 
physiological relevant substrate is required to determine if mutations within LRRK2 
increase or affect its kinase activity.
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CHAPTER 5: IDENTIFICATION OF PROTEIN
INTERACTORS FOR LRRK2
INTRODUCTION
LRRK2 encodes a 2527 amino acid protein of unknown function but with multiple 
domains, as discussed in chapter 3. Sequence analysis indicates that LRRK2 is 
comprised of two enzymatic domains and several protein-protein interaction domains 
(Figure 22).
N-TERMINUS LRR ROC COR KINASE WD40
HEAT/ARM  REPEATS L R R  REPEATS KINASE D O M A IN  WD40 DOM AIN
Figure 22: The predicted domains within LRRK2; the N-terminus containing HEAT/ARM repeats, 
LRR domain, ROC domain, COR domain, kinase domain and WD40 domain. The images below 
each domain are the predicted structures of that domain. These images were kindly provided by Dr. 
Jinhui Ding.
The predicted structure of the N-terminal region of LRRK2 (approximately 900aa) is not 
clearly defined. This region contains potential ARM repeats (residues 180-660) and 
ankyrin repeats (residues 690-860) 418 although some analyses suggest that this region is
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similar to the HEAT repeats 400 which are unique to LRRK2. ARM and HEAT repeats 
are similar 401,430 apart from the number o f  helices p resen t401. Therefore, although the 
N-terminus has repeat units, there are questions about which exact motifs are present and 
how these are structured. Both ARM/HEAT repeats are involved in mediating protein- 
protein interactions, including those involved in nuclear transport, vacuolar transport, 
translation, and cytoskeleton organization, suggesting a range o f potential roles for this 
region 400’418’430.
The LRR m otif family, consist o f 2-42 motifs o f 20-30 amino acids in length 431 and are 
found in a variety o f cytoplasmic, membrane and extracellular proteins. LRRK2 is 
predicted to contain 13 LRRs and based on structural modeling, folds into a horseshoe (or 
arc) shape with parallel p-strands followed by an a-helix 432. Although proteins 
containing LRRs are associated with widely divergent functions, including signal 
transduction, cell adhesion and apoptosis 430'432, a common function shared for all of 
them is that they appear to provide a structural framework for the formation o f protein-
400 431 432protein interaction ’ ’
The putative ROC GTPase domain o f LRRK2 belongs to the ROCO family 3" ,  in which 
the predicted GTPase (Roc) is always found in conjunction with a COR domain, the 
function o f which is unknown. GTPases act as switches within the cell, cycling between 
GTP-bound (generally active conformation) and GDP-bound (inactive conformation) 
forms. GTPases are involved in a variety o f cellular processes including vesicular 
trafficking and transport 433'435.
The kinase domain o f LRRK2 was initially identified as part o f the kinome p ro jec t3%, 
and is predicted to be a mitogen-activated protein kinase kinase (MAPKKK) 400’418. This
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signaling cascade activates a downstream MAP kinase kinase via activation-loop 
phosphorylation. Substrates o f activated MAPKs are involved in a diverse range o f 
functions such as transcription, mitochondria protein and cellular trafficking 436.
The C-terminus o f LRRK2 contains a potential WD40 domain. WD40 domains have 
been identified in diverse proteins such as transcriptional regulators, RNA processing 
complexes and proteins involved in vesicle formation and trafficking proteins 399’400’418’ 
437. Each WD40 repeat contains a four-stranded, antiparallel p-pleated sheet and, 
together, these repeats form a circular bladed propeller-like structure. The predicted 
WD40 domain o f LRRK2 comprises seven such repeats. This seven-bladed propeller is 
thought to form a rigid platform for reversibly interacting with proteins, possibly 
including those that contain other WD40 domains 437,438.
As these motifs are involved in numerous and diverse functions, a yeast two hybrid 
screen was undertaken to identify binding partners o f LRRK2, to help elucidate the 
normal function o f LRRK2.
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MATERIALS AND METHODS
The yeast two hybrid systems was initially created 439 using the GAL4 protein which is 
comprised o f two domains: the DNA binding domain and the activation domain. Without 
either o f these domains, GAL4 protein is unable to bind to its consensus sequence and 
activate gene transcription. The bait protein, for which interactors are to be found, is 
fused to the DNA binding domain o f the GAL4 protein. A library o f  proteins is fused to 
the activation domain and are referred to as the prey proteins. When the bait and prey 
protein interact, the DNA binding domain and the activation domain o f the GAL4 protein 
are brought in close proximity and are able to activate the transcription o f genes 
containing the GAL4 consensus sequence (Figure 23). Commonly used selection 
markers are auxotrophic mutants (histidine and adenine) and chromogenic mutants 
(LacZ). If the two proteins interact, these genes are transcribed and are able to grow on 
media lacking histidine and adenine. The p-galactosidase enzyme from the LacZ marker 
hydrolyzes X-gal to release a blue colored product, allowing for further selection of 
positively interacting proteins. The overall method used for the yeast two hybrid is 
displayed in figure 24.
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Figure 23: Schematic representation o f a yeast two hybrid screen for protein-protein interactions. 
Only if the bait and prey protein interact can the DNA binding domain and activation domain be 
brought into close proximity and activate transcription of the various selection genes. Yeast that are 
able to grow on nutrient deficient media and are able to catalyze the break down of X-gal into a blue 
color are indicative o f a positive interaction.
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(due to multiple plasm ids still within the  yeast) they were 
transform ed into E-coli and PC R  sc re en e d  to identify all p lasm ids 
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Figure 24: General Methodology followed for yeast two hybrid assay of LRRK2. Regions indicated 
by red lines under the ideogram of LRRK2 were cloned into yeast expression vector, pGBKT7. 
Protein expression of individual constructs was verified and auto-activation in yeast was excluded for 
each construct. All constructs were screened against a human brain cDNA library. Yeast able to 
grow on nutrient deficient media and catalyze the break down of X-gal, were re-streaked several 
times. Prey constructs were subsequently isolated and sequenced.
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Cloning LRRK2 cDNA for veast constructs for veast two hybrid assays:
Fragments o f LRRK2 cDNA representative o f its predicted functional domains were 
amplified (Table 10), and subsequently cloned into pGBKT7 (Clontech).
Primer Name Primer Sequence (5'-3') Primer Sequence (3'-5')
N-TERMNUS AAAAAACATATGGAAGTT GATAGTCAGGCTGAAC AAAAAAGTCGACGCCTCCTTAAGAGCAAGCTGAT
LRR AAAAAACATATGTCCTGACTCTTCTATGGACAGTG AAAAAAGTCGACGCAACGCTGTAATACGGCATC
RAS AAAAAACATATGCTGACATCTCTGGATGTCAG AAAAAAGTCGACCATGCAGGCTTTGCGTTGCTT
ARM AAAAAACATATGTATGACGCAGCGAGCATTGTAC AAAAAAGTCGACAATGGTGAGCCTTGGTTGATC
KINASE AAAAAACATAT GTGACCTGCCT AGAAATATTAT GTTG AAAAAAGTCGACCCCAGACACAATCCAGCTTTCCTT
m o AAAAAACATATGTGGAGGTAGAATAGTAGAGGG AAAAAAGTCGACCTTACTCAACAGATGTTCGTCTC
Table 10: Primer sequences used to am plify the domains of LRRK2 and clone them into the yeast 
expression vector pGBKT7
Products were amplified using Pfu turbo polymerase (Promega). All annealing 
temperatures during PCR cycling were set to 60°C with extension times adjusted to 
match the PCR product size (lkb/m in). All products were cloned into the yeast 
expression vector, pGBKT7 (Clontech). Clones were sequenced (Sequencing protocol -  
pg 55-56) to ensure that no mutations were present and to ensure that all cDNAs were in 
frame with the protein tag (N-MYC) and GAL4 DNA binding domain (DB).
Correct clones (bait vectors) were subsequently transformed into yeast to test for 
autoactivation o f selection markers and protein expression by western blotting using 
antibodies directed against the MYC tag (Western Blot Protocol, pg 93-95).
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Transformation o f Yeast (AH 109 and Y187)
Solutions: 
lx  TE/LiAc recipe
• 1.10.2 g L iA c.2H 20
• 2. 1 ml 1M Tris-HCl stock solution
•  3. 1 ml 0.1 M EDTA stock solution + 88 mL distilled water.
• 4. 80 ml distilled water; adjust pH to 7.5 with acetic acid; adjust volume to 
100 ml with distilled water
50% PEG stock solution
• 100 g polyethylene glycol 4000; adjust to 200 ml with distilled water.
40% PEG/LiAc Solution 
For 50ml
• 40ml o f 50% PEG
• 10ml o f 1 x TE/LiAc solution
YPD medium
• 20g/L Difco peptone
• lOg/L Yeast Extract
• 20g/L Agar
•  15ml/L 0.2% adenine hemisulfate
• Adjust pH to 6.5 and autoclave.
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• After cooling to 55 °C, add 50ml/L o f sterile 40% stock solution
•  Add Kanamycin to final concentration o f 10-15mg/L
• Make up volume to 1L
SD dropout media
• 6.7g/L yeast nitrogen base without amino acids
• 20g/L Agar (for plates only)
• 850ml o f water
• 100ml o f appropriate sterile 10X Dropout solution (e.g. -TRP, -LEU, -
TRP/-LEU, -LEU/-TRP/-ADE/-HIS) -  recipe and protocol for 10X 
dropout solution (Clontech, Protocol #PT3024-1, pg 55).
Method:
1. Inoculate 1ml YPDA with 2-3mm colonies. Vortex
2. Incubate at 30°C for 16-18 hr with shaking (250rpm) to stationery phase 
(OD6oo> 1.5) in 50ml o f YPDA
3. Transfer overnight culture into 300ml o f YPDA (OD600 = 0.2 -  0.3). Incubate 
for a further 3 hrs (OD6oo<1)
4. Collect cells by centrifugation at lOOOxg for 5mins at room temperature
5. Remove supernatant and re-suspend in sterile TE
6. Pool cells and centrifuge at lOOOxg for 5min at room temperature
7. Remove supernatant
8. Resuspend in 1.5ml o f sterile lx  TE/LiAC
9. Add 0.1 ug o f plasmid and 0.1 mg o f sonicated salmon sperm
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10. Add 0.1ml o f yeast competent cells and mix well by vortexing
11. Add 0.6ml o f freshly prepared PEG/LiAC solution
12. Incubate at 30°C for 30min with shaking (200rpm)
13. Add 70ul o f DMSO. Mix by gentle inversion
14. Heat shock at 42°C for 15min.
15. Chill cells on ice l-2min
16. Centrifuge cells at 14k rpm for 5secs at room temperature.
17. Remove supernatant
18. Re-suspend cells in 500pl o f lxTE
19. Plate on the appropriate drop-out media
Verification o f LRRK.2 veast protein expression and suitability as bait proteins 
To determine if the constructs were expressing the bait proteins, protein was extracted as 
per Clontech’s instruction manual (Protocol # PT3024-1, Version # PR13103, Pg 12-13). 
Proteins were run on SDS polyacrylamide gels (Western blot protocol, pg 93-95) and 
immuno-blotted with anti-MYC antibody (Clone 9E10, Roche Molecular Biology).
All bait vectors were tested for autoactivation o f different selection markers (-LEU, -
TRP, -ADE, -HIS, X-GAL). Yeast containing the various LRRK2 bait constructs and the
control prey (pGADT7 -  encoding the T-antigen) were mated (Protocol # PT3024-1, 
Version # PR13103, Pg 44) and plated onto the following selection medias (Protocol # 
PT3024-1, Version # PR 13103, Pg 21 Table VI):
1. -LEUCINE (-LEU) -  selects for prey vector (pGADT7)
2. -TRYPTOPHAN(-TRP) -  selects for bait vector (pGBKT7)
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3. -LEUCINE/-TYRPTOPHAN(-LEU/-TRP) -  selects for prey and bait vectors
4. -LEUCINE/-TRYPTOPHAN/-HISTIDINE/-ADENINE (-4aa) -  selects for 
protein interaction
All plates were incubated for a total o f  2 weeks to detect auto-activation o f selection 
markers including X-gal (Protocol # PT3024-1, Version # PR13103, Pg 25).
Library screening with LRRK2 bait constructs
Matings between LRRK2 constructs and pretransformed human brain cDNA libraries 
were performed as per manufacturer’s recommendations (Clontech, protocol manual 
PT3183-1 pg 37-44). Mating mixtures was plated directly onto quadruple drop out media 
-LEU/-TRP/-ADE/-HIS. After three weeks, colonies were re-streaked a minimum of 
three times onto fresh quadruple drop out media, to aid in plasmid segregation (loss o f 
non-interacting plasmids). Colony lift filter assays (Protocol # PT3024-1, Version # 
PR13103, Pg 25) were performed on final re-streak plates to test for expression o f p- 
galactosidase. Clones able to activate expression o f all selection markers were 
subsequently grown in quadruple drop out media for plasmid extraction.
Mating mixtures were also plated onto control plates, -LEU, -TRP and -LEU/-TRP to 
determine mating efficiencies and the number o f cDNA clones screened. Manufacturer’s 
protocol and calculations were followed (Protocol #PT3183-1 pg 32-33)
Plasmid Extraction from Yeast 
Method
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1. Pick single yeast colonies (2-3mm in diameter) and grow overnight at 30°C 
with shaking (230-250rpm) in quadruple (-LEU/-TRP/-ADE/-HIS) dropout 
media
2. Following day, pellet cells at 5K rpm for lOmins
3. Remove supernatant and resuspend in approx 200pl o f water.
4. Add lOOpl o f glass beads (Sigma) to each well or tube and vortex vigorously 
for 5 minutes.
5. Freeze (-20°C)/thaw samples twice. Between each freeze/thaw cycle, vortex 
samples vigorously for 5 minutes.
6. Add 200pl o f phenol:chloroform:isoamyl alcohol (25:24:1)
7. Vortex at high speed for 5 min
8. Spin tubes at 14K rpm for 5 mins. Spin 96 well plates at 5K rpm for 30 mins.
9. Transfer aqueous phase to new tube or plate
10. Add 8pl o f 10M ammonium acetate and 500(4.1 o f 100% ethanol.
11. Place tubes and plates at -80°C overnight
12. Centrifuge tubes at 14K rpm for lOmin at 4°C. Centrifuge plates at 5K rpm
for 1 hr at 4°C
13. Discard supernatant and resuspend pellets in 200pl o f 70% ethanol.
14. Centrifuge tubes at 14K rpm for lOmin at 4°C. Centrifuge plates at 5K rpm 
for 30min at 4°C.
15. Discard supernatant
16. Air dry and resuspend pellet in 20pl o f H2O.
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Amplification and sequencing o f  inserts in prey vector:
Plasmids extracted from yeast were amplified using (5’ and 3’ ADY insert PCR primers, 
Clontech) and run on 1% agarose gels. Plasmids were sequenced using T7 (5’-3’) 
primer. Plasmids were only sequenced in the forward direction as it was not possible to 
sequence through the polyA-tail. As re-streaking o f plasmids did not always remove all 
non-interacting plasmids, plasmids pools that did not sequence were transformed into 
XL-gold competent cells (Stratagene) and 10 bacterial colonies were picked to identify 
all plasmids within the original yeast colony. These were extracted using plasmid 
extraction kits (Qiagen) per manufacturer’s protocol and subsequently sequenced (DNA 
sequencing reaction, pg 55-56).
PCR cocktail and conditions for amplification o f inserts in prey vector:
Component Amount per reaction
Plasmid from yeast 2pl
Primer 1 (lOpM) lpl
Primer 2 (1 OpM) lpl
lOx PCR buffer 2.5pl
5x Q solution 5 pi
Qiagen Taq (5units/pl) 0.2pl
dNTPS (25mM each dNTP) 0.4pl (Final concentration o f each dNTP 200pM)
Distilled H2O 12.9pl (Total volume 25pl)
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PCR cycling conditions 
1 cycle: 95°C -  5min
35 cycles: 95 °C -  30 seconds
60 °C -  30 secs 
72°C -  2min 
1 cycle: 7 2 ° C - 5 m i n
1 cycle: 4 ° C - H O L D
PCR products were subsequently analyzed on 0.7% agarose (American Bioanalytical) 
gels in lxTAE.
Bioinformatics: Determination o f proteins encoded by prey vectors 
Once all sequences had been obtained, they were first blasted against the NCBI database 
(http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi). If there was no significant similarity to 
any known genes, the plasmid was not considered for further validation. If the sequence 
within the prey vector had significant similarity to a known gene, sequence within the 
prey vector was translated. The prey vector had to be in frame with the GAL4 DB and 
encode for at least 10 amino acids for further consideration. Having multiple 
independent clones for the same protein was considered additional evidence for a true 
interaction.
Confirmation o f interaction between LRRK2 and FEZ2.
O f the clones that were identified, the interaction between the N-terminus o f LRRK2 and 
FEZ2 (Fasciculation and elongation factor zeta 2) was chosen for further validation
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because multiple independent clones were identified for FEZ2, with yeast colonies 
containing the interacting proteins appearing during the first week post plating, indicating 
a relatively strong interaction.
The bait vector, encoding the N-terminus o f LRRK2, was retransformed into yeast strain 
AH 109 and the prey vector, encoding a portion o f FEZ2, was retransformed into yeast 
strain Y187 (Transformation o f yeast, pg 116-119). The prey vector was tested for auto­
activation, just as the initial bait vectors were (pg 120). Both yeast strains were 
subsequently mated and plated onto quadruple dropout media to re-test the phenotype 
(Clontech, protocol manual PT3183-1 pg 37-44). The FEZ2 construct isolated from the 
original yeast two hybrid was mated with the individual domains o f LRRK2. The prey 
vector encoding FEZ2 (pGADT7) and the bait vector encoding LRRK2 (PGBKT7) were 
swapped into the opposing vectors to ensure the interaction was not being driven by 
either o f the protein tags or GAL4 yeast protein sequences in conjunction with either 
FEZ2 or LRRK2.
Refinement o f interacting region between LRRK2 and FEZ2
In order to identify the key region o f interaction between LRRK2 and FEZ2, segments o f 
FEZ1, FEZ2 and the N-terminal region o f LRRK2 were amplified and cloned into the 
appropriate yeast expression (Table 11). The N-terminus o f LRRK2 was divided into 
eight equally sized fragments overlapping by approximately 250bp (Figure 25A). FEZ1 
and FEZ2 were divided into 5 fragments, harbouring different portions o f the N-terminus, 
coiled-coil domain and C-terminus (Figure 25B). To determine if LRRK2 specifically 
bound to FEZ2, a homolog o f FEZ2 was used, FEZ1.
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PRIMER NAME PRIMER SEQUENCE (FORWARD) PRIMER SEQUENCE (REVERSE)
NTERl AAAAAACATATGATGGCTAGTGGCAGCTGTCA AAAAAACATATGATGGCATCAAAAATTAACAT
NTER2 AAAAAACATATGGTGCAGCAGGTGGGTTGGTCAC AAAAAACATATGCACTCATAGGGAATGCTTTC
NTER3 AAAAAACATATGATGCACTCATTTCCAGCCAATG AAAAAACATATGAACAGGCTTCCAGCCAAAAC
NTER4 AAAAAACATATGTGCTGTTTGCTCCATAGGCT AAAAAACATATG1TCAGCCACTTCGGGAGAAT
NTER5 AAAAAACATATGTTGTnTGGCTGGAAGCCTGTT AAAAAACATATGTATCCTCCCTGGATTCTTCT
NTER6 AAAAAACATATGCAGGCATCTGCGAATGCATTGTCAAC AAAAAACATATGTCCATAGCACCTTCCAGGGA
NTER7 AAAAAACATATGCATGAGACATCATTACCAGTG AAAAAACATATGCACGCTCTCTCTAGCATCAC
NTER8 AAAAAACATATGGATCAACAGTITCTAAACCTCTG AAAAAACATATGAAnTCCATCGCTGCCTGAG
PRIMER NAME PRIMER SEQUENCE (FORWARD) PRIM ER SEQUENCE (REVERSE)
FEZ1NTERMMJS AAAAAACATATGATGGAGGCCCCACTGGTGAGTCTGGATGA AAAAAACATATGGGACCAGTTGTTGTTGAAGG
FEZ1C0ILED COH AAAAAACATATGTATGAAGGGCTGAGGCACAT AAAAAAC ATATG GCACCGTGATAAAGGAGTTC
FEZ1CTERMNUS AAAAAACATATCCTTATTGAGGTTCAGAACAAGCAGAAGGAG AAAAAACAIATGTTAGGTAGGGCAGAGCACT
FEZlcDNA AAAAAACATATGATGGAGGCCCCACTGGTGAG AAAAAACATATGTTAGGTAGGGCAGAGCACTT
FEZ2NTERMMS AAAAAACAIATGATGGCGGCGGACGGGGACTGGCAGGATITC AAAAAAGGATCCCCGGTACTAGACCTCTTGAG
FEZ2C0ILED COIL AAAAAACATATGAGGTCTAGTACCGGCAGTTAT AAAAAAG GATCCCATTCTTCCCATTCTGAGAG
FEZ2CTERMMJS AAAAAAGAATTCTCTCAGAATGGGAAGAATGAG AAAAAAGGATCCCTATGTAGGACACAGAACTTTCAG
FEZ2cDNA AAAAAAGAATICATGGCGGCGGACGGGGACTG AAAAAAG GAT CCAAGTTCTGTGTCCTACATAG
Table 11: Refinement o f interacting region between FEZ1, FEZ2 and LRRK2. FEZ1, FEZ2 and 
LRRK2 N-terminal (NTER) primer sequences used to create yeast constructs encoding different 
regions o f FEZ1 and FEZ2 and HEAT domain. PCR fragments were digested and cloned into the 
appropriate yeast expression vector.
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N-TERMINAL REGION
499bp-167aa______ 1060b p-353aa
8 1 1bp-271aa 1380bp-460aa
1039bp-347M______ 1570bp-523aa
1246bp-416aa 1760bp-586aa
14 8 0 b p -4 9 4 a a _ 2 1 5 0 b p -7 16aa
2062bp-688aa 2590bp-863aa
B)
1bp-1aa
FEZ1 CONSTRUCTS
1179bp-393aa 1bp-1aa
FEZ? CONSTRUCTS
1143bp-381aa
N-terminus Colled Coil C-terminus 
Domain
N-terminus Coiled Coil C-terminus 
Domain
1bp-1aa
1bp-1aa
660bp-220aa 1bp-1aa 620bp-207aa
661 bp-221 aa
------
1bp-1aa
607bp-203aa 820bp-293aa
1179bp-393aa
820bp-273aa 1179bp-393aa
607bp-203aa 1143bp-381aa
863bp-288aa 1143bp-381aa
1bp-1aa 1179bp-393aa 1bp-1aa 1143bp-381aa
Figure 25: Ideogram of constructs created to refine the interacting region between LRRK2 and 
FEZ1/2. A) The N-terminal region o f LRRK2 (H1-H8) was divided into 8 overlapping fragments. 
B) Various FEZ I and FEZ2 constructs were made, containing combinations of the N-terminus, coiled 
coil region and the c-terminus of each protein. Constructs were sequence verified and tested for 
auto-activation of selection markers and for protein expression.
126
FEZ1 and FEZ2 fragments were cloned into pGATDT7 and LRRK2 N-terminal 
fragments were cloned into pGBKT7. Clones were sequenced to ensure there were no 
mutations and the cDNA was in frame with the protein tag (MYC or HA) and Gal4 
sequences. Protein expression o f each construct was verified via western blot. 
Constructs were tested for auto-activation by mating with a control vector (pGADT7 prey 
vectors were mated with pGBKT-p53; pGBKT7 bait vectors were mated with pGADT7- 
T antigen), plating onto quadruple dropout media and performing a P-galactosidase 
colony lift assay (Protocol # PT3024-1, Version # PR13103, Pg 25). FEZ constructs 
were also mated to the various domains o f LRRK2 (LRR, ARM etc) to determine if 
constructs encoding larger portions o f FEZ 1/2 could bind to additional fragments o f 
LRRK2. The various constructs o f FEZ1/FEZ2 as well as full length FEZ1/FEZ2 (Figure 
25B) were mated with each segment o f  the n-terminal o f LRRK2 (Figure 25A) as well as 
the other domains (i.e. LRR, ROC etc) o f LRRK2.
RESULTS
Yeast expression o f LRRK2 domains and suitability as bait vectors 
As LRRK2 possesses multiple predicted protein interaction motifs, a yeast two hybrid 
screen was performed to identify potential binding partners. The Clontech 
MATCHMAKER system with pre-transformed human brain cDNA library was chosen 
for these experiments. LRRK2 was divided and cloned as six fragments, encoding each 
of its predicted domains (Figure 26A). Bait constructs were transformed into yeast and
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tested for protein expression (Figure 26B) and autoactivation of selection markers. All 
constructs expressed the correct size protein.
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Figure 26: Regions and expression of LRRK2 bait proteins. A) Schematic representation of the 
predicted domains of LRRK2. Areas underlined in red represent cDNA cloned into the yeast 
expression vector. B) a-MYC blot of yeast extract demonstrating expression of the different LRRK2 
bait vectors.
After two weeks, colonies were not observed on either -LEU/-TRP/-ADE or -LEU/- 
TRP/-ADE/-HIS agar plates. Colonies on -LEU/-TRP plates were tested for auto­
activation of the P-galactosidase selection marker by colony lift filter assay. None of the 
bait vectors displayed auto activation of the selection markers
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Identification o f protein interactors for LRRK2
Following confirmation o f bait vectors expressing correct size protein and the absence o f 
any auto-activation o f the selection markers, yeast expressing the bait vectors were mated 
to yeast pre-transformed with a human brain cDNA library (Clontech). Mating mixtures 
were plated on a series o f different dropout medias (-LEU, -TRP, -LEU/-TRP) to 
determine mating efficiencies (Table 12).
Batt Protein No of Viable cfWml 
on SD -LEU
No of Viable cfa/ml 
on SD TRP
No of Viable cfb/ml 
on SD -LEU/TRP
% mating 
efficiency
No of clones 
screened
HEAT 5x106 5x108 4x105 8 4.8x106
LRR 3x106 3x108 lx l  O5 3.3 1.2x106
RAS 4.7x106 4x107 3.1xl05 6.6 3.7x106
ARM 7.8x106 6x107 3.6x105 4.6 4.3x106
KINASE 6.8x106 2x107 5.7x105 8.4 6.8x106
WD40 lx l  07 2x108 3.6x105 3.6 4.3x106
Table 12: Mating efficiencies and the number o f cDNA clones screened for each bait protein.
After three weeks, plasmids were extracted from all positive clones and sequenced. All 
clones encoding a protein fragment o f at least ten amino acids and exhibiting significant 
similarity to a known protein are listed below (Table 13). Common false positives in 
yeast two hybrids, such as ribosomal and heat shock proteins 
(http://www.fccc.edu/research/labs/goIemis/InteractionTrapInWork), were discounted 
and not studied further.
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IN T E R A C T O R S W ITH  THE N-TERM INUS
GENE NAM E N O  O F CLO NES
FASCICULATION A N D  ELONGATION PROTEIN ZETA 2 27
MKL1 GENE 9
ADENYLATE K INA SE 5 8
PROSAPOSIN 8
PROTEASOM E fPROSOME. M ACR O PAIN) SUBUNIT. ALPH A TYPE 6
M R N A  FOR SERTA D O M A IN  CONTAINING 1 VARIANT 6
C D N A . FLJ20902 3
ZINC FINGER HOM EOBOX IB 5
PROTEIN PH O SPH ATASE 2 5
SEROLOGICALLY DEFINED COLON CANCER ANTIGEN 1 5
SECRETED PROTEIN. ACIDIC. CYSTEINE-RICH ( 5
CHROM OSOM E 14 OPEN READING FRAM E 43. M RNA 4
C D N A  CLONE IM A O E5239272 4
C D N A  FU 34891 FIS 4
CTAGE-5B PROTEIN 4
FULL-LENGTH C D N A  CLONE CS0DKD08YI09 OF HELA CELLS 3
H.SAPIENS M R N A  FOR LON PROTEASE-LIKE PROTEIN 3
CD NA: F U 22042  FIS 3
F U 40142  PROTEIN 3
PI-3-KINASE-RELATED K IN A SE SM G-1. 3
HYPOTHETICAL PROTEIN BC011880 3
M R N A ; C D N A  DKFZP686H13259 3
M YOSIN. LIOHT POLYPEPTIDE K INASE 3
BRO M ODOM AIN CONTAINING 4, 3
SOLUTE CARRIER FAM ILY 6. M EM BER 17 (SLC6A17 3
A T P ASE. H + TRANSPORTING 3
GENE FOR HIPPOCALCIN 2
KOYT BINDING PROTEIN 2 M R N A 2
STATHM IN-LIKE 2 M R N A 2
CTD 2
OROWTH ASSO CIATED PROTEIN 43 2
DEHYDROGENASE/REDUCTASE 2
CYTOCHROME C O XID ASE SU BUNIT VB. M R N A 2
TRANSLOKIN. M R N A 2
CYCLIC A M P  PHOSPHOPROTEIN 2
U M  D O M AIN ONLY 4 2
ANKYRIN REPEAT A N D  SO CS BOX-CONTAINING 8 2
NHP2 NON-HISTONE CHROM OSOM E PROTEIN 2-U K E 2
PEPTIDYLPROLYLISOMERASE A 2
KUNITZ-TYPE PROTEASE INHIBITOR 2
K-ALPHA-1 M R N A  FOR UBIQUITOUS A L PH A -T U B U U N 2
NEURONAL PENTRAX3N I 2
H U M A N  N33 PROTEIN FORM  2 (N33) GENE 2
TUBULIN, ALPHA 2
PROTEASE. SERINE. 13 (PRSS15), 2
OROWTH ASSO CIATED PROTEIN 43 2
BETA III SPECTRIN 2
NEURONATIN 2
PQ LOOP REPEAT CONTAINING 1 CPQLC1 2
C D N A  CLONE IM AOE 45 13433 1
CHROM OSOM E 19 CLONE LLNLR-262C5 1
D N A  M ETHYLTRANSFERASE 1 ASSO CIATED PROTEIN 1 1
HIPK1 HOM EODOM AIN-INTERACTING PROTEIN K INASE-1 1
NEL-LIKE 1 1
BRG1-BINDING PROTEIN ELD/OSA1 1
ARM ADILLO  REPEAT CONTAINING 8 1
BERNARDINELLI-SEIP CONGENITAL LIPODYSTROPHY 1
PROTEASE. SERINE. 15 1
C D N A  FLJ46677 FIS 1
C D N A  FLJ46859 FIS 1
MITOGEN-ACTIVATED PROTEIN K INA SE 1 1
M R N A ; C D N A  DKFZP686C195 1
SM A L L  HISTONE FAM ILY CLUSTER 1
TRIPARTITE M OTIF-CONTAINING 2. M R 1
UBIQUITIN B. 1
M R N A  FOR ARID4B VA RIA NT PROTEIN 1
M ITOCHONDRIAL CARRIER HOMOLOG I 1
NUCLEAR PROTEIN LOCALIZATION 4. M R N A 1
M A ST L  M ICROTUBULE SERINE/THREONINE KINASE-LIKE 1
TM ED8 TRA N SM EM BR A N E E M P24P 1
NEUROENDOCRINE DIFFERENTIATION FACTOR M RNA 1
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I N T E R A C T O R S  W IT H  T H E  L R R  D O M A I N
G E N E  N A M E N O  C L O N E S
M K L 1 G E N E 9
T A C C 1 -L IK E  P R O T E IN 8
P R O T E A S O M E  (P R O S O M E , M A C R O P A IN ) SU B U N IT . A L P H A  T Y P E 7
2 ,.3 '-C Y C L IC  N U C L E O T ID E  3 ‘ P H O S P H O D IE S T E R A S E 6
H Y P O T H E T IC A L  P R O T E IN  F L T 22175 5
F L J 2 0 9 0 2 5
D K F Z P 6 8 6 H 1 3 2 5 9 4
Z IN C  F IN G E R  H O M E O B O X  IB 3
C L O N E  P P 5 6 4 4  U N K N O W N 3
F L J34891  F IS 3
C H R O M O S O M E  X  O P E N  R E A D IN G  F R A M E  5 3 3
S M A L L  H IS T O N E  F A M IL Y  C L U ST E R 2
P R O T O  C A D H E R IN  G A M M A  S U B F A M IL Y  C 2
P L E C K S T R IN  H O M O L O G Y , S E C 7 A N D  C O IL E D -C O IL  D O M A IN S 2
K IN E S IN  F A M IL Y  M E M B E R  4 A 2
H IG H -M O B IL IT Y  G R O U P  N U C L E O S O M A L  B IN D IN G  D O M A IN  2 2
R N A  P O L Y M E R A S E  H  14 0  K D A  S U B U N IT 2
O R 2 B 2 1
U B IQ U IT IN  B 1
P R O T E IN  T Y R O S IN E  P H O S P H A T A S E , R E C E P T O R  T Y P E 1
P R O L IF E R A T IO N -IN D U C IN G  P R O T E IN  8 1
D K F Z P 6 8 6 D 0 2 4 9 1
A D A P T E R -R E L A T E D  P R O T E IN  C O M P L E X  3 D E L T A 1
M O N O C Y T E  T O  M A C R O P H A G E  D IF F E R E N T IA T IO N -A S S O C IA T E D 1
M IT O  G E N -A C T IV A T E D  P R O T E IN  K IN A S E  K IN A S E  K IN A S E  15 1
M IT O G E N -A C T IV A T E D  P R O T E IN  K IN A S E  1 1
H Y P O T H E T IC A L  P R O T E IN  B C 0 1 188 0 1
H IG H -M O B IL IT Y  G R O U P  N U C L E O S O M A L  B IN D IN G  D O M A IN  2 1
E 2 A -P B X 1 -A S S O C IA T E D  P R O T E IN 1
C L U ST E R IN 1
F L J 2 3 5 8 7  F IS , 1
INTERACTORS WITH THE ROC DOMAIN
GENE NAME NO CLONES
LRRK2 9
ZINC FINGER HOMEOBOX IB, 3
ZINC FINGER PROTEIN, 3115 BP 2
TRANSMEMBRANE AND COILED-COIL DOMAIN FAMILY 2 2
SIALIC ACID-BINDING IG-LIKE LECTIN 1
INTERACTORS WITH THE COR DOMAIN
GENE NAME NO CLONES
KCNK3 CHANNEL 5
TRANSFORMATION-RELATED PROTEIN 2 3
BETA-1,3 -N  - ACET YLGLU C O S AMIN YLTRAN SFERASE 3
LANC LANTEBIOTIC SYNTHETASE COMPONENT C-UKE 1 2
LEUCINE RICH REPEAT NEURONAL 5 2
ENOYL COENZYME A HYDRATASE 1 1
GATA ZINC FINGER DOMAIN CONTAINING 2A 1
DKFZP5660134 1
MYOSIN, LIGHT POLYPEPTIDE KINASE (MYLK 1
DIPEPTTDYL PEPTIDASE IV 1
AP OLIP OPROTEIN E 1
SERINE PALMITOYLTRANSFERASE 1
AT RICH INTERACTIVE DOMAIN 4B 1
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IN T E R A C T O R S  W IT H  T H E K IN A S E  D O M A IN
G E N E  N A M E N O  C L O N E S
C S 0 D I0 4 1 Y C 0 2  O F P L A C E N T A  C O T  25-N O R M A L IZ E D 21
N U C L E O SID E  D IPH O SPH A T E  L IN K E D  M O IE T Y  X -T Y PE  M OTIF 3 13
SIM ILAR TO  ATAXLN 2-B IN D IN G  P R O T E IN  1 11
C A L C IU M /C A L M O D U L IN -D E P E N D E N T  PR O T E IN  K IN A S E  TL IN H IBITO R 8
M IC R O T U B U L E -A SSO C IA T E D  PR O T E IN . RP/EB FA M IL Y 8
R A B 1A , M EM BER R A S O N C O G E N E  F A M IL Y 6
R A N  G TPA SE A C T IV A T IN G  PR O T E IN  1 6
M O D U L A T O R  OF A P  O PT O  SIS 1 (M O  A P I) 6
C A L M O D U L IN  B IN D IN G  T R A N SC R IP T IO N  A C T IV A T O R  2 6
D K F Z P 6 8 6 D 12126 5
E3F1 A L PH A 7
END O TH ELIAL D IFFE R E N T IA T IO N . SPH IN G O L IPID  G -PR O T E IN -C O U PL E D 4
V ISIN IN -L 3K E  1 4
C A L C IU M /C A L M O D U L IN -D E PE N D E N T  P R O T E IN  K IN A S E  H INH IBITO R 4
Z Y X IN . 4
M A K O R IN . R IN G  FIN G E R  P R O T E IN . 1. 3
G L Y C O G E N  SY N T H A SE  K IN A S E  3 A L P H A 3
C D C 45 CELL D IV IS IO N  C Y C L E  4 5-L IK E 2
F U 4 6 5 5 0  FIS 2
GOLGI R E A SSE M B L Y  ST A C K IN G  PR O T E IN  1 2
L O C 4 4 0 7 5 2 2
R A N  GTP A S E  A C T IV A T IN G  PR O T E IN  1 2
T U B U L IN . A LPH A . U B IQ U IT O U S. 2
U B I Q U m N  A SSO C IA T E D  PR O T E IN  2-L IK E 2
Z IN C  FIN G E R  PR O T E IN  3 95 2
F O R  F IB R O B L A ST  G RO W TH  F A C T O R  RECEPTO R 3 2
PR O T O C A D H E R IN  G A M M A  SU B F A M IL Y  C . 4 2
REG ULA TING  SY N A P T IC  M E M B R A N E  E X O C Y T O SIS 4 2
M IT O G E N -A C T IV A T E D  PR O T E IN  K IN A S E  1 2
L -C A B P1 2
N E U R O  C H O N D R IN 2
H ETERO G E NEO US N U C L E A R  R IB O N U C L E O P R O T E IN 2
M A P/M IC R O T U B U L E  A FFIN IT Y -R E G U L A T IN G  K IN A SE  3 2
C Y T O C H R O M E  C O X ID A SE  SU B  U N IT  3 (C O X 3) 1
A D P-E T B O SY L A T IO N -L IK E  F A C T O R  6 IN T E R A C T IN G  PR O TEIN 1
A M Y L O ID  B ETA  P R E C U R SO R  P R O T E IN  B IN D IN G  PRO TEIN 1
A P E X  N U C L E A SE 1
F L J20643 FIS 1
FL J26635  FIS 1
W D  REPEAT A N D  S O C S  B O X -C O N T A IN IN G  1 1
P R O T E A SO M E  (P R O SO M E , M A C R O P A IN ) 2 6 S  SU B U N IT , N O N -A T P A S E 1
INTERACTORS WITH THE WD40 DOMAIN
GENE NAME NO CLONES
RANT BLbLDLtSTG PROTEIN 9 io
BICAUDAL-D 5
CALSYNTENIN 1 3
PHOSPHODIESTERA.SE 4D INTERACTING PROTEIN 2
GLUTAMATE RECEPTOR, IONOTROPIC 2
GEISra FOR HIPPOCALCIN 1
FIBRONECTTN TYRE III DOM AIN CONTAINING 3A 1
Table 13: List o f all proteins identified as potential interactors for LRRK2. Potential interactors are 
separated by the portion o f  LRRK2 used as the bait protein and the num ber o f independent clones 
identified for each interactor are indicated. All proteins listed above were able to transcribe the 
expression o f all selection markers.
132
Confirmation o f interaction between FEZ2 clone and LRRK2:
O f the potential protein interactors identified, FEZ2 was pursued for further analysis as 
(a) 27 independent clones interacted were recovered, (b) all clones encoded a continuous 
protein sequence greater than 10 amino acids and (c) all clones activated expression of all 
selection markers. To ensure the interaction was not a false positive, FEZ2 clones were 
isolated from yeast and retransformed with the individual domains o f LRRK2 and a 
negative control (pGBKT7-p53). The FEZ2 clone only interacted with the N-terminal 
region and did not auto-activate any of the selection markers (Figure 27A). To ensure 
that interaction was being driven by FEZ2 and LRRK2 protein sequences, and not GAL4 
protein sequences in a specific conformation with FEZ2 and the N-terminus, the 
interaction was reversed. FEZ2 was fused with the DNA binding domain (DB) and N- 
terminal o f LRRK2 (NTER) was fused with the activation domain (ADY). NTER-DB 
and FEZ2-ADY and FEZ2-DB and NTER-DB interacted (Figure 27B), indicating the 
GAL4 protein sequences were not influencing the conformation of either protein and 
driving the interaction.
'  HEAT+X 
T antigen
FEZ2+
WD40
DB
+NTER domain 
AEH-FEZ2 
fragment
B)
DB
+FEZ2 fragment 
AD+NTER  
domain
133
Figure 27: Retest o f interaction between FEZ2 and LRRK2 in yeast. A) Retransformation o f FEZ2 
clone extracted from yeast with all domains o f LRRK2 on quadruple dropout media. pGBKT-p53 
was used a negative control with FEZ2, to ensure that the FEZ2 clone did not autoactivate selection  
markers and pTD-1 was used as a negative control to demonstrate the N-terminus o f  LRRK2 
(NTER) construct did not auto-activate any o f  the selection makers. Only FEZ2 and the NTER  
construct are able to activate all selection markers including p-galactosidase. B) Fusing the NTER  
construct to the DNA binding domain (DB) and FEZ2 to the activation domain (AD) and vice versa, 
maintains the interaction as both proteins in either state are able to activate all selection markers 
when plated on quadruple dropout media.
Refinement o f interacting region between FEZ2 and LRRK2:
From the initial yeast two hybrid screen, an interaction occurred between the N-terminal 
region o f LRRK2 (laa-793aa) and the coiled coil region o f FEZ2 (21 laa-306aa). To 
refine the region o f interaction, the N-terminal o f LRRK2 was broken down into 8 
regions each encoding approx 160aa (Figure 28). FEZ1 and FEZ2 were broken down 
into a total of 5 constructs encoding different combinations o f the N-terminus, coiled coil 
region and the C-terminus (Figure 29). All proteins were transformed and assessed for 
protein expression and ability to auto-activate any o f the selection markers (Figure 28 and 
29).
One construct (LRRK2 construct-H2) was able to auto-activate selection markers and 
grew on quadruple dropout media. All constructs expressed protein at the predicted 
molecular weight apart from full length FEZ1 and FEZ2, which migrated at 
approximately 5kDA higher than predicted from their amino acid sequence. The 
constructs were re-sequenced to ensure that the cDNAs were correct but no additional 
sequences were identified. The high relative molecular weight observed may reflect post
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translational modification o f these proteins, although this statement requires further 
investigation as no modifications o f FEZ proteins have been reported.
A )
N-TERMINAL REGION
1bp-1aa
1 bp-1 a a _______500bp-166aa
H2
H3
H4
H5
H6
H7
H8
229bp-77aa 790bp-263aa
499bp-167aa 1060bp-353aa
811 bp-27 la a ______ 1380bp-460aa
1039bp-347aa 1570bp-523aa
2590bp-863aa
1246bp-416aa_____ 1760b p-586aa
1480bp-494aa 2150bp-716aa
2062bp-688aa 2590bp-863aa
HI H2 H3 H4 H5 H 6 H7 H8
50kDa
Figure 28: Yeast expression of LRRK2 N-terminal fragments used to refine the interaction with 
FEZ1/2. Protein extract from yeast transformed with the smaller fragments o f the N-terminal of 
LRRK2 (A). (B) a-MYC western blot demonstrating protein expression of N-terminal bait vectors.
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1 bp-1 aa
FEZ1 CONSTRUCTS
1179bp-393aa 1bp-1aa
FE22 CONSTRUCTS
1143bp-381aa
N-terminus Coiled Coil C-terminus 
Domain
N-terminus Coiled Coil C-terminus 
Domain
1bp-1aa
1bp-1aa
660bp-220aa 620bp-207aa
820bp-273aa
661bp-221aa 820bp-273aa
661bp-221aa
1bp-1aa
1bp-1aa 880bp-293aa
: o
1179bp-393aa
607bp-203aa 820bp-293aa—<zzo—
607bp-203aa 
—
1143bp-381aa
820bp-273aa 1179bp-393aa 863bp-288aa 1143bp-381aa
FEZ1 C O N STR UC TS FEZ2 CONSTRUCTS
150kDA
lOOkDA
75kDA
50kD A
37kD A
25kD A  
20k DA
1 2
150kDA
lOOkDA
75kDA
50kDA
37kDA
25k DA 
20kDA
150kDA
lOOkDA
75k DA
50kDA
37kDA
1 2
Figure 29: Yeast expression of FEZ1/2 constructs used to refine interaction with LRRK2. Protein 
extract from yeast transformed with smaller constructs of FEZ! and FEZ2 (upper diagram). (Lower 
image) A) FEZI constructs (1.N-terminus, 2. N-terminus + coiled coil domain, 3. coiled coil domain, 
4. coiled coil domain + C-terminus 5. C-terminus) B) FEZ2 constructs (1.N-terminus, 2. N-terminus +
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coiled coil domain, 3. coiled coil domain, 4. coiled coil domain + C-terminus 5. C-terminus) C) 1. Full 
length FEZ1 2. FEZ2 Full length. a-HA blot.
Refining the region o f interaction between LRRK2 and FEZ1/FEZ2 demonstrated that a 
strong interaction could only occur if FEZ1 or FEZ2 contained the coiled coil domain. 
Without the coiled coil region, there was either no binding (in the case o f FEZ1) or 
reduced affinity, as was the case for FEZ2. Only one part o f the N-terminal region o f 
LRRK2 was responsible for the binding between FEZ1 and FEZ2, the region between 
amino acids 494 and 863. This region is predicted to contain multiple ankyrin repeats, 
which are commonly involved in protein interactions. However, the C-terminal region o f 
FEZ2, also bound to the LRR and COR domains o f LRRK2, suggesting that additional 
sequences may strengthen the interaction between LRRK2 and FEZ2.
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Bait vector
Prey vector
NTER
H1
NTER
H2
NTER
H3
NTER
H4
NTER
H5
NTER
H6
NTER
H7
NTER
H8
FEZ1 N-TERMINUS - -
FEZ1 NTERMINUS/COILED COIL - -
FEZ1 COILED COIL ++ ++
FEZ1 COILED COIUC-TERMINUS + ++
FEZ1 C-TERMINUS - -
FEZ1 FULL LENGTH ++ ♦ +
pGADT7-T antigen + - -
N .  Bait vector 
Prey vector
NTER LRR ROC COR KINASE WD40 Empty pGBKT7
FEZ1 N-TERMINUS -
FEZ1 NTERMINUS/COILED COIL 4-M-
FEZ1 COILED COIL +++
FEZ1 COILED COIL/C-TERMINUS +++
FEZ1 C-TERMINUS -
FEZ1 FULL LENGTH +++
pGADT7-T antigen ■
Bait vector
Prey vector
NTER
H1
NTER
H2
NTER
H3
NTER
H4
NTER
H5
NTER
H6
NTER
H7
NTER
H8
FEZ2 N-TERMINUS - -
FEZ2 NTERMINUS/COILED COIL + ++
FEZ2 COILED COIL + ++
FEZ2 COILED COIL/C- 
TERMINUS ++ ++
FEZ2 C-TERMINUS - -
FEZ2 FULL LENGTH + ++
pGADT7-T antigen + - -
Bait vector
Prey vector
NTER LRR ROC COR KINASE WD40 Empty pGBKT7
FEZ2 N-TERMINUS + - -
FEZ2 NTERMINUS/COILED COIL + - -
FEZ2 COILED COIL -*-+ - -
FEZ2 COILED COIL/C-TERMINUS ++ ++ +
FEZ2 C-TERMINUS - - -
FEZ2 FULL LENGTH +++ +++ ++■*»
pGADT7-T antigen - - -
Table 14: Results o f matings between FEZ1, FEZ2 and various LRRK2 constructs. The strength o f  
interaction was determined by growth rate and degree o f X-gal activity assessed relative to
138
interaction between p53 and the T antigen (positive control): + weak activation o f X-gal, ++ medium  
activation o f X-gal, +++ strong activation o f X-gal.
DISCUSSION
In order to conduct large protein-protein interaction screen, a yeast two-hybrid is a logical 
choice, as one can screen thousands o f potential interactors. This method suffers from a 
high false positive, with some estimates as high as 30%, as well as a false negative rate. 
There are many reasons for this:
1) Both bait and prey proteins are fused to the GAL4 DNA binding domain and the 
activation domain respectively and individually, may possess sufficient similarity 
to the intact GAL4 protein. Consequently, either protein may bind to the GAL4 
consensus sequence without requiring the presence o f its partner (auto-activation). 
Auto-activation o f the selection markers can be avoided by testing individual bait 
or prey proteins but this is not possible if one uses a library as there are potentially 
millions o f different protein fragments to test. This can be overcome by re-testing 
the auto-activation ability o f the potential interesting prey proteins chosen for 
further study as I did during our investigation.
2) All selection markers are encoded by genes in the nucleus, so both the bait and 
prey protein have a nuclear localization signal (NLS) fused to their N-termini. 
Furthermore, both proteins are expressed at significantly high levels. A 
combination o f forcing two proteins at high levels into the same compartment o f 
cell can generate artificial protein-protein interactions.
3) The expression o f some proteins may either be toxic or beneficial to yeast cells. 
Proteins that are toxic to yeast cells are unlikely to be identified as potential
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protein interactors. Conversely, proteins which promote cell survival may allow 
yeast to survive more successfully in media lacking certain amino acids and 
nutrients leading to an over-representation o f these proteins in yeast two hybrid 
screens.
4) Yeast are often maintained on highly selective media for up to 3-4 weeks prior to 
re-streaking. This can often lead to mutations in the promoter region o f the 
selection markers leading to autoactivation. Yeast with activating mutations do 
not require an interaction to occur to drive the expression o f selection markers. 
Yeast harbouring such mutations, are at a select advantage to grow. Re-streaking 
can overcome this false positive but a more effective strategy is to only consider 
proteins that are represented by multiple clones.
As a result o f the inherent drawbacks associated with this technique, the Clontech GAL4 
two-hybrid system III was selected for the LRRK2 protein interaction screen. In this 
system, the AH 109, into which the bait construct is transformed, contains several 
different selection markers under the control o f unique promoters. As a result, the 
likelihood o f autoactivation o f all selection markers by either bait or prey protein alone, is 
greatly decreased. Furthermore, premade libraries are pretransformed into a yeast strain 
allowing screening o f a greater number o f cDNA clones as mating yeast is a more 
efficient method than transforming the bait vector into yeast containing a library.
Many potential protein interactors were identified for LRRK2 (Table 13), such as the 
amyloid p precursor binding protein (APPBP1) and glycogen synthase kinase 3-alpha 
(GSK3a). As APPBP1 and GSK3a are involved in the control and/or function o f the 
amyloid precursor protein 440 441 and TAU 442, mutations within LRRK2 could alter TAU
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aggregation and deposition ’ via interactions with these two proteins. However not 
all proteins listed in Table 13 were retransformed into yeast to confirm the interaction and 
each domain was only screened for protein interactors once. Therefore, further validation 
o f the protein interactors is required. This can be done either by repeating the yeast two 
hybrid screen for each domain or by the use o f alternative methods for protein-protein 
interactions.
Although the validity o f the proteins identified above remain in question, none o f the 
proteins previously identified as LRRK2 interactors, PARKIN 412, HSP90/p50cdc37 414 
were identified in the screen apart from LRRK2 itself. This suggests that either previous 
reports o f LRRK2 interactors are not robust or the YTH screen used here has a significant 
false negative rate. Furthermore, numerous proteins have been shown to bind to proteins 
mutated in PD 87,210,2 1 222,231,443 446 but these proteins also did not appear in the yeast 
two hybrid.
Alternative and independent protein interaction screens using the same bait proteins or 
full length LRRK2 may potentially identify interactors that overlap with the yeast two 
hybrid hits or aid in the discovery o f novel binding partners:
1) Immunoprecipitation: The basic premise allows for the isolation o f the bait 
protein from mammalian cells along with any interacting proteins that form a 
stable complex. Once the bait protein and interacting proteins are isolated, the 
protein is digested and analyzed via mass spectrometer, peptide library or protein 
sequencing. A distinct advantage o f immunoprecipitation over YTH is that it 
allows for the isolation o f a complex o f proteins as well as single interactors. In 
addition, post-translational modifications will be present if IPs can be conducted
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in mammalian cells. However optimization o f the purification procedure is 
required to enrich the protein interactor over background while maintaining the 
interaction.
2) Protein affinity purification involves covalently coupling the bait protein to a 
matrix such as sepharose. Cell extracts are subsequently passed through the 
column and under appropriate conditions different ligand proteins can be selected 
for. Weakly bound proteins can washed off using similar strategies employed in 
co-IP experiments. There are several advantages to this method:
a. This techniques is potentially sensitive as one can immobilize high levels 
o f bait protein and thus detect relatively weak interactions
b. As with yeast two hybrid screens, one can test all proteins within a cell 
extract without bias and the majority o f proteins within mammalian cell 
extracts, will be correctly modified and folded dependent on the solvent 
conditions.
c. If the interaction between two proteins actually occurs as either a complex 
or via a third protein, the accessory proteins will often be present within 
the cell extract. However, one has to be careful that the interaction is 
specifically tested between the two proteins and recognize if a third 
protein is required for the interaction.
3) Protein micro arrays: A relatively recent technology, proteins are spotted onto a 
nitrocellulose membrane. The bait protein is either tagged in vitro with biotin or 
purified from cells expressing a tagged version. The bait protein is incubated with 
the array after blocking, washed to remove non-specific binding and the bait
142
protein is detected either using antibodies to the tag (fluorescent) or streptavidin 
conjugated to fluorescent dyes. This is a rapid, although limited (only 5000 
proteins present on the array), method for the detection o f protein-protein 
interactions. Once the protein is purified, the whole procedure can be achieved in 
a day. However as with any array, the entire process is completed in vitro 
therefore validation o f the interaction is required in vivo. The proteins are also 
immobilized on the membrane and therefore if the protein is not in the correct 
conformation, there may be a significant false-negative rate.
At present, full length LRRK2 can only be expressed at relatively low levels in 
mammalian cells, therefore purification is inherently difficult increasing the 
likelihood o f a false positive due to precipitation o f non-specific proteins.
4. Mammalian Two hybrids -  an extension o f the yeast two hybrid system into 
mammalian cells. If bait and prey protein interact they are able to drive the 
expression o f either the chloramphenicol transacetylase (CAT) gene or another 
antibiotic resistance gene. The advantage o f this method over the yeast system is 
that, proteins are more likely to be correctly post translational modified and 
folded. In addition, one could use full length LRRK2 as the bait protein 
potentially identifying more relevant interactors. Compared to the yeast two 
hybrid, this method is both more time consuming, expensive and potentially at 
risk o f a greater false positive rate as there is only one selection marker compared 
to three in the yeast system.
All the methods described above require that the interaction be further investigated by
using independent experimental approaches, as many o f the methods are extremely
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sensitive, and proteins that do not normally co-exist in the same cellular compartment 
may be inappropriately exposed to one another.
In the current study one specific interaction was selected for validation. FEZ2 was 
chosen for follow-up as it activated all selection markers and met other criteria for a true 
interaction including the number o f clones recovered, the presence o f an open reading 
frame and the activation o f selection markers upon retransformation. A total o f 27 clones 
identified FEZ2 as binding partner o f the N-terminal o f LRRK2, all o f which included the 
coiled coil region o f FEZ2 (21 laa-306aa). The interaction could be recapitulated upon 
re-transformation and swapping the bait and prey proteins into the opposite vector 
maintained the interaction. A mapping study was undertaking to determine the exact 
region o f binding. As there was considerably homology between the coiled coil domains 
o f FEZ 1 and FEZ2, I determined if LRRK2 specifically bound to FEZ2 or if there was a 
motif common to both proteins.
Initially the interaction had occurred between the N-terminal o f LRRK2 and the coiled 
coil region o f FEZ2. This was subsequently mapped to between residues 494 and 863 o f 
LRRK2 and the coiled coil domain (residues 21 laa-306aa) o f FEZ2. Without the coiled 
coil domain o f FEZ1 and FEZ there was either no interaction (as was the case for FEZ1) 
or minimal interaction (as was the case for FEZ2) with LRRK2. Upon mating FEZ2 
constructs containing the C-terminus and full length FEZ2, an interaction was observed 
between the LRR and ROC domains suggesting that these motifs may play additional 
roles in binding FEZ2. To verify this result, constructs expressing FEZ 1/2 with/without 
the coiled coil domain need to be mated with constructs containing residues 494-863aa o f  
LRRK2, or in conjunction with the LRR and/or ROC domains.
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Even though and the interaction between LRRK2 and FEZ2 was confirmed in several 
ways in yeast and mapped to a specific region, it is still possible that the two proteins 
only bind each other in the yeast nucleus and do not interact in vivo. Thus, alternative 
methods were explored to verify this interaction in mammalian cells.
145
CHAPTER 6: CONFIRMATION OF INTERACTION
BETWEEN LRRK2 AND FEZ2 IN MAMMALIAN CELLS.
INTRODUCTION
Many proteins operate in conjunction with other proteins as complexes to regulate a 
variety o f processes, such as cell cycle control, differentiation, protein folding, signaling, 
transcription, translation, and transport. Protein interactions can be stable or transient and 
can also be either strong or weak 447, 448. Stable interactions are those associated with 
proteins that are purified as multi-subunit complexes and are best studied by co- 
immunoprecipitation, pull-down or far-Western methods. Transient interactions are 
expected to control the majority o f cellular processes and are temporary in nature, 
typically requiring a set o f conditions that promote the interaction. Transient interactions 
are generally best observed by cross-linking or label transfer methods.
Numerous in vitro techniques have been developed to confirm and study protein 
interactions, each with their own advantages and the type of information they can impart 
447,448 (jab jg  i 5 ) jn v jtro affinity-based strategies can be direct, such as those utilized 
for pull-down assays or far-Western analysis or indirect, such as the typical co- 
immunoprecipitation experiment that is mediated by an antibody against a target antigen 
that in turn precipitates an interacting protein. Affinity-based methods can be highly 
sensitive with some methods capable o f detecting weak interactions 448. In addition, 
methods such as co-immunoprecipitation, pull-down assays, far-Western analyses and
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label transfer methods allow all proteins in the sample to compete equally for the bait 
protein.
As there were no antibodies that recognized endogenous FEZ2 or LRRK2 and the type o f 
interaction (transient or stable) was unknown, the method chosen to initially investigate 
the FEZ2/LRRK2 interaction was co-immunoprecipitation. Confocal microscopy was 
also used to exclude the possibility that the two proteins were normally prevented from 
interacting by virtue o f being in different cellular compartments,
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in vitro Methods Description
Co-lmm unoprecipitat ion
(Co-IP)
An im m unoprecipitation (IP) experim ent d e s ig n e d  to 
affinity purify a baitprotein antigen to g e th e r  with its 
binding partner  using a specific antibody ag a in s t  th e  
bait.
Cross-linking R e a g e n ts
S tra te g ie s  involve homo- or heterobifunctional r e a g e n ts  
w h o s e  chem ica l  c ross- l inks  m a y  or m a y  not be 
reversed. N ea re s t  neighbors  ( s u s p e c te d  to interact) in 
vivo or in vitro c a n  be t rapped  in their c o m p le x e s  for 
further s tudy.
F ar -W este rn  A nalys is
The antibody probe in a typical W e s te rn  blot de tec tion ,  
is su b s t i tu te d  with an appropriately labeled  bait protein 
a s  the  probe. D etection  can  be radioisotopic , 
ch e m ilu m in e sce n t  or colorimetric, depend ing  on the  
probe label
Label Transfer
Involves a spec ia l ized  cross-linking agen t with several 
important fea tures .  T h e se  include heterobifunctionality 
for s te p w ise  cross-linking, a d e tec tab le  label and 
reversibility of th e  cross-link be tw een  binding partners . 
Upon reduction of the  c ross- linked  com plex  a binding 
partner  (prey protein) acqu ires  th e  label from a bait 
protein tha t  w a s  first modified with the  reagent.  The 
label is typically u se d  in th e  detec tion  p r o c e s s  to 
iso late  or identify th e  unknown prey protein.
F lu o re sc e n c e  
R e s o n a n c e  Energy 
Transfer (FRET)
In th is  techn ique ,  two different f luorescen t m o le cu le s  
(fluorophores) are genetically  fused  th e  two proteins  of 
interest. W h e n  two proteins are ex trem ely  c lo s e  to one 
ano ther  (20-100A) energy is transferred  from th e  donor 
fluoroohore to the  a c c e p to r  flurophore.
Protein Interaction 
Mapping
Utilizes an “artificial p ro tea se"  on a bait protein to 
initiate co n tac t -d e p en d e n t  c leav ag es  in th e  prey protein 
in the  p r e s e n c e  of specific reac tan ts .  The nonspecif ic  
c leavage f ragm en ts  p roduced  by th e  artificial p ro te a se  
ca n  be an a ly z ed  to m ap  th e  co n tac t  s i t e s  or interface 
of a known protein: protein interaction.
Pull-Down A s s a y s
An affinity ch rom atography  m ethod  tha t  involves using a 
t a g g e d  or labeled bait to c re a te  a specific affinity matrix 
tha t  will enab le  binding and purification of a prey protein 
from a ly sa te  sa m p le  or o ther  protein-containing 
mixture.
Surface  P la sm o n  
R e s o n a n c e
R e la te s  binding information to small c h a n g e s  in 
refractive ind ices  of la se r  light reflected from gold 
su r fa ce s  to which a bait protein h a s  b ee n  a t tac h ed .  
C h a n g e s  are proportional to the  ex ten t  of binding. 
Spec ia l  labels  and sa m p le  purification are not 
n e c e s s a r y ,  and an a ly s is  occ u rs  in real time.
NMR (Nuclear M agnetic  
R e so n a n c e )
M ethod tha t  ca n  provide insights  into th e  dynam ic  
interaction of proteins in solution.
M a s s  S p e c t ro s c o p y
U sed  in concer t  with affinity-based m e th o d s ,  s u c h  a s  
co -IPs ,  to iso la te  binding par tne rs  and c o m p le x e s  and 
identify th e  co m p o n en t  proteins using s ta n d a rd  m a s s  
spec tra l  m e th o d s ,  e .g .,  MALDI-TOF and m a s s  
sea rch inq  of bioinformatics d a t a b a s e s .
Table 15: Descriptions of methods commonly used to confirm and analyze protein-protein
interactions.
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MATERIALS AND METHODS
Cloning o f  FEZ 1 and FEZ2
cDNA primers for FEZ1 and FEZ2 were designed (Table 11) to amplify full length 
cDNA from human brain cDNA. cDNAs for FEZ1 (NCBI accession number: 
NM 005103) and FEZ2 (NCBI accession number: N M O O 1042548) were cloned into 
pCR8/GW/TOPO to generate a gateway entry clone, verified by sequencing and 
transferred to mammalian expression vectors with N-terminal V5 or GFP tags (Chapter 3, 
pg 91). Constructs were transiently transfected into COS7 cells and analyzed by western 
blotting using antibodies directed against the tags (Western blotting protocol; Chapter 3, 
pg 93-95).
Colocalisation of FEZ 1/2 and LRRK2
COS7 cells were co-transfected with GFP-FEZ1/FEZ2 and V5-LRRK2. FEZ1/FEZ2 
were also co-transfected with mutant forms o f LRRK2 (mutants and corresponding 
kinase dead). Transfection protocol was as described above (Chapter 3, pg 92). 
Transfected cells were stained and fixed as described above (Chapter 3, pg 97-98). The 
following primary antibodies were used; monoclonal anti-GFP (ROCHE) and polyclonal- 
V5 (SIGMA) and the appropriate secondary antibody (anti-mouse AlexaFluor 488 and 
anti rabbit AlexaFluor 568). Slides were imaged using confocal microscopy.
149
Co-immunoprecipitation o f  FEZ1/FEZ2 and LRRK2
There are presently no antibodies that recognize the endogenous form o f either LRRK2 
or FEZ 1/2. Therefore, both proteins were tagged with either GFP or V5. FEZ2 was 
cloned into the gateway expression vectors pcDNA3.1/nV5-dest and pcDNA-DEST53. 
Co-transfections were carried out as described above (Mammalian cell transfections, pg 
92). The total amount o f DNA for co-transfections was the same as that used for single 
plasmid transfections except molar ratios o f each vector was used.
CO-IP Method (Fig 30T
1. Remove media from cells and wash twice with ice cold PBS.
2. Scrape cells into ice cold PBS and centrifuge at 5000xg for 10 min.
3. Remove supernatant and resuspend pellet in 250pl o f ice cold lysis buffer (see 
individual co-IP experiments, in results section, for recipe o f lysis buffer)
4. Place cells on ice for 30mins
5. After 30mins, add lOOpl o f 50% slurry o f protein G agarose (Amersham).
6. Rotate cells with protein G for two hours at 4°C.
7. Centrifuge lysates with protein G for lOmins at lOOOOxg
8. Remove supernatant and save an aliquot to run on SDS page and western blotting 
-  precleared input.
9. Incubate remaining lysates with 2pg o f the appropriate (Monoclonal anti-GFP 
(ROCHE) and anti-V5 (Invitrogen)) antibody and 50pl o f 50% slurry o f protein G 
agarose.
10. Rotate cells overnight at 4°C.
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11. Following day, centrifuge lysates for lmin at lOOOxg at 4°C.
12. Remove supernatant and save an aliquot to run on SDS page and western blotting
13. Resuspend agarose pellet with wash buffer, invert 4-5 times and centrifuge for 
lmin at lOOOxg at 4°C. Remove and discard supernatant.
14. Repeat step 13 a total o f 5 times
15. Resuspend agarose pellet in Laemmeli loading buffer (Bio-Rad) with 5% p- 
mercaptoethanol and boil for 15mins at 65°C.
16. Centrifuge samples for 1 min at lOOOg.
17. Run supernatant on SDS page and analyze by western blotting (Western blot 
protocol, Chapter 3; pg 93-95).
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I m m o b i l i z e  L R R K 2  t o  P r o t e i n  
G w i t h  a n t i - L R R K 2  a n t i b o d y .  
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Figure 30: Schematic representation of co-immunoprecipitation protocol. An antibody (monoclonal 
or polyclonal) against a specific target antigen is allowed to form an immune complex with that 
target in a sample, such as a cell lysates. The immune complex is then captured on a solid support to 
which either Protein A or Protein G has been immobilized (Protein A or G binds to the antibody, 
which is bound to its antigen). Any proteins not co-precipitated on the support are washed away. 
Finally, components of the bound immune complex (both antigen and antibody) are eluted from the 
support and analyzed by SDS-PAGE followed by Western blotting to verify the identity of the 
antigen.
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A variety o f factors were varied to try and assess the requirements for interaction between 
FEZ2 and LRRK2:
1) NaCl concentration: This is used to break up ionic interactions and its 
concentration was varied from 50mM to 150mM
2) Detergent type and concentration: Two non-ionic detergents with low 
denaturing potential were used to minimize non-specific interactions 
whilst maintaining native structure of the protein. Lysis buffers contained 
no detergent, between 0-0.5% of NP-40 (PIERCE) or between 0.1%-1% 
Triton-X-100 (BIO-RAD) detergents.
3) Other: pH and co-factors (e.g. glycerol, phosphatase inhibitor levels) were 
varied to test specific requirements for interaction.
RESULTS
Following the robust demonstration o f an interaction between FEZ2 and LRRK2 in a 
yeast two-hybrid model system, verification o f the interaction in mammalian cells was 
attempted.
Expression o f FEZ 1 and FEZ2
Amplification o f FEZ 1 (NCBI accession no: NM005103) and FEZ2 (NCBI accession no: 
NM 001042548) cDNA resulted in amplicon sizes corresponding to published sequences 
(1 179bp and 1143bp respectively; Figure 31). Verified constructs were transiently 
transfected into COS7 and analyzed by western blot with antibodies directed against the 
tag (Figure 32).
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FEZ1 and FEZ2 have predicted molecular weights o f 45kDA and 42kDA respectively. 
However, both proteins migrate at approximately 5kDA higher than predicted (Figure 
32), when tagged with either V5 (expected molecular weight; 46Kda or 44kDA for FEZ1 
and FEZ2 respectively) or GFP (expected molecular weight; 72kDA and 69Kda for FEZ1 
and FEZ2 respectively). This is consistent with the similar size differences between 
observed and expected molecular weights in yeast experiments and suggests that FEZ1 
and FEZ2 are post-translationally modified, although the nature of this modification is 
not known.
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Figure 31: Multiple protein sequence alignment for FEZ2 and its homologous proteins. Region in 
red represents alternative start codons, purple represents region identified as interacting m otif for 
LRRK2 in initial yeast two hybrid screen and yellow represents an in frame exon identified during
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cDNA cloning of FEZ2. 1-mouse FEZ2, 2 rat FEZ2,3 human FEZ2 isoform 1, 4-human FEZ2 
isoform 2, 5-human FEZ!.
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Figure 32: Mammalian COS-7 cells transfected with FEZ1 and FEZ2 constructs. A) V5 immunoblot. 
1) V5-FEZ1 and 2) V5-FEZ2. B) aGFP immunoblot 1) GFP-FEZ1 and 2) GFP-FEZ2. Both FEZ1 
and FEZ2 run at higher molecular weights than predicted (see text).
Co-localization of FEZ 1. FEZ2 and LRRK2
In the yeast two-hybrid experimental paradigm, if two proteins are to interact and activate 
expression of the selection markers, they have to enter the nucleus. Therefore both 
proteins, in addition to being fused to a GAL4 protein sequence, contain nuclear 
localization signal (NLS) which ensures that the majority of proteins move to the nucleus. 
However, the same two proteins may not reside in the same cellular compartment o f 
mammalian cells. Therefore it is important to assess the subcellular localization of 
LRRK2 and FEZ1/FEZ2 in mammalian cells.
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To address this, COS7 cells were co-transfected with FEZ1/FEZ2 and LRRK2. 
FEZ1/FEZ2 were also co-transfected with mutants forms o f LRRK2 (mutants and 
corresponding kinase dead) to determine if kinase activity influenced the cellular 
localization o f FEZ1/FEZ2 as previous reports o f FEZ2 449 suggested a re-localization 
from the plasma membrane to the cytoplasm when phosphorylated by PKC^.
Both LRRK2 and FEZ1/FEZ2 co-localize in the cytoplasm (Figure 33, 34 and 35). 
Mutant forms o f LRRK2 and kinase dead versions do not change the localization o f 
FEZ1 or FEZ2 (Figure 34). Previous reports o f FEZ2 suggest that protein is plasma 
membrane bound 449. However, these authors used a FEZ2 cDNA sequence with an 
alternative start codon, without an additional exon found in our cDNA cloning 
experiments (Figure 32) and the experiment was conducted in PC -12 cells. Thus, at least 
in transfected COS7 cells, LRRK2 and FEZ1/FEZ2 reside in the cytoplasm. 1
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Figure 33: Colocalisation o f FEZ1 and FEZ2 with LRRK2 and its mutants in COS7 cells. FEZ1 and FEZ2 are labeled in green (bottom left o f  
quadrants E-H) and LRRK2 in red (Upper right o f quadrants E-H). A) N-terminal V5 tagged FEZ1 B) N-terminal GFP V5 tagged FEZ1 C) N- 
terminal V5 tagged FEZ2 D) N-terminal GFP tagged FEZ2 E) N-terminal V5 FEZ1 and N-terminal MYC wild type LRRK2 F) N-V5 FEZ2 and N- 
MYC wild type LRRK2 G) N-V5 FEZ1 and N-MYC kinase dead LRRK2 H) N-V5 FEZ2 and N-MYC kinase dead LRRK2. The bottom right of  
quadrants E-H shows the merged red and green channels. Magnification x63
157
Figure 34: Coiocalisation of FEZ1 and FEZ2 with LRRK2 mutants in COS7 cells. I) N-V5 FEZ1 and N-MYC R1441C LRRK2 J) N-V5 FEZ2 and N- 
MYC R1441C LRRK2 K) N-V5 FEZ1 and N-MYC R1441C kinase dead LRRK2 L) N-V5 FEZ2 and N-MYC R1441C kinase dead LRRK2 M) N-V5 
FEZ1 and N-MYC Y1699C LRRK2 N) N-V5 FEZ2 and N-MYC Y1699C LRRK2 O) N-V5 FEZ1 and N-MYC Y1699C kinase dead LRRK2 P) N-V5 
FEZ2 and N-MYC Y1699C kinase dead LRRk2. FEZ1 and FEZ2 are labeled in green (bottom left o f quadrants) LRRK2 in red (upper right of 
quadrants), the (bottom right of each quadrant) represents merges between the channels. Nuclei are stained with Hoechst (blue, upper left of each 
quadrant). Magnification x63
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Figure 35: Localization o f LRRK2 within COS7 cells: Q) N-MYC wild type LRRK2 R) N-MYC kinase dead LRRK2 S) N-MYC R1441C LRRK2 T) 
N-MYC R1441C kinase dead LRRK2 U) N-MYC Y1699C LRRK2 V) N-MYC Y1699C kinase dead LRRK2. Nuclei are stained with Hoechst (blue).
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Co-immunoprecipitation of FEZ 1/2 and LRRK2
As the interaction between FEZ2 and LRRK2 had only been observed in yeast and 
had not been replicated with full length LRRK2, both proteins were co-expressed in 
mammalian cells and each of the two proteins immuno-precipitated. If FEZ2 binds to 
LRRK2, precipitation o f one protein would also result in precipitation o f the other. 
Initially, FEZ2 was precipitated and washed in buffers only containing 150mM NaCl. 
However, the interaction and wash buffer were not sufficiently stringent, as without 
any FEZ2 present; LRRK2 precipitated suggesting there was no specific binding of 
LRRK2 either to the antibody or protein G agarose (Figure 36: lane 3 and 4).
Figure 36: Effect of NaCl on the interaction between FEZ2 and LRRK2. Lysis and wash 
conditions: 50mM HEPES pH 7.4, 150mM NaCl, 5mM EDTA, protease inhibitor cocktail 
(Roche), 1 X HALT (PIERCE), 0.5mM PMSF lmM  DTT. Cells were lysed in the above buffer 
and proteins were precipitated with monoclonal GFP (FEZ2). Proteins and antibody complex 
were attached to protein G agarose and washed 5 times. Proteins were eluted and analyzed by 
western blotting with antibodies to GFP and V5. Under these conditions, LRRK2 precipitated in
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the presence of FEZ2 (lanes 1 and 2) but LRRK2 also precipitated in the absence of FEZ2 (Lane 
3 and 4). Abbreviations: IN-INPUT, IP-IMMUNOPRECIPITANT
The detergent, NP-40 (PIERCE) was subsequently added to reduce and disrupt non­
specific interactions. The concentration of NP-40 was systematically raised (0.1%,
0.25% and 0.5%) and eventually increased to 0.5% at which point no interaction was 
observed between LRRK2 and FEZ2 (Figure 37).
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Figure 37: Effect o f NP-40 detergent on the interaction between FEZ2 and LRRK2. Lysis and 
wash conditions: 50mM HEPES pH 7.4, 150mM NaCl, 0.5% NP-40, 5mM EDTA, protease 
inhibitor cocktail (Roche), 1 X HALT (PIERCE), 0.5mM PMSF ImM DTT. Cells were lysed in 
the above buffer and proteins were precipitated with either monoclonal GFP (LRRK2) or V5 
(FEZ2). Proteins and antibody complex were attached to protein G agarose and washed 5 times. 
Proteins were eluted and analyzed by western blotting with antibodies to GFP and V5. Under 
these conditions, neither FEZ2 nor LRRK2 precipitated when LRRK2 (lane 3) or FEZ2 (lane 6) 
were precipitated. Abbreviations: IN-INPUT, SUP-SUPPERNATANT, IP-
IMMUNOPRECIPITANT
161
NP-40 is a relatively mild detergent with a low micell count and thus may not lyse the 
cells very efficiently leading to overall low protein concentrations. As a consequence 
the detergent was switched to TritonX-100 as this has a higher micelle count and 
disrupts membranes more efficiently.
The concentration of TritonX-100 was systematically increased to 1%, at which point 
no interaction was observed between LRRK2 and FEZ2. NaCl levels were decreased 
to 50mM, in case 150mM was too stringent and broke interaction between FEZ2 and 
LRRK2. However, no interaction occurred at 50mM NaCl (Figure 38).
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Figure 38: Effect o f Triton detergent on the interaction between FEZ2 and LRRK2. Lysis and 
Wash conditions: 50mM HEPES pH7.4, 50mM NaCl, 1% Triton, 5mM EDTA, protease 
inhibitor cocktail (Roche), lxHALT, 0.5mM PMSF, ImM DTT. Cells were lysed in the above 
buffer and proteins were precipitated with either mono-clonal GFP (FEZ2) or V5 (LRRK2). 
Proteins were eluted and analyzed by western blotting with antibodies to GFP and V5. Under 
these conditions, neither LRRK2 nor FEZ2 precipitated when FEZ2 (lane 3) or LRRK2 (lane 6)
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were precipitated respectively. Abbreviations: IN-INPUT, SUP-SUPPERNATANT, IP-
IM M UNOPRECIPITANT
As varying the concentration o f NaCl or detergent either resulted in no interaction or 
non-specific binding, additives were included in lysis and wash buffers to try and 
stabilize the interaction. The first additive used was glycerol as this can stabilize 
hydrophobic interactions and decrease the protein unfolding rate, thus potentially 
maintaining the native structure o f FEZ2 and LRRK2. In the presence o f glycerol, 
FEZ 1/2 bound to LRRK2 (Figure 39, Lane 2 and 4). In addition several other 
interactions previously reported were also recreated. FEZ1 has been reported to 
hetero-dimerise with FEZ2 450 and under these conditions, FEZ1 does bind to FEZ2 
(Figure 39, Lane 5 and 6). Furthermore, LRRK2 can homo-dimerise under these 
conditions (Figure 39, lane 7 and 8) 409,414. However, as an extra control for non­
specific binding, PINK1 was co-transfected with LRRK2. It is hypothesized that 
PINK1 is unlikely to interact directly with LRRK2, as PINK1 is a serine/threonine 
kinase any interaction with LRRK2 is liable to be transient and thus unlikely to be 
detected by this method. In addition PINK1 is primarily a mitochondrial located 
protein 232, 244, 451 whereas LRRK2 is cytoplasmic, lessening the opportunity for 
interaction between the two.
Based on the result below (Figure 39), the addition o f glycerol acted to stabilize all 
protein interactions.
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Figure 39: Effect of glycerol on the interaction between FEZ2 and LRRK2. Lysis and Wash 
conditions: 50mM HEPES pH7.4, 150mM NaCl, 1% Triton, 5mM EDTA, protease inhibitor 
cocktail (Roche), lxHALT, 0.5mM PMSF and 7.5% glycerol, ImM DTT. Cells were lysed in the 
above buffer and proteins were precipitated with either monoclonal antibodies to GFP or V5. 
Proteins were eluted and analyzed by western blotting with antibodies to GFP and V5. Under 
these conditions, precipitation of FEZ2/1 (lanes 2 and 4, respectively) also precipitated LRRK2. 
FEZ! and FEZ2 were also able to hetero-dimerise (lane 5) and LRRK2 was also able to self- 
interact (lane 8). However, precipitation of PINK1 also precipitated LRRK2 (lane 10). 
Abbreviations: IN-INPUT, IP-IMMUNOPRECIPITANT
Varying the type and concentration o f detergent used, as well as varying NaCl levels 
and the presence of glycerol did not result in a stable interaction between FEZ 1/2 and 
LRRK2 that was specific. As FEZ1/FEZ2 can be phosphorylated but PKZC, 449, 452 
and LRRK2 may auto-phosphorylate 409 411 414 or be phosphorylated, NaF was added, 
a serine/threonine phosphatase inhibitor, to determine if one or both the proteins
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require the addition o f a phosphate group prior to an interaction occurring. NaF had 
been previously added as a component of the HALT cocktail (PIERCE), but higher 
levels (50mM) were used in this experiment.
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Figure 40: Effect o f NaF on the interaction between FEZ2 and LRRK2. Lysis and Wash 
conditions: 50mM HEPES pH7.4, 150mM NaCl, 1% Triton, 5mM EDTA, protease inhibitor 
cocktail (Roche), IxHALT, 0.5mM PMSF and 7.5% glycerol, ImM DTT, 50mM NaF, lm M  
Na3V 0 4. Cells were lysed in the above buffer and proteins were precipitated with either 
monoclonal GFP or V5. Proteins were eluted and analyzed by western blotting with antibodies 
to GFP and V5. Under these conditions, precipitation of FEZ2/1 (lanes 1 and 2, respectively)
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also precipitated LRRK2. FEZ1 and FEZ2 were also able to hetero-dimerise (lane 3) but 
LRRK2 was not able to interact with itself (lane 4). FEZ1/2 and LRRK2 did not precipitate in 
the absence of LRRK2 or FEZ1/2 respectively (lane 7 through 10) and LRRK2 did not 
precipitate in the presence of PINK1 (lane 5). Abbreviations: IN-INPUT, IP-
IMMUNOPRECIPITANT
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Figure 41: Verification of the interaction between FEZ2 and LRRK2 only in the presence of 
NaF. Lysis and Wash conditions for lane 1: All buffers contained 50mM HEPES pH7.4, 50mM 
NaCl, 1% Triton, 5mM EDTA, protease inhibitor cocktail (Roche), 0.5mM PMSF and 7.5%  
glycerol, ImM DTT. Lysis and wash buffers for lane 2: as in lane 1 plus 50mM NaF. Lysis and 
wash buffers for lane 3: as in lane 1 plus 50mM NaF and ImM Na3VO.i. Lysis and wash buffers 
for lane 4: as in lane 1 plus ImM Na3V 0 4. Cells were lysed in the appropriate buffer and
166
proteins were precipitated with either mono-clonal GFP (FEZ2) or V5 (LRRK2). Proteins were 
eluted and analyzed by western blotting with antibodies to GFP and V5. Under these conditions, 
precipitation o f FEZ2 only resulted in the co-IP o f LRRK2 and vice versa in the presence o f NaF 
(lanes 3 and 4). Abbreviations: IN-INPUT, IP-IMM UNOPRECIPITANT, IB-IM M UNOBLOT
Precipitation o f FEZ1 and FEZ2 resulted in the co-precipitation o f LRRK2 (Figure 40 
lanel and 2) and vice versa. Under these conditions, precipitation o f FEZ2 resulted in 
precipitation o f FEZ1 (Figure 40; lane 3) 450 but LRRK2 did not interact with itself 
(Figure 40; lane 4). In addition LRRK2 did not interact with the non-specific control, 
PINK1 (Figure 40; lane 5) and LRRK2 did not precipitate on its own (Figure 40; lane 
10).
To determine if serine/threonine or tyrosine phosphorylation was required for the 
LRRK2/FEZ2 complex to form, the proteins were precipitated in buffers without NaF 
and Na3VC>4 , with either 50mM NaF or ImM Na3VC>4 and in the presence o f both 
types o f inhibitors. Cells were lysed and proteins precipitated as described above. 
Only in the presence o f NaF, did LRRK2 precipitate with FEZ2 and vice versa 
(Figure 41; Lane 2 and 3). Therefore, FEZ2 and LRRK2 appear to specifically 
interact, but the interaction requires the presence o f NaF and is relatively unaffected 
by the presence o f Na3V0 4 .
DISCUSSION
Currently, very little is known about the function o f FEZ2, with the majority o f 
research focused on its homolog, FEZ1. FEZ2 is ubiquitously expressed in 
mammalian tissues 449. FEZ1 is exclusively expressed in the brain where it appears to
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be involved in neuritogenesis upon phosphorylation by PKC£ 452>453. Knockout o f the 
FEZ1 homolog from Drosophila and C-elegans (UNC-76) leads to locomotion and 
axonal transport defects 452,454,455. The mechanism by which FEZ1 increases axonal 
outgrowth is not well understood but the UNC-76 appears to form complex with 
UNC-69 (SOCO-mammalian homolog), which promotes axonal growth and normal 
presynaptic organization 455. It has also been shown that FEZ1 is able to homo- 
dimerise and to hetero-dimerise with FEZ2 but the consequences o f this are currently 
unknown 45°. Given the role o f FEZ1 in axonal outgrowth and normal synaptic 
function, FEZ2 and LRRK2 may co-operate in maintaining SN neuritic length and 
branching, and makes FEZ2 a good functional interactor for LRRK2. In support o f 
this hypothesis, recent evidence has suggested that LRRK2 plays a role in 
maintaining neuronal morphology in vitro and in v iv o 415.
A variety o f factors were varied to try and confirm the interaction between FEZ2 and 
LRRK2 in mammalian cells. To efficiently detect interactions in these systems, the 
bait protein concentration should be in excess o f the molar Kd o f the interaction. The 
expression levels o f LRRK2 were potentially limiting as this protein was more 
weakly expressed than FEZ 1/2, so the type and concentration o f the detergent used to 
lyse the cells were varied to maximize the amount o f this protein extracted. Triton- 
X I00 most efficiently released LRRK2 from the cells.
Secondly, to stabilize hydrophobic interactions thus stabilizing protein interactions 
and promote the re-folding o f protein into their native conformation, glycerol was 
added. With the presence o f glycerol the binding between FEZ2/LRRK2 binding as 
well as LRRK2 self interaction and FEZ1/FEZ2 hetero-dimerisation were recreated.
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However, too much glycerol can also increase the possibility o f inappropriate protein- 
protein interactions, which appeared to be the case here as LRRK2 could precipitate 
with PINK1. Therefore, we considered that these interactions were not physiological 
under these conditions.
To determine if phosphorylation o f FEZ2 and LRRK2 was necessary for the 
interaction to occur, the concentration o f NaF, a serine/threonine phosphatase 
inhibitor, was increased. Under these conditions, LRRK2 interacted with FEZ 1/2, 
none o f the proteins precipitated in the absence o f the other and LRRK2 did not 
interact with PINK1. To confirm the effect o f NaF on the interaction between FEZ2 
and LRRK2, cells were lysed in various buffers with or without the presence of 
Na3VC>4 . This demonstrated that FEZ2 and LRRK2 only interact in the presence of 
NaF.
NaF has two effects, either o f which may promote LRRK2 binding to FEZ 1/2. 
Firstly, NaF may prevent the serine/threonine dephosphorylation o f either protein and 
only in there phosphorylated states can the two proteins interact. In support o f the 
hypothesis that phosphorylation is required for the interaction, FEZ1 and FEZ2 can 
be phosphorylated by PKC£ 449, 452, a serine/threonine kinase, and LRRK2 may be
A 1 Rphosphorylated by an upstream kinase . There are no identified phospho-sites o f 
LRRK2, but phosphorylation prediction software (NETPHOS), suggests there is 
potentially a large region o f serine phosphorylation in the LRR domain o f LRRK2; an 
area which has been shown to bind to full length FEZ. If phosphorylation o f either 
protein promotes interaction, the interaction should be inhibited in the presence o f 
serine/threonine phosphatases or serine/threonine kinase inhibitors (e.g.
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staurosporine, SIGMA). Na3VC>4 , a tyrosine phosphatase inhibitor, does not promote 
the interaction suggesting that serine/threonine phosphorylation is important in 
FEZ2/LRRK2 complex formation or NaF may promote the interaction between the 
two by a different mechanism.
The second role o f NaF is less well understood. As mentioned previously, LRRK2 
contains a ROC domain which, in part, can bind to FEZ2. The ROC domain is a 
GTPase and cycles between GDP-bound and GTP bound states, which are 
accompanied by large conformational changes 456. This cycle is partly modulated by 
guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). 
In general, GTP binding is thought to promote binding o f the GTPase to target or 
“effector” proteins, whereas hydrolysis o f GTP to GDP, in conjunction with GAPs, 
results in dissociation o f these interactions. Exchange factors can then act to remove 
GDP allowing GTP to bind. Such conditional binding to target proteins allows 
GTPases to function as molecular switches in a number o f cellular processes. NaF 
has been reported to stabilize other GTP-dependent interactions in mammalian cells 
and in this case might restrict LRRK2 to a favorable conformation for an interaction 
with FEZ2, most probably in a GTP ‘on’ bound state 457. Although the mechanism o f 
action o f NaF is not known, it has been suggested that other fluorides (such as 
aluminium tetrafluoride) stabilize GDP bound GTPases in their transition states by 
mimicking the y-phosphate group of. The hypothesis that NaF affects FEZ2/LRRK2 
interactions via altered GTP binding and/or hydrolysis can be tested in multiple ways:
1) Adding excess levels o f GTPyS (a non-hydrolyzable form o f GTP) or 
GDPpS (which competes with GTP for GTPase activation) will either
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prevent or strengthen the interaction between LRRK2 and FEZ2. If 
FEZ2 is bound to LRRK2/GTPyS, GTPyS cannot be hydrolyzed and 
subsequently will stay bound to FEZ2.
2) Mutations can be created within LRRK2 that can either abolish 
GTPase (e.g. K 1347A) activity or make it constitutively active by 
mutating key residues in one o f four loops that interact with GTP (e.g. 
T1343G or R1398Q) 399-403 458.
The effects o f NaF on either phosphatase inhibition or altered GTP binding may not 
be mutually exclusive. Phosphorylation may activate LRRK2, allowing GTP and 
FEZ2 to bind. Additionally, GTP binding to LRRK2 may cause subsequent auto­
phosphorylation o f LRRK2 and/or phosphorylation o f FEZ2 and might promote an 
interaction between the two proteins.
Understanding the mechanism behind the FEZ2 and LRRK2 interaction could 
provide important insights into the pathways and mechanistic control o f LRRK2. If 
LRRK2 phosphorylation is necessary for the interaction with FEZ2, it would be 
important to understand how LRRK2 phosphorylation is regulated. It was recently 
shown that PARKIN binds to Epsl5, an adaptor protein that is involved in epidermal 
growth factor (EGF) receptor endocytosis and trafficking. Binding and ubiquitylation 
o f Epsl5 by PARKIN required stimulation by EGF 459, thus promoting neuronal 
survival via the Akt pathway. By analogy to this and many other examples, 
extracellular signaling may lead to the post translational modifications o f LRRK2, 
allowing the interaction to occur and potentially controlling neuronal outgrowth and 
survival.
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If GTPase function is necessary for the interaction between LRRK2 and FEZ2, 
clarifying how the ROC domain o f LRRK2 affects the interaction may also aid in our 
understanding o f how LRRK2 is controlled. At present, it has only been shown that 
LRRK2 can bind to GTP 416 and that artificial mutations within the ROC domain 416 
appear to decrease kinase activity. However, pathogenic mutations within this region 
do not appear to directly increase kinase activity 409, thus studying this interaction 
may help determine the effect o f these mutations on the function o f the ROC domain 
and, hence, LRRK2.
The functional consequences o f the interaction between FEZ2 and LRRK2 are 
unknown, but as FEZ 1/2 have been reported to increase neuritic outgrowth 449’452 454> 
460, the effects o f co-transfection o f LRRK2 and FEZ2 on neuritogenesis may be of 
interest. Recent evidence suggests that the normal function o f LRRK2 is to maintain 
neuronal length and branching 415. Mutations within LRRK2 cause progressive 
reduction in neurite length and branching, while knockdown o f LRRK2 leads to 
increased neurite length and branching 4I5. It would be o f interest to know if this 
phenotype is enhanced or suppressed after FEZ2 is knocked out or if such phenotypes 
can be rescued by over-expression o f FEZ2. These experiments would not prove that 
proteins physically interact but would support a common pathway o f action.
In summary, an interaction between LRRK2 and FEZ2 is supported by yeast mapping 
data, co-localization and CO-IP experiments. Further work is needed to verify the 
interaction in vivo, investigate the functional consequences o f  the interaction and if 
the interaction is significant in the pathogenesis o f LRRK2-linked PD.
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CONCLUSION
Over the last decade, there have been considerable advances in the discovery o f genes 
responsible for monogenic forms o f PD. Together, the known genes account for 
approximately 2% o f all PD cases, while mutations within LRRK2 alone account for 
approximately 1-2% of sporadic PD and 7-8% of familial PD. As light is shed upon 
the molecular mechanisms behind the pathogenesis o f PD, it is expected that there 
will be a significant improvements in the treatment o f symptoms in PD.
Our discovery o f LRRK2 mutations has provided clinical researchers with a large 
patient pool with a single defined genetic etiology in which to study disease onset, 
progression and response to treatment. Given that an estimated 10,000 PD patients in 
North America alone may have the G2019S mutation there are undoubtedly a very 
large number o f subjects who carry this mutation and have not developed disease. 
Based on current penetrance figures, one would estimate that 30% o f these mutation 
carriers will eventually manifest disease. Large cohorts o f asymptomatic subjects 
will be relatively easy to identify by assessing siblings and children o f patients with 
G2019S linked disease. This group o f subjects affords us the opportunity to not only 
identify signs and symptoms o f disease that may be used as specific early indicators 
o f PD, but also provide a cohort o f patients in whom the efficacy o f neuroprotective 
agents can be tested.
LRRK2 mutations may also be useful in allowing us to develop novel models o f PD 
in a number o f systems. As yet, there is no data available from in vivo models, but 
from in vitro studies three discernable phenotypes have been associated with LRRK2
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mutations: aggregation formation, toxicity and increased kinase activity and it is 
thought that these three effects are linked. The identification o f interactors, such as 
the self interaction o f LRRK2 and the interaction with FEZ2, will hopefully elucidate 
the normal function o f LRRK2 and the mechanisms that underlie its pathogenesis. 
Understanding what LRRK2 does and how mutations result in PD, will hopefully 
produce a readily quantifiable endpoint believed to be related to the pathological 
processes o f the disease. This will also allow high throughput screening o f molecular 
libraries o f compounds for inhibitors of pathogenic processes.
Even though research on LRRK2 is at an early stage, continued research into and 
therapies directed towards LRRK2 are likely to have a great clinical impact and may 
bring us closer to understanding the pathogenic processes underlying PD.
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